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Mammalian reproduction is driven by gonadotrophin -releasing hormone (GnRH) - a 
decapeptide released from hypothalamic neurones into the pituitary portal blood 
vessels. The aim of this thesis was to study structure- function relationships of the G- 
protein coupled GnRH receptor (GnRH -R), and has focused on the identification of 
key amino acids involved in GnRH ligand- receptor interactions as well as the role of 
putative disulphide bridge formation within the receptor itself. In addition, the role 
of disulphide bridge formation has also been explored in another G- protein coupled 
receptor (GPCR), the thyrotrophin- releasing hormone receptor (TRH -R). 
Comparative sequence analysis and computer molecular modelling approaches were 
used to target potentially important amino acids for site -directed mutagenesis study. 
Wild -type and receptor mutants were then expressed in mammalian cells, and 
receptor binding, expression, and activational properties compared between 
constructs. 
The majority of GPCRs contain two conserved extracellular Cys residues which 
have been postulated to form a covalently linked disulphide bridge structure. In the 
GnRH -R, these Cys residues are positioned at Cys 114 and Cys 195 in the first and 
second extracellular loops respectively. In addition, the GnRH -R contains two non - 
conserved Cys residues at Cys 14 in the amino terminus and Cys 199 in the second 
extracellular loop. Substitution of these Cys residues to serine resulted in a loss of 
ligand binding. A comparative study in the TRH -R, substituting the conserved 
extracellular Cys residues, Cys98 and Cys 179, to either serine or alanine, confirmed 
these findings. This data suggests that extracellular Cys residues, through putative 
disulphide bridge formation, may maintain the tertiary extracellular structure of the 
receptor and therefore facilitate ligand- receptor binding. Further studies, using 
chemical modifying reagents, have indicated that Cys residues with free sulfhydryl 
groups may also be important in TRH -R binding. 
The GnRH -R despite its structural homology to other GPCRs exhibits some unique 
features. These differences include the interchange of a highly conserved Asp and 
Asn residue in the transmembrane (TM) domains. Individual substitutions of Asn87 
ix 
Abstract X 
(in TM II) to Asp87 and Asp318 (in TM VII) to Asn318, revealed that Asn87 is 
important for GnRH agonist and antagonist binding whereas Asp318 is important for 
receptor activation. To investigate if the function as well as the position of these 
amino acids were transposed, a double mutation substituting both residues 
simultaneously was generated. However, this mutant receptor showed only a small 
degree of GnRH agonist binding, indicating that the functional role of these specific 
residues is not interchangeable. 
Amongst GPCRs, the GnRH -R is particularly suitable for three dimensional 
molecular modelling and computer aided simulations because of its short 
extracellular and intracellular domains. Using this approach, it has been possible to 
predict putative amino acids involved in ligand- receptor interactions. During this 
study, GnRH molecular models have evolved from a template predicted by the 
Baldwin model to a series of energy minimised computer generated three 
dimensional structures. To simulate GnRH ligand- receptor interactions, a model of 
the native GnRH peptide has also been constructed. The initial Baldwin model 
highlighted a series of TM located polar amino acids in TM II, TM III, TM IV and 
TM VII of the GnRH -R. Both the position and nature of these amino acids rendered 
them capable of interacting with the GnRH ligand. Mutations at these sites 
identified two residues, His305 located at the TM VII/extracellular interface and 
Asn314 in TM VII, that were potentially important for GnRH -R binding. 
Further modelling studies, using GnRH ligand- receptor computer simulations, 
predicted that amino acids Phe312 in TM VII and Leu83 in TM II may interact with 
Trp3 and Leu7 in the GnRH ligand respectively. Substituting these amino acids to 
residues of either similar, different or neutral hydropathicity, showed that a 
hydrophobic amino acid was essential for GnRH -R binding at position 312 and for 
receptor activation at residue 83. Altogether, 15 sites within the GnRH -R have been 
experimentally modified and the information derived from site -directed mutagenesis 
studies has been ï utilised to redefine the structure of the molecular models. 
In conclusion, the formation of a putative disulphide bond between extracellular 
cysteine residues in both the GnRH -R and TRH -R is important in maintaining 
tertiary protein structure. In addition, amino acids located in TM II and TM VII are 
essential for binding interactions between GnRH and its receptor. Analysis of 
structure -function relationships, particularly using this dual biochemical and 
Abstract xi 
molecular modelling approach, will greatly facilitate rational drug design. In the 
light of the enormous clinical applications of GnRH and its analogues, information 
regarding the mechanisms of hormone -receptor interactions will be of benefit in the 
development of new and novel drugs for clinical use in reproductive medicine. 
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1 Introduction 
1.1 Physiological Background 
The identification of the gonadotrophin- releasing hormone (GnRH) decapeptide 
structure in the early 1970s (Burgus et al, 1972; Matsuo et al, 1971) stands as one of 
the great landmarks in reproductive endocrinology. GnRH and its synthetic analogues 
are now widely used in clinical endocrinology, not only to treat reproductive disorders 
but also in the management of hormone -dependent neoplasms. Under normal 
physiological circumstances, GnRH is released in a pulsatile manner from the 
hypothalamus and transported to the anterior pituitary gland via the portal blood 
vessels. GnRH binds to a specific receptor located in gonadotroph cells, the GnRH 
receptor (GnRH -R), stimulating the synthesis and release of luteinising hormone (LH) 
and follicle -stimulating hormone (FSH). Moreover, with the elucidation of the 
GnRH -R amino acid sequence in the 1990s (Tsutsumi et al, 1992) it is now possible 
to study structure -function relationships in both GnRH and its receptor. 
1.2 Aim of the study 
The primary aim of this PhD study was to examine structure -function relationships in 
the GnRH -R and to identify amino acids within the receptor that are crucial mediators 
of (i) receptor structure, (ii) receptor binding and (iii) receptor activation. 
1.3 Importance of the study 
It is imperative to understand the normal molecular mechanisms underlying GnRH 
ligand- receptor activation so that pathological conditions, resulting from imbalances in 
the normal system, can be recognised and effectively treated. Currently, GnRH and 
its analogues are widely used clinically, and knowledge regarding the mechanism of 
GnRH- induced receptor activation could be exploited to further improve treatment 
regimes. The identification of specific amino acid interactions between the GnRH 
ligand and receptor has enormous implications for rational drug design. If the atomic 
1 
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spatial arrangement of residues involved in ligand- receptor binding can be mapped, 
then drugs can be specifically manufactured to interact with these critical residues. 
Moreover, this would allow for de novo synthesis of highly specific analogues with 
greater receptor efficacy. In addition, this approach would also facilitate combinatorial 
methods of drug design, as existing libraries could be screened for compounds with a 
complementary structure to the active receptor site. Ultimately, the use of rational 
drug design will aid in the generation of safer and more clinically acceptable 
compounds and hopefully extend to the development of orally active, non -peptide, 
GnRH analogues. 
1.4 Fundamental experimental approaches 
In this study, site -directed mutagenesis was chosen as a means of accessing the role of 
targeted amino acids. This technique allows small changes to be incorporated into the 
receptor cDNA sequence, thereby changing its final protein structure. Any significant 
alterations in the binding and activational properties of these modified 'mutant' GnRH- 
Rs were then tested accordingly. Site -directed mutagenesis only permits the 
concurrent alteration of one or two amino acids. As the rat GnRH -R contains a total 
of 327 amino acids it would be impractical to modify every individual receptor 
residue. Therefore, it was important to design a suitable strategy, whereby amino 
acids located in the positions most likely to affect ligand binding and receptor 
activation were targeted. Two methods were employed to facilitate this task. 
The first method utilised sequence information from other heptahelical G- protein 
coupled receptors (GPCRs), whilst the second method relied on molecular modelling 
studies. The GnRH -R belongs to the GPCR superfamily - a family of proteins 
characterised by seven transmembrane (TM) a helices. These helices are linked 
together by stretches of hydrophilic amino acids which form intracellular loops (il) and 
extracellular loops (el). Site -directed mutagenesis studies have been carried out in 
other GPCRs and as all these receptors share the same overall topographical structure, 
information derived from one receptor can often be useful in predicting or determining 
structure -function relationships in other related receptors. 
The molecular modelling approach has proved particularly useful in giving insight into 
the possible three -dimensional structure of GPCRs (Donnelly and Findlay, 1994; 
Perlman et al, 1994b). Two molecular models of the GnRH -R have been utilised 
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during the course of this study, the Baldwin model (Baldwin, 1994) and a computer 
derived model of the GnRH -R (P L Taylor, MRC, Reproductive Biology Unit, 
Edinburgh). In addition, Dr Taylor has also constructed a computer model of GnRH. 
Furthermore, these models have been integrated together to allow computer 
simulations of putative ligand- receptor interactions. 
However, whilst molecular modelling approaches are now widely used to predict 
putative drug- receptor interactions, these models are still only hypothetical. Definitive 
structural determination can only be achieved by means of two /three -dimensional 
crystallography which is the ultimate goal of scientific endeavour in this area. 
1.5 General experimental procedures 
In this study, attention has focused on targeting amino acids which are potential 
determinants of GnRH tertiary receptor structure or form part of the ligand binding 
pocket. In total, four experimental studies have been undertaken and these have 
concentrated on putative bonding interactions between individual receptor residues as 
well as those between the ligand and its receptor. 
1.5.1 Amino acid involvement in receptor tertiary structure 
The first study investigated the role of conserved extracellular cysteine (Cys) residues 
in the GnRH -R and their participation in disulphide bond formation. Four mutant 
receptors were generated, converting all the extracellular Cys residues to serines (Ser) 
viz: Cys 14Ser, Cys 114Ser, Cys 195Ser and Cys 199Ser. A comparative study was 
also carried out involving another pituitary GPCR, the thyrotrophin- releasing hormone 
receptor (TRH -R). In this experimental study, the extracellular Cys residues were 
substituted for either serine or alanine (Ala) [Cys98Ser, Cys 100Ser, Cys 179Ser, 
Cys98Ala, Cys 100Ala and Cys 179Ala]. In addition, Cys- specific chemical 
modifying agents were also used to further characterise the role of Cys residues in the 
TRH -R. The remaining experimental chapters relate to the identification of important 
residues in the GnRH -R ligand binding pocket. 
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1.5.2 Amino acid involvement in GnRH ligand binding 
The second series of experiments investigated the role of GnRH -R residues asparagine 
87 (Asn87) in TM II and aspartic acid 318 (Asp318) in TM VII. These amino acids 
were targeted because of their unusual positions relative to other GPCRs. In most 
other GPCRs, an Asp and an Asn residue are located at these TM II and TM VII sites 
respectively. However, in the GnRH -R these amino acids appear to have transposed 
positions. To investigate their functional role in ligand- receptor binding, two single 
mutations were generated substituting the Asn for Asp (Asn87Asp) and the Asp for 
Asn (Asp318Asn), together with a double reciprocal mutation 
(Asn87AspAsp318Asn). 
The final two experimental investigations have utilised information derived from the 
Baldwin model and the computer generated models of the GnRH -R respectively. The 
Baldwin model of the GnRH -R highlights the presence of polar amino acids in the TM 
domains and TM/extracellular interface of the receptor. Seven amino acid residues 
were targeted for study, glutamic acid 90 (G1u90) positioned in TM II, two lysine 
residues (Lys) one at the TM III/extracellular interface (Lys 115) and the other in TM 
III (Lys 121), glutamate 174 (Gln 174) in TM IV, histidine (His305) at the TM 
VII/extracellular interface and two Asn residues one at the TM VI/extracellular 
interface (Asn304) and the other in TM VII (Asn314). The amino acid side chains of 
these polar residues pointed towards the central channel created by the TM helices and 
thus were in an ideal position to interact with the ligand. These amino acids were 
mutated as follows, Glu90 to G1n90 (Glu90Gln), Lys 115/Lys 121 to arginine (Arg) 
[Lys 115Arg and Lys 121Arg], His305 to Arg (His305Arg) and Asn304 /Asn314 to 
Asp (Asn304Asp and Asn314Asp). 
The last experimental study examined the role of two GnRH -R amino acids, leucine 
83 (Leu83) in TM II and phenylalanine 312 (Phe312) in TM VII. These amino acids 
were identified as potentially important mediators of receptor binding function through 
computer -aided ligand- receptor simulations. The position of GnRH in the ligand- 
receptor simulated models revealed that Leu83 and Phe312 were positioned in close 
proximity to Leu7 and Trp3 in GnRH respectively. The spatial orientation of these 
pairs of amino acids was such that hydrophobic interactions might possibly occur 
between them. To investigate any possible bonding interactions, each site was 
mutated either to another hydrophobic residue [Leu to valine (Val) and Phe to tyrosine 
(Tyr)] or to a hydrophilic amino acid [Leu to lysine (Lys) and Phe to Arg]. In 
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addition, each site was also mutated to a smaller Ala residue. Therefore, in total 6 
different mutations were generated i.e. Leu83Val, Leu83Lys, Leu83Ala, Phe312Tyr, 
Phe312Arg and Phe312Ala. 
1.6 Structure of thesis 
This introduction has aimed to place the overall study in a much broader context by 
highlighting the importance and relevance of scientific based structure -function 
investigations in the field of novel drug design. The following section outlines the 
structure of the subsequent chapters of this thesis. 
Chapter 2 reviews the current literature and is divided into two major parts. Section 1 
deals with the role of GnRH as a hypothalamic- pituitary hormone, including the 
regulation of its synthesis and release from the hypothalamus, its actions at the 
pituitary gland and the clinical uses of its synthetic analogues. The second section 
focuses in depth on the precise interactions between GnRH and its pituitary receptor. 
This section also examines the structure and activational properties of the GnRH -R, 
the similarities and differences of these features compared to other GPCRs, and 
GPCR structure- function relationships. Factors regulating GnRH -R gene expression 
are also discussed. The final part of this section is devoted to the localisation and 
possible endocrine function of GnRH and its receptor outside the hypothalamic - 
pituitary axis. 
Chapter 3 describes the experimental methodology used in the study, including 
protocols for standard molecular biology techniques, methods for site -directed 
mutagenesis, stable /transient expression of DNA, Northern Blot analysis, ligand- 
induced total inositol phosphate measurements and receptor binding assays. 
Molecular models of GPCRs are now widely used to predict ligand- receptor 
interactions. The basis of these models is the structural determination of two 
heptahelical proteins, bacteriorhodopsin and rhodopsin. Chapter 4 highlights the 
structural elucidation of these two proteins, together with their advantages and 
disadvantages as templates for other GPCRs models. Methods underlying the 
construction of the Baldwin GnRH -R model and the computer generated models of the 
GnRH ligand and receptor are also outlined. 
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The experimental results are contained within Chapters 5 -8. Chapter 5 focuses on the 
role of GnRH -R Cys residues in disulphide bridge formation. A comparative study of 
another GPCR, the TRH -R, also examines the role of these residues using site - 
directed mutagenesis. In addition, the role of Cys residues has also been investigated 
using Cys- specific chemical modifying reagents. Chapter 6 examines the role of 
GnRH -R amino acids Asn87 and Asp318 in ligand binding and receptor activation. 
Chapter 7 deals with the function of TM located polar amino acids Glu90, Lys 115, 
Lys 121, Gln 174, Asn304, His305 and Asn314, identified by the GnRH -R Baldwin 
model while Chapter 8 analyses the structure- function roles of Leu83 and Phe312, 
highlighted in the computer- derived model of the GnRH -R. 
Chapter 9 focuses on ways of monitoring mutant receptor expression levels and 
Chapter 10 summarises and concludes the work carried out during the course of this 
study, outlining future developmental research. 
2 Literature Review 
2.1 Hypothalamo- Pituitary Interactions 
The concept of neuro- endocrine regulation of pituitary function was first suggested by 
Harris and Green in 1949 (Harris and Green, 1945). Under normal physiological 
conditions the pituitary gland responds to the endocrine and metabolic needs of the 
body and releases appropriate hormones into the peripheral circulation. These 
hormones in turn act to regulate the cellular growth, differentiation and function of 
specific target organs. Regulation of anterior pituitary hormone secretion is dependent 
on humoral signals from the hypothalamus, feedback regulation from peripheral 
hormones, non -humoral neurotransmitter signals, together with paracrine and 
autocrine action of pituitary growth hormones and factors (Asa et al, 1995). The 
balance of these chemical and neuronal signals determines the amount and pattern of 
hormone secretion and allows complex feed -back regulation. The hypothalamus 
forms the final pathway between the neuronal circuitry of the brain and the endocrine 
function of the pituitary gland and can thus be regarded as the key regulator of 
adenohypophyseal hormone release (Yen, 1991). 
2.1.1 Hypothalamus 
The hypothalamus, a primitive structure largely unchanged throughout evolution, is 
located at the base of the forebrain. Despite a poorly defined anatomical region, the 
hypothalamic sulcus is generally regarded as the superior boundary, the lamina 
terminalis is considered as the anterior border, while the medial forebrain bundle limits 
its position laterally and the mamillary complex provides the caudal margin. The 
hypothalamic blood supply is derived from arterial branches of the circle of Willis 
together with the superior hypophyseal artery. As well as being extensively 
vascularised, the hypothalamus is also a strongly innervated organ with afferent and 
efferent fibres connecting the hypothalamus with other regions of the brain including 
the forebrain, limbic system, visual cortex, thalamus and the brain stem. The 
regulation of hypothalamic function by chemical signals from the blood and /or 
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cerebrospinal fluid (CSF) along with neurotransmitters released locally from afferent 
neurons, is only possible due to these neuronal and vascular networks. 
The concept of neurosecretory cells was first proposed by Ernst Scharrer and co- 
workers in the 1930's (for review see Reichlin, 1987). Neurons in the hypothalamus 
form clusters, known as nuclei, which are responsible for the production and secretion 
of hypothalamic- releasing and inhibitory factors (Figure 2.1). The hormones oxytocin 
and vasopressin are produced in the magnocellular cell bodies of the supraoptic (SON) 
and paraventricular nuclei (PVN) and are transported along the nerve axons, 
constituting the hypothalamic -hypophyseal tract, to the neurohypophysis. Smaller 
parvocellular secretory neurons, responsible for the secretion of hypophysiotrophic 
hormones, are primarily found in the preoptic area, arcuate nucleus and ventromedial 
nucleus; although a few such cells are also present in the SON and PVN. The 
tuberoinfundibular tract arises from the parvocellular neurons and carries 
hypophysiotrophic hormones to the median eminence where they are released into the 
primary portal plexus and travel in the hypophyseal portail veins to a secondary plexus 
overlying the anterior pituitary gland (Figure 2.1). 
Figure 2.1 Diagrammatic representation of the hypothalamic -pituitary axis 
(following page) 
The blood supply to the median eminence is derived from the superior hypophyseal artery. This artery 
forms a primary capillary plexus in the medium eminence and hypophyseal portal vessels arising from 
it terminate in the anterior pituitary gland. The posterior pituitary is supplied directly from the 
inferior hypophyseal artery. Axons from the parvocellular neurons, carrying hypophysiotrophic 
hormones, terminate close to the primary capillary plexus. Axons from the magnocellular neurons of 
the PVN and SON terminate directly in the posterior pituitary gland. Adapted from Johnson and 
Everitt, 1995. 






























To date five classical hypophysiotrophic peptide hormones, thyrotrophin- releasing 
hormone (TRH) (Guillemin et al, 1971), gonadotrophin- releasing hormone (GnRH) 
(Burgus et al, 1972; Matsuo et al, 1971), somatostatin or somatotroph- releasing 
inhibitory hormone (SRIH) (Brazeau et al, 1973), corticotrophin -releasing hormone 
(CRH) (Vale et al, 1981) and growth hormone -releasing hormone (GHRH) 
(Guillemin et al, 1982) have been isolated, and their role in the regulation of anterior 
pituitary hormone synthesis and secretion extensively studied. Other factors, e.g., 
neurotransmitters and neuropeptides, shown to influence anterior pituitary hormone 
release include catecholamines (dopamine (DA), adrenaline, noradrenaline, serotonin 
and histamine), acetylcholine, y- aminobutyric acid (GABA), opioid peptides and 
vasoactive intestinal peptide (VIP). The precise action of many of these factors is 
unknown but the roles of dopamine and VIP in the regulation of prolactin (PRL) 
secretion have been more precisely established (Abe et al, 1985; Jonathan, 1985). 
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Many of the hypothalamic- releasing hormones have also been localised outside the 
hypothalamic- pituitary axis including the brain, spinal cord, autonomic nervous 
system, gastrointestinal, respiratory and reproductive tracts (Yen, 1991). A potential 
role for these peptides in cellular communication prior to the development of the 
neuronal or endocrine systems has been postulated by Kreiger (1983). 
2.1.2 The pituitary gland 
The pituitary gland, positioned in the sella turcica, is derived from two ectodermal 
components. Rathke's pouch, formed from the roof of the buccal cavity, develops 
into the anterior pituitary and intermediate lobe whilst the floor of the third ventricle 
forms the pituitary stalk and posterior pituitary. 
The posterior lobe is composed of magnocellular neurosecretory nerve endings. 
Oxytocin and vasopressin with their corresponding neurophysin molecules are 
synthesised in the SON and PVN, packaged into granules and transported through the 
nerve axons, via the pituitary stalk, to the posterior pituitary. When stimulated, the 
neurosecretory cells fire action potentials and exocytose hormones directly into the 
capillary vessels of the inferior hypophyseal artery. Cholinergic and noradrenergic 
fibres synapse with the SON and PVN and have been shown to stimulate hormone 
release, while inhibitory regulation occurs by dopaminergic and opioidergic pathways. 
Purification of oxytocin and vasopressin by du Vingneud et al (1954) revealed that 
both these hormones have a nonapeptide structure requiring a disulphide bond 
between cysteine residues (at positions 1 and 6) for biological activity. Oxytocin is 
released in response to peripheral stimuli from cervical stretch receptors or from 
suckling stimulus at the breast, and its action in the cervix promotes foetal expulsion 
during labour whereas in the mammary gland it causes milk release. The main 
physiological stimulus for the release of vasopressin is provided by alterations in body 
fluid balance, an increase in osmotic pressure being counterbalanced by the action of 
vasopressin on water reabsorption from the kidneys. 
In contrast, the anterior lobe is made up of different endocrine cell types namely 
somatotrophs, córticotrophs, lactotrophs, gonadotrophs and thyrotrophs. 
Hypothalamic- releasing /inhibiting hormones bind to specific anterior pituitary cell 
surface receptors and in doing so alter their structural conformation. This change in 
receptor structure triggers a second messenger cascade system, causing an increase in 
intracellular calcium levels ([Ca2 +]i), and ultimately hormone exocytosis. 
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Regulation of anterior pituitary hormone secretion by hypothalamic- releasing and 
inhibitory factors together with their downstream target action is illustrated in Figure 
2.2. 
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Figure 2.2 Control of anterior pituitary hormone release 
Control of anterior pituitary horinone secretion by hypo thalamic -stimulatory /inhibitory factors and 
the ensuing regulation of trophic hormone secretion. The effect of trophic hormones on their 
downstream target tissues is also highlighted. Adapted from (Asa et al, 1995). 
ACTH, adrenocorticotrophic hormone; CRH, corticotrophic hormone; DA, dopamine; FSH, follicle - 
stimulating hormone; GHRH, growth hormone -releasing hormone; GnRH, gonadotrophin -releasing 
hormone; IGF -1, insulin -like growth factor 1; LH, luteinising hormone, PRL, prolactin; SRIH, 
somatostatin- releasing inhibitory hormone; TRH, thyrotrophin -releasing hormone; TSH, 
thyrotrophin; VIP, vasoactive intestinal polypeptide. 
Chapter 2 Literature Review 12 
Somatotroph cells constitute approximately 50% of the cells in the adenohypophysis 
and are responsible for the production of growth hormone (GH). GH synthesis and 
secretion is regulated by two hypophysiotrophic factors, GHRH stimulates its release 
whereas SRIH has an inhibitory action. Once released into the circulation GH 
promotes the growth of bone, soft tissue and viscera either directly or indirectly 
through the stimulation of insulin -like growth factor 1 (IGF -1). 
Corticotroph cells are the second most numerous cell type comprising approximately 
15 -20% of the adenohypophyseal cell population. These cells are responsible for the 
production of pro -opiomelanocortin (POMC) and its many derivatives, including 
adrenocorticotrophin hormone (ACTH), melanocyte- stimulating hormone (MSH), 
lipotrophic hormone and endorphins. Synthesis and release of ACTH from 
corticotroph cells is stimulated by CRH, and once released into the peripheral 
circulation its action is generally confined to the adrenal cortex where it stimulates 
steroid synthesis. 
Lactotrophs represent approximately 15% of the total anterior pituitary cell population 
and are responsible for the production of PRL. Unlike other adenohypophyseal 
hormones their regulation is controlled primarily through the tonic inhibitory actions of 
a catecholamine, DA, rather than a hypophysiotrophic hormone. However, TRH and 
VIP have been.shown to stimulate PRL release in vitro (Kosh et al, 1977; Nagy et al, 
1988). The actions of PRL are mainly in breast tissue where it is responsible for 
stimulating the growth of mammary tissue and supporting milk secretion. 
Gonadotroph cells constitute approximately 10% of adenohypophyseal cells and 
produce the gonadotrophin glycoprotein hormones, LH and FSH, which have a 
critical function in reproduction. The structure of gonadotroph genes is discussed in 
section 2.3.2. The rate of gonadotrophin synthesis and secretion is primarily 
controlled by the one factor, GnRH. LH stimulates steroid hormone production in the 
gonads whilst FSH stimulates follicle growth and estrogen production in the ovary. 
FSH also regulates Sertoli cell function together with the maturation of developing 
spermatids in the testis. A more detail description of gonadotrophin secretion and its 
regulation is discussed in section 2.3.3. 
The least common cell type in the anterior pituitary gland are the thyrotroph cells, 
constituting only 5% of the total cell population. Thyrotroph cells produce thyroid- 
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stimulating hormone (TSH), also known as thyrotrophin, and this glycoprotein 
hormone, like LH and FSH, consists of a common a subunit and a hormone specific ß 
subunit. Its production is stimulated by TRH and inhibited by SRIH and once 
released from the anterior pituitary, TSH travels to the thyroid gland promoting the 
synthesis and secretion of thyroid hormones. 
2.2 Gonadotrophin -releasing hormone (GnRH) 
The mammalian form of GnRH (mGnRH) was first isolated from porcine (Matsuo et 
al, 1971) and ovine (Burgus et al, 1972) brains in the 1970s. Since then six different 
forms have been identified and named according to the animals they were isolated 
from: chicken I (cGnRH -I), catfish (cfGnRH), chicken II (cGnRH -II), dogfish 
(dfGnRH), salmon (sGnRH) and lamprey ( 1GnRH). Their structures are illustrated in 
Table 2.1. Present throughout vertebrates from cartilaginous fish to primitive placental 
mammals, c -GnRH II is the longest conserved, arising over 500 million years ago 
(Sherwood et al, 1993). The mammalian form appeared 'more recently', 
approximately 400 million years ago, and can be found in the descendants of primitive 
bony fish. Non -mammalian vertebrates express multiple forms of GnRH and each 
form is characterised by a tissue -specific distribution pattern, suggesting different 
peptides have different regulatory roles. Mammals are unusual as only one form of 
GnRH has been identified (King et al, 1988): however, other GnRH forms are 
capable of causing the release of mammalian LH and FSH but, generally with much 
less potency. cGnRH -I, structurally the closest to the mammalian form, shows only a 
3% LH releasing activity compared with mGnRH. Paradoxically cGnRH -II and 
dfGnRH, with 3 amino acid substitutions compared to mGnRH, show a greater ability 
to release gonadotrophs compared to cGnRH -I (Sherwood et al, 1993). 
2.2.1 Embryonic development and migration of GnRH neurons 
GnRH immunoreactive cells originate in the olfactory placode and during foetal life 
migrate from the nasal region towards the anterior forebrain in association with the 
nerve terminalis and vomeronasal nerve (Schwanzel -Fukuda and Pfaff, 1989). Neural 
cell adhesion molecules provide a scaffold along which the clusters of GnRH neurons 
migrate to their final destination shortly before birth (Schwanzel -Fukuda et al, 1992). 
Failure of GnRH migration from the olfactory epithelium results in Kallman's 
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Syndrome, a disease characterised by hypogonadotrophic hypogonadism and anosmia 
(Schwanzel -Fukuda et al, 1989). 
Species Amino acid 1 2 3 4 5 6 7 8 9 10 
Mammalian mGnRH pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly -NH2 
Chicken I cGnRH -1 pGlu His Trp Ser Tyr Gly Leu Gln Pro Gly -NH2 
Catfish cfGnRH pGlu His Tip Ser His Gly Leu Asn Pro Gly -NH2 
Chicken II cGnRH -II pGlu His Tip Ser His Gly Tip Tyr Pro Gly -NH2 
Dogfish dfGnRH pGlu His Trp Ser His Gly Trp Leu Pro Gly -NH2 
Salmon sGnRH pGlu His Trp Ser Tyr Gly Trp Leu Pro Gly -NH2 
Lamprey 1GnRH pGlu His Tyr Ser Leu Glu Tip Lys Pro Gly -NH2 
Table 2.1 Structure of GnRH peptide from different species 
Structure of the mammalian (m), chicken (c) I and H, dogfish (df), catfish (cf) and lamprey (1) GnRH. 
All the species identified to date share 50% homology with the same amino acids in positions 1, 2, 4, 
9 and 10. 
2.2.2 Localisation of GnRH neurons in the brain 
GnRH immunoreactive cells are diffusely scattered in the brain. In primates, the 
highest concentration of GnRH neurons can be seen in the arcuate nucleus of the 
mediobasal hypothalamus and the preoptic area of the anterior hypothalamus (Yen, 
1991). Two prominent nerve bundles, the infundibular and preopticoterminal tract, 
are formed from the projection of these fibres to the median eminence and organosum 
vasculosum of the lamina terminalis (OVLT) respectively. In total, approximately 50- 
75% of all GnRH neurons terminate in the median eminence, releasing their 
hypophysiotrophic hormones into the primary pituitary portal plexus (Merchenthaler et 
al, 1990). GnRH neurons tend to be distributed in a species- specific pattern and in 
rodents the most prominent clusters of cell bodies are present in the dorsal and medial 
septal nuclei, the nucleus of the diagonal band of Broca, the anterior hypothalamic 
nucleus and the OVLT (Silverman et al, 1979). Immunocytochemical techniques have 
also localised GnRH neurons in the olfactory bulb, amygdala and hippocampus. 
Direct synaptic connections between these and other neuronal systems suggest that 
GnRH may function as a neurotransmitter and/or neuromodulator. In addition to its 
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well established role in the control of anterior pituitary hormone secretion, GnRH is 
also thought to regulate female sexual behaviour. Evidence supporting this hypothesis 
has been presented by Pfaff and co- workers who demonstrated infusion of GnRH into 
the rat medial preoptic area, arcuate nucleus, ventromedial hypothalamus, midbrain 
central grey and spinal cord facilitates lordosis (Pfaff et al, 1994). In particular, the 
ventromedial hypothalamic nuclei have been implicated in co- ordinating female sexual 
behaviour. Steroidogenic factor -1 (SF -1), an important factor in pituitary- specific 
expression of gonadotrophins, appears critical in the formation of the ventromedial 
hypothalamic nuclei (Ikeda et al, 1995). 
2.2.3 Gene structure and regulation 
GnRH is cleaved from a larger precursor molecule composed of a signal peptide, 
GnRH decapeptide sequence, a processing site (Gly- Lys -Arg) and a 56 amino acid 
peptide, known as the GnRH associated peptide (GAP) (Seeburg and Adelman, 
1984). GnRH and GAP co- localise in hypothalamic neurons, and pituitary cell culture 
experiments have shown that low doses of GAP promote the release PRL in vitro 
(Seeburg et al, 1987). GAP may also be involved in the packaging and processing of 
the GnRH hormone, a role illustrated by the hypogonadal mouse model. These 
animals lack the region of the GnRH gene that codes for GAP, and as a result do not 
release GnRH and so are sexually immature (Seeburg et al, 1987). 
The mammalian GnRH gene contains 4 exons. The first exon codes for the 5' 
untranslated region with the second exon coding for the signal peptide, the GnRH 
decapeptide sequence and the processing signal, and the third/fourth for GAP and the 
3' untranslated region (Seeburg and Adelman, 1984). Regulation of gene 
transcription occurs through the activation of transcription factors, and analysis of the 
rat GnRH gene sequence reveals DNA binding elements for transcription factors 
similar to Oct -1, Tst -1 and Pit -1 (Kepa et al, 1992). Although these binding sites are 
present in the gene structure there is no direct evidence regarding their regulatory 
function. An estrogen response element (ERE) has now also been identified in the 
human GnRH gene (Radovick et al, 1994). 
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2.2.4 GnRH secretion from hypothalamic neurons 
Knobil in 1980, demonstrated that GnRH was released from the hypothalamus in a 
pulsatile fashion - a process initiated, controlled and regulated by the GnRH pulse 
generator. Studies examining the mechanism of action of the pulse generator have 
been difficult as hypothalamic GnRH neurons are few in number, highly dispersed 
and difficult to identify. The development of an immortalised GnRH hypothalamic 
neuronal cell line, GT -1 (Mellon et al, 1990), has resolved this problem but care 
should be taken in extrapolating information from tumour -derived cell lines to normal 
physiological situations. However, much of the knowledge obtained from GT -1 cell 
lines has been substantiated by other experimental approaches using primary foetal 
hypothalamic cell cultures, hypothalamic tissue and in vivo animal models. In 
addition to neuronal regulation, glial cells are also thought to regulate the GnRH pulse 
generator (Melcangi et al, 1995). 
2.2.5 Regulation of GnRH pulse generator activity 
Autoregulation by GnRH 
The ability of GT -1 cells to survive independently in culture and secrete synchronised 
pulses of GnRH, in the absence of other cell types, implies that the pulse generator 
activity endogenously resides in the GnRH neurons. Several lines of evidence 
suggest that this system may be autoregulated by GnRH. Experiments using a 
perfused culture system, have demonstrated that treatment of GT -1 neurons with 
GnRH results in a transient increase in peptide release followed by suppression of 
basal pulsatility (Stojilkovic et al, 1994a). The Cat+ dependent nature of these effects 
suggests a receptor- mediated process. Moreover, GnRH -R protein and mRNA have 
been detected in these cells (Krsmanovic et al, 1993). Together, these findings imply 
that regulation of the pulse generator activity is primarily controlled by the 
autoregulatory actions of GnRH. 
GT -1 cells provide a good in vitro model to study hypothalamic hypophysiotrophic 
regulation, as neuronal activity can be modulated to mimic physiological situations. 
Continuous infusion of GnRH into a GT -1 cell perfusion system results in patterns of 
GnRH pulse frequency activity and amplitude similar to that observed during the 
preovulatory LH surge (Stojilkovic et al, 1994a). 
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Modulation of GnRH secretion by other factors 
Neurotransmitters, hormones and other factors have also been postulated to modulate 
GnRH gene expression and secretion, either directly, through specific cell surface 
receptors or indirectly, through interconnecting neuronal pathways. 
Factors thought to act directly through receptor specific interactions include GABA, 
excitatory amino acids, catecholamines, neuropeptide Y and endothelin (Spergel et al, 
1994; Stojilkovic et al, 1994a). It is also well documented that steroids, in particular 
estrogens, have an important role to play in regulating GnRH secretion. A direct 
action of estrogen in regulating GnRH gene expression, is suggested by the presence 
of an ERE in the human GnRH gene (Radovick et al, 1994). In addition, the 
identification of estrogen receptors in GnRH neurons further suggests that this steroid 
can regulate the activity of GnRH neurons directly (Radovick et al, 1994). Other 
steroids are also thought to be involved in modulating GnRH neuronal activity and 
studies of GT -1 neurones have identified both androgen (Poletti et al, 1994) and 
glucocorticoid receptors (Chandran et al, 1994). 
Steroids have also been shown to influence GnRH regulation through the activation of 
interconnecting neuronal systems. The progesterone metabolite 
tetrahydroprogesterone, for example, stimulates GnRH release in GT -1 cells via the 
neurotransmitter GABA (El Etr et al, 1995). Endogenous opioids have also been 
implicated in GnRH regulation and are thought to inhibit GnRH release through 
suppression of excitatory adrenergic influence (Nazian et al, 1994). Furthermore, 
Calogero and co- workers have shown that the inhibitory actions of both PRL and 
CRH on GnRH pulsatile release involves the activation of opioid interneurons 
(Calogero et al, 1994). In vivo studies have also demonstrated the involvement of 
opioid interneurons, as the effects of estrogen on GnRH secretion in ovariectomised 
monkeys (Grosser et al, 1993) together with the action of neuropeptide Y on GnRH 
release in rats (Xu et al, 1993), can be blocked by the opioid antagonist naloxone. 
GnRH pulsatile secretion can be modulated by many factors and this diverse 
regulation is also reflected in the signal transduction pathways activated. Protein 
kinase A and C activation are responsible for many of the Cat+ dependent events and 
recently, nitric oxide has been postulated as having an important second messenger 
function (Mahachoklertwattana et al, 1994). 
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2.3 GnRH - Its action at the pituitary 
Once released into the portal circulation GnRH travels to the anterior pituitary where it 
binds to specific receptors located on pituitary gonadotroph cell membranes (section 
2.6). Ligand- receptor binding induces micro- aggregation and dimerisation of receptor 
molecules (Conn et al, 1984) and the resulting receptor conformational change triggers 
a complex series of intracellular signal transduction events. These signals stimulate 
gonadotrophin hormone synthesis and their packaging into secretory granules. LH 
and FSH are finally exocytosed from the gonadotroph cells into general circulation and 
transported to their target organs - the gonads. 
2.3.1 Structure of gonadotroph cells 
Immunoperoxidase staining of gonadotrophs reveals that many of these cells are 
immunopositive for both hormones (Horvath and Kovacs, 1995). However, the 
existence of monohormonal producing cells and variations in the number of cells 
staining for both LH and FSH suggests that gonadotrophin production alters with 
functional demand. As yet, it is unclear whether these observations reflect different 
cell subpopulations or merely cells in different secretory phases. At the ultrastructural 
level gonadotrophs are large oval cells, with short profiles of dilated rough endoplasm 
reticulum (ER), containing an electron lucent substance, a ring -like Golgi complex and 
secretory granules. Gonadotrophins are localised within secretory granules and are 
categorised by cell size and granin content. Small (150 -250 nm in diameter) electron 
dense granules contain primarily LH and secretogranin II, while large granules (350- 
450 nm) contain mostly FSH, with a small amount of LH, together with 
chromogranin A (Asa et al, 1995; Famworth, 1995). 
The mechanisms controlling the differential secretion of LH/FSH from gonadotroph 
cells are largely unknown. Gonadotrophs phasically secrete LH and FSH in response 
to a GnRH- induced rise in [Ca2 +]i. FSH (but not LH) secretion is also regulated 
independently of GnRH, in a tonic manner, via mechanisms involving non -steroidal 
factors. The existence of different regulatory systems may be indicative of separate 
signal transduction networks and their independent activation could provide the 
stimulus for physically distinct exocytosis pathways. It has been postulated that the 
large, mainly FSH- containing secretory granules or possibly the synaptic -like 
vacuoles selectively respond to activin, inhibin and follistatin. In this way, non- 
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steroidal factors may differentially regulate FSH secretion (Farnworth, 1995). The 
potential mechanisms underlying such regulation, however, have still to be elucidated. 
2.3.2 Structure of gonadotroph genes 
Each glycoprotein hormone consists of a common a subunit and a different ß subunit 
which is responsible for conferring hormone specificity. a and ß subunits are linked 
by covalent disulphide bonds and are only biologically active in this heterodimeric 
structural form. The a subunit gene contains four exons and three introns. Cyclic 
adenosine monophosphate (cAMP) regulates gene transcription by binding to a 
specific DNA sequence. A 18 bp palindromic cAMP response element (CRE) together 
with a cAMP protein binding site have been identified in the 5' flanking region of the 
gene (Gharib et al, 1990). Mellon and co- workers have identified a region in all 
mammalian a subunit genes responsible for conferring gonadotroph specificity. The 
accordingly named gonadotrophin specific element (GSE) binds a 54 kDa protein, 
known as GSE- binding protein 1 (GSEB1) (Horn et al, 1992), and this has recently 
been identified as the orphan nuclear receptor SF -1 (Barnhart and Mellon, 1994). 
Experiments, incorporating the proximal 1.6 kb 5' flanking sequence of the human 
gene into primary pituitary cell cultures and transgenic mice, have shown that this 
portion of the gene is responsible for its expression (Burrin and Jameson, 1989). 
The LH ß and FSH ß subunit genes each contain 3 exons and 2 introns. Sequence 
analysis reveals that an ERE is present in the 5' flanking regions of each gene but, 
apart from this consensus sequence, the two ß subunits share little homology (Gharib 
et al, 1990). The region of the LH ß or FSH 13 gene responsible for conferring 
biological specificity has still be to identified (Fallest et al, 1995; Kumar and Low, 
1994). 
2.3.3 Regulation of gonadotrophin secretion 
Regulation of gonadotrophin secretion occurs at various sites along the hypothalamic - 
pituitary axis. Direct modulation of anterior pituitary function can either increase 
(positive feedback) or decrease (negative feedback) the sensitivity of gonadotrophs to 
GnRH. Alternatively, regulation of the hypothalamic GnRH pulse generator activity 
(see section 2.2.5) directly, or indirectly through modulation of interconnecting 
neuronal systems, affects FSH and LH secretion from the pituitary. In many 
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instances regulation at both these sites is known to occur and steroid factors, in 
particular, play a fundamental role in the regulation of gonadotrophin release. 
Regulation by GnRH 
GnRH- mediated regulation of gonadotrophin synthesis and secretion has been studied 
extensively in animal models in vivo and in pituitary cell cultures in vitro. Knobil 
showed that gonadotrophin secretion could be re- established in rhesus monkeys 
lacking endogenous GnRH (as a result of hypothalamic lesions) by exogenous 
pulsatile administration of the hormone (Knobil, 1980). In addition to its affects on 
hormone secretion GnRH also alters the level of gonadotrophin gene expression. In 
cell culture systems the effects of GnRH are controversial but it is generally thought to 
stimulate the transcription of all gonadotrophin subunits (Ben -Menahem and Noar, 
1994; Shupnik, 1990). The rate of transcription of each subunit is however 
differentially regulated by GnRH with faster pulse frequencies increasing a and LH ß 
subunit expression, whereas slower frequencies stimulate only the expression of the 
FSH ß subunit gene (Bhasin and Swerdloff, 1995). This observation has led to 
speculation that the differential secretion of LH and FSH from the anterior pituitary 
gland is dependent on the pattern of GnRH pulses. 
Regulation by steroids 
In primates and rats, estradiol both inhibits and stimulates gonadotrophin gene 
expression and hormone secretion (Gharib et al, 1990). It has been postulated that the 
inhibitory actions of estrogens are mediated mainly through the hypothalamus (Wray 
et al, 1989; Yamaji et al, 1992; Shupnik et al, 1989), whereas the stimulatory actions 
occur at the anterior pituitary gland (Knobil, 1980; Kamel et al, 1987). However, 
negative effects of estrogens at the level of the pituitary gland have also been 
demonstrated by Knobil (1980), who observed that estrogen treatment of 
hypothalamic -lesioned monkeys resulted in a suppression of LH secretion. Evidence 
to support a hypothalamic site for positive estrogen regulation has also been shown 
(Kamel et al, 1987). 
A great deal of uncertainty surrounds the role of progesterone in the control of 
gonadotrophin secretion. During the luteal phase of the human, monkey and sheep 
menstrual cycle, when progesterone concentrations are at their highest, LH pulse 
frequency is decreased (Hauger et al, 1977; Soules et al, 1984; Van -Vugt et al, 1984). 
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In the rat, however, progesterone appears to alter GnRH pulse amplitude (Weick and 
Noh, 1984). Hypothalamic regulation of GnRH release by progesterone is thought to 
involve opioidergic pathways (El Etr et al, 1995; Van-Vugt et al, 1984). Progesterone 
may also act to enhance both the stimulatory and inhibitory effects of estradiol on 
gonadotrophin regulation (Bhasin and Swerdloff, 1995). 
Non -steroidal regulation 
Additional non -steroidal factors have been identified that are capable of modifying 
FSH gene expression and secretion. The hormones inhibin, activin and follistatin 
were first isolated in the gonads but have since been discovered in the anterior pituitary 
gland. Their localisation within the pituitary gland suggests that local paracrine and 
autocrine feedback mechanisms may be in operation (Bhasin and Swerdloff, 1995). 
2.4 GnRH analogue design 
The manufacture of GnRH analogues was made possible by the development of solid 
phase peptide synthesis (Merrifield, 1963) and more than 3000 analogues have been 
made to date. The majority of work has endeavoured to generate more potent 'super - 
agonist' compounds, with an increased receptor affinity and a reduction in peptide 
degradation. 
2.4.1 GnRH agonists 
GnRH agonists with an increased potency are achieved by replacing the glycine (Gly) 
amide at position 10 with an ethylamide (Fujino et al, 1972) or substituting the Gly at 
position 6 with a D -amino acid (Monahan et al, 1973). The most clinically used 
analogues are [D -Leu6, Pro9, NEt] -GnRH (Leuprolide, Abbott Laboratories), [D- 
Trp6, Pro9, NEt] -GnRH (Salk Institute), [N- Bzl- D -His6, Pro9, NEt] -GnRH 
(Histrelin, Ortho Population Council), [D- Nal(2)6] -GnRH (Nafarelin, Syntex), [D- 
Ser(But)6, Pro9, NEt] -GnRH (Buserelin, Hoechst -Roussel) and [D- Ser(But)6, Aza- 
G1y10] -GnRH (Zoladex, ICI), which are 50 -200 times more potent than GnRH. 
Analogues with modifications in other positions are generally uncommon but [N -Me- 
Leu7] -GnRH and [1- 1 -Na13 ] -GnRH also show agonist properties (Karten and Rivier, 
1986). Although many compounds have been synthesised with amino acid 
substitutions in positions 1, 2, 4, 5, 8 and 9 none of these compounds show an 
increase in receptor affinity compared to the native peptide ( Karten and Rivier, 1986). 
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2.4.2 Antagonists 
Antagonists bind to the recognition site within the receptor but prevent the 
conformational structural changes that activate the signal transduction pathway. The 
rationale behind the design of GnRH antagonists is their potential use as safe, non - 
steroidal female contraceptive agents and in 1972, Vale and co- workers manufactured 
the first antagonist [des- His2] -GnRH (Vale et al, 1972). The next major breakthrough 
came with the manufacture of [D -Phe2, D -Ala6] -GnRH (Corbin and Beatty, 1975) 
which was the first antagonist to inhibit ovulation in rats. Additional modifications at 
position 3, [D -Phe2, D -Trp3, D -Lys6] -GnRH (Seprodi et al, 1978), further increased 
the antagonist affinity but none of these compounds could be clinically used due to 
their histaminic side effects. The second generation of antagonists, known as the 4 -F 
antagonists, contained a substitution at position 1 ([Ac -2 -D -Nall, 4 -F -D -Phe2, D- 
Trp3, D -Arg6] -GnRH) together with further substitutions at positions 2, 3, and 6. 
This greatly enhanced potency, but the anaphylactic side effects remained (Karten and 
Rivier, 1986). More recently designed analogues such as Antide ([Nal-Lys,(Ac-D - 
Nall, D -4 -Cl -Phe2, D -Pal3, Nic -Lys5, D -Nic -Lys6, Ip -Lys8, D- A1a10] -GnRH) and 
Cetrorelix ([Ac -D -Nall, D -4 -Cl -Phe2, D -Pal3, D -Citó, D- A1a10] -GnRH) cause much 
lower levels of histamine release and are particularly promising for clinical use. 
With advances in protein technology it is now possible to synthesise antagonists with 
a very high biological potency. Structure -activity studies have shown that the most 
potent analogues contain D -Nal or D -Qal in position 1, D- pC1Phe in position 2, D -Pal 
in position 3, cPzACAIa or PicLys in position 6, ILys or Arg in position 8 and D- 
AlaNH2 in position 10 (Janecka et al, 1994). When designing drugs, clinical tolerance 
is also an important factor to consider. In the case of GnRH antagonists, side effects 
have greatly limited their therapeutic use and studies have shown that histamine release 
results from the presence of a D -amino acid at position 6 combined with a highly basic 
Arg at position 8 and a cluster of hydrophobic residues at the amino terminus (Schmidt 
et al, 1984). It is now possible to reduce the histaminic effects by substituting Arg8 
with isopropyllysine (ILys) (Janecka et al, 1994). 
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2.5 Clinical uses of GnRH 
The clinical applications of GnRH and its analogues has been comprehensively 
reviewed by Barbieri (1992), Conn and Crowley (1994) and Sandow (1983). 
Therefore only directly relevant information will be covered in this section. 
The pulsatile secretory nature of endogenous GnRH allows dual manipulation of 
gonadotrophin secretion by exogenously administered GnRH or its analogues. 
Pulsatile administration of low doses of GnRH /GnRH agonists results in the 
stimulation of gonadotrophin secretion and has important clinical applications in 
conditions requiring activation of the pituitary -gonadal system. In contrast, 
continuous administration of high doses of GnRH agonists desensitises pituitary 
GnRH -Rs, so preventing gonadotrophin release ('selective medical 
hypophysectomy'), and consequently inhibiting ovarian and testicular steroid 
production ('medical castration'). Chronic GnRH administration can therefore be 
applied to medical situations requiring suppression of the pituitary- gónadal axis. The 
main problem associated with GnRH agonist- induced pituitary/gonadal suppression is 
the initial stimulation of LH and FSH secretion before receptor desensitisation occurs. 
In many cases it can take upto 14 days to fully suppress the pituitary- gonadal axis and 
the gonadotrophins initially released can aggravate certain disease states which is 
particularly undesirable in the treatment of hormone dependent neoplasms. 
GnRH treatment has been successfully used to restore normal reproductive function to 
patients suffering from hypogonadotrophic hypogonadism, characterised by a 
complete absence of GnRH secretion. Exogenous administration of GnRH, at rates of 
12 pulses / 24 hours in males and - 18 -24 pulses / 24 hours during the follicular 
phase or - 6 -10 pulses / 24 hours during the mid -luteal phase of the cycle in 
menstruating females, establishes normal gonadotrophin secretory patterns (Crowley 
et al, 1985). Activation of the pituitary -gonadal axis by pulsatile administration of 
GnRH has also been successfully employed to accelerate gonadal development in 
cryptorchidism and to induce ovulation in women suffering from primary /secondary 
amenorrhea. 
GnRH agonist-induced suppression of the pituitary gonadal axis has many clinical 
applications being successfully used to delay gonadal maturity in children with 
precocious puberty, decrease the incidence of spontaneous LH surges in in vitro 
fertilisation programmes as well as in the treatment of polycystic ovarian disease and 
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pre -menstrual syndrome. Additionally, GnRH agonists have important therapeutic 
value in treating diseases stimulated by sex hormones. Estrogen- dependent conditions 
such as endometriosis and uterine fibroids can be effectively treated by GnRH 
agonists: however, the hypoestrogenic state produced by prolonged medical castration 
results in post -menopausal like symptoms. Recent evidence suggests that the hot 
flushes and bone density loss can be alleviated by the reintroduction of small doses of 
estrogen/progestin without compromising the overall outcome of the treatment regime 
(Lemay et al, 1994). 
2.5.1 Treatment of hormone -dependent neoplasms 
GnRH agonists are now widely used in the treatment of hormone- dependent prostate 
and breast cancers and may also have beneficial effects in the treatment of ovarian 
epithelial cancer, ovarian sex cord stromal tumours and endometrial cancer (clinical 
trials ongoing) (Emons and Schally, 1994). In addition to the withdrawal of sex 
steroids, the antiproliferative action of GnRH on neoplastic tissue may be direct 
through GnRH -Rs present in the tumour cells (see subsections 2.13.2 -5). 
The main disadvantage of GnRH agonist- induced pituitary -gonadal suppression is the 
initial aggravation, known as 'disease flare', resulting from gonadotrophin stimulation 
of steroid production. However, it is possible to immediately reduce gonadotrophin 
secretion by using GnRH antagonists to directly block the pituitary GnRH -R ligand 
binding site. Realisation of the therapeutic potential of GnRH antagonists resulted in 
the synthesis of many antagonist compounds but their clinical use has been 
complicated by severe histaminic side effects. Recently new antagonists have been 
developed and clinical trials have shown that Cetrorelix is effective in the treatment of 
advanced carcinoma of the prostate (GonzalesBarcena et al, 1994). The potential use 
of GnRH antagonists for the treatment of other gynaecological disorders, including 
polycystic ovarian disease, endometriosis and uterine fibroids, is also under review 
(Reissmann et al, 1994). 
2.6 The pituitary GnRH -R 
GnRH binds with high affinity to receptors located in pituitary gonadotroph cell 
membranes. Whilst the amino acid structure of the ligand was identified in the early 
1970s (Burgus et al, 1972; Matsuo et al, 1971) it took another 20 years to elucidate the 
structure of the receptor. The main problem was the low concentration of protein 
Chapter 2 Literature Review 25 
receptor in pituitary tissue but this was successfully resolved with the development of 
aT3 -1 cells, a gonadotroph cell line containing approximately 2 -5 pmols GnRH -R per 
mg of protein (Horn et al, 1991). A cDNA library was generated from aT3 -1 mRNA 
and this provided the starting material for the cloning of the mouse GnRH -R cDNA. 
2.6.1 Molecular cloning of mammalian GnRH -R 
In 1992, Tsutsumi et al, cloned the mouse GnRH -R cDNA using a polymerase chain 
reaction (PCR) based homologous screening strategy. Degenerate oligonucleotides 
with consensus sequences to TM III and TM VI domains of other GPCRs were used 
as primers in PCR reactions with an aT3 -1 derived DNA template. The novel PCR 
sequences were then tested for their ability to block GnRH -R expression using a 
Xenopus oocyte hybrid arrest expression system. This experimental approach relies 
on an antisense oligonucleotide (derived from the sequence obtained in PCR) blocking 
the expression of the appropriate receptor in Xenopus oocytes. One of the 
oligonucleotides generated fulfilled this criteria and was used as a probe to isolate a 
full length clone from an aT3 -1 cDNA library. The mouse GnRH -R cDNA sequence 
derived using this method has since been confumed by two other independent groups 
(Perrin et al, 1993; Reinhart et al, 1992). Sequences of the rat (Eidne et al, 1992; 
Kaiser et al, 1992; Perrin et al, 1993), human (Chi et al, 1993; Kakar et al, 1992), 
cow (Kakar et al, 1993) and sheep GnRH -Rs (Brooks et al, 1993; Tiling et al, 1993) 
have also been determined. The sequences of the five different species of GnRH -R 
isolated to date are illustrated in Figure 2.3. 
2.6.2 Primary amino acid structure of the mammalian GnRH -R 
The mouse and rat GnRH -R is composed of 327 amino acids but the human, sheep 
and cow sequences contain an additional amino acid in the second extracellular 
domain. Interestingly, the GnRH -R shares the greatest sequence homology with the 
interleukin -8 receptor and not with any other hypophysiotrophic releasing -hormone 
receptor. The GnRH -R is classified as a member of the G- protein coupled receptor 
(GPCR) superfamily and contains certain characteristics common to this group. 
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Figure 2.3 Amino acid sequence of the GnRH -R in different mammalian species 
Amino acid sequence of the human (Kakar et al, 1992), cow (Kakar et al, 1993), sheep (Brooks et al, 
1993), mouse (Tsutsumi et al, 1992) and rat GnRH -R (Eidne et al, 1992; Perrin et al, 1993). 
Identical amino acids are represented as and conservative substitutions by I. Position of the TM 
domains are based on the alignment of Henderson's bacteriorhodopsin model (Henderson et al, 1990). 
Chapter 2 Literature Review 27 
Hydropathicity analysis of the receptor structure reveals seven stretches of 
approximately 20 -25 hydrophobic amino acids which are thought to cross the 
membrane bilayer. Linked to these TM domains are an amino (NH2) terminus, three 
hydrophilic extracellular loops (el), three intracellular loops (il) and a carboxy (COOH) 
terminal region. 
Electron diffraction studies of two heptahelical proteins, bacteriorhodopsin and 
rhodopsin (Henderson et al, 1990; Schertler et al, 1993), have shown that the TM 
domains form a helices and are arranged together around a hydrophilic pore (see 
section 4.1.1). All GPCRs are thought to adopt this structural configuration. 
2.7 GPCRs - Common structural features 
Sequence alignment of many GPCRs has shown that certain amino acid residues 
occupy conserved positions (Probst et al, 1992). Furthermore, it has been suggested 
that these conserved residues mediate common structural changes ensuing from 
ligand- receptor activation (Baldwin, 1994). A great deal of information can be derived 
by comparing the common and unique features of one receptor subgroup with another 
and much of the early work on structure- function relationships was carried out in ß 
adrenergic receptors. The following subsection deals with the common features of 
GPCRs and those features which are unique to the GnRH -R. 
2.7.1 Glycosylation sites 
The majority of GPCRs contain conserved consensus sequences (Asn -X- Ser/Thr) for 
N- glycosylation of Asn residues. The role of glycosylation in structure -function 
relationships has been examined in catecholamine and glycoprotein receptor subtypes. 
In the ß adrenergic receptor two glycosylation sites have been identified, at Asn6 and 
Asn 15 (Rand et al, 1990), and the substitution of either Asn for Gln results in a 
receptor with normal binding properties but at a reduced level of expression. From 
these experiments it was postulated that receptor glycosylation may have a role in 
protein trafficking to the cell surface. A role for N- linked glycosylation in 
glycoprotein hormone binding has also been proposed, as substitution of glycosylated 
Asn residues in TSH/LH receptors results in a loss of hormone binding (Russo et al, 
1991; Zhang et al, 1991). However, further studies in this receptor group have 
revealed that loss of receptor binding is mediated directly by the Asn residue itself and 
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not from a failure of carbohydrate attachment (Lui et al, 1993). All mammalian forms 
of the GnRH -R contain two potential glycosylation sites at Asn18, in the NH2 
terminus of the receptor, and at Asn 102 in el 1. The mouse and rat form of the 
GnRH -R contain an additional site at Asn4. Photoaffinity labelling studies have 
shown that the mouse GnRH -R is glycosylated at Asn4 and Asn18 but not at Asn 
102. Substitution of Asn4, Asn18 or Asn102 with Gln yielded mutant receptors with 
normal binding affinities for GnRH analogues but reduced receptor expression. 
Glycosylation of the GnRH -R therefore appears critical in expression and stability of 
the receptor structure (Davidson et al, 1995). These results together with those 
obtained from studies in the ß adrenergic receptor suggest that the main role of Asn - 
linked oligosaccharides is in the regulation of cell surface protein expression. 
However, in some receptors, such as the muscarinic M2 receptor, glycosylation is not 
involved in hormone binding or receptor expression suggesting that the effects of N- 
linked receptor glycosylation are receptor specific. 
2.7.2 Disulphide bridge formation 
A striking feature of most GPCRs is a pair of conserved cysteine (Cys) residues in the 
el 1 and el 2. These Cys residues are thought to form a covalently linked 'disulphide 
bridge' structure and their function has been studied in many heptahelical receptor 
proteins. Site -directed mutagenesis studies in rhodopsin have indicated that conserved 
extracellular Cys residues are involved in receptor expression (Karnik et al, 1988) and 
the stabilisation of the light -activated protein (Davidson et al, 1994). Similar studies 
have been carried out with the muscarinic M1 (Savarese et al, 1992), ß adrenergic 
(Dohlman et al, 1990) and angiotensin II receptors (Yamano et al, 1992). Many 
GPCRs also contain non -conserved Cys residues in their extracellular domains. The 13 
adrenergic receptor contains four extracellular Cys residues and it is thought that these 
residues form two disulphide bridges with, paradoxically, each bond occurring 
between a conserved Cys and a non -conserved Cys residue (Noda et al, 1994). 
Although it is not known exactly which Cys residues in the extracellular domains of 
the GPCRs are able to form disulphide bonds, it has been proposed that extracellular 
disulphide links are important in stabilising the three -dimensional inter -helical receptor 
structure (Baldwin, 1994). The rat GnRH -R contains four extracellular Cys residues 
with the two conserved residues at positions 114 and 195 in the el 1 and el 2 
respectively. The additional non -conserved two Cys residues lie at position 14 in the 
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NH2 terminus and position 199 in the el 2 (Eidne et al, 1992). The role of these Cys 
residues in putative disulphide bond formation will be investigated in Chapter 5. 
2.7.3 Amino acids involved in ligand- induced conformation changes 
Following ligand- receptor binding all GPCRs activate a specific concert of G- proteins 
present on the inside of the cell membrane. Whilst the actual mechanisms responsible 
for transducing the signal across the membrane are unknown, it is postulated that 
ligand activation induces a conformational change in the receptor structure triggering a 
signal transduction cascade mechanism. It is reasonable to presume that there are 
common features of GPCRs which could facilitate this process and helix breaking 
proline (Pro) residues, commonly present in the TM domains of many GPCR, may 
fulfil this function (Probst et al, 1992). The rat GnRH -R contains a series of 
conserved Pro residues at positions Pro173 (TM IV), Pro222 (TM V), Pro281 (TM 
VI) and Pro315 (TM VII) and these amino acids are thought to be involved in the 
transfer of energy from agonist binding to conformational changes in the intracellular 
domain (Millar et al, 1993). Additional Pro residues are also located at Pro96 (TM II) 
and Pro 128 (TM IV) and these together with an Asn 53 (TM I), the sequence Phe -X- 
X- Cys -Trp -X -Pro (TM VI) and Asp -Asn -Ser (TM HIM 3) (Sealfon and Millar, 1995) 
have also been implicated as potential molecular switches in the GnRH -R binding - 
transduction relay mechanisms (Millar et al, 1993). 
2.7.4 Ligand binding in GPCRs 
Amino acids contained within TM III appear to be particularly important in ligand- 
receptor binding. In the a adrenergic, ß adrenergic, and muscarinic M1 receptors an 
Asp in TM III is necessary for the maintenance of high affinity agonist and antagonist 
binding. This amino acid is thought to interact with the positively charged amine head 
group of the ligand (Savarese and Fraser, 1992). In the GnRH -R, a Lys residues lies 
in TM HI, at a position analogous to Asp 113 in the ß adrenergic receptor, and this 
residue may also be important in agonist- induced receptor binding. Site -directed 
mutagenesis studies show that substitution of Lys to Arg in both the rat (see Chapter 
7) and human (Zhou et al, 1995) GnRH -R does not affect receptor function. 
However, substitution of Lys 121 to Gln (in the human GnRH -R) resulted in a 
receptor with a decreased agonist affinity but with an apparently intact high affinity 
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antagonist binding site. The function of Lys 121 in GnRH -R binding is further 
considered in Chapter 7. 
2.7.5 Relationship between GnRH and the GnRH -R structure 
Site -directed mutagenesis studies often highlight key amino acids within a receptor 
structure that are important for ligand binding. However, to fully map a receptor 
ligand binding domain it is also essential to examine the structure of the ligand so that 
specific interactions between residues in the ligand and those in the receptor can be 
identified. Analysis of the GnRH amino acid sequences (Table 2.1, pg14) reveals a 
50% homology between the 6 different species with position 8 as the most variable. 
Chemical studies have indicated that mGnRH interacts with at least 2 carboxyl groups 
in the receptor (Hazum, t987) and the positively charged nature of Arg8, in the 
mammalian peptide, makes it a likely candidate for such interactions. Recently, ionic 
binding between Arg8 in the peptide and Glu301 in the GnRH -R has been proposed 
(Davidson et al, 1994) and it has been postulated that this interaction conforms the 
ligand into a special structural entity which facilitates receptor binding. Tyr and Trp 
residues within the GnRH -R structure have also been implicated in GnRH binding 
(Keinan and Hazum, 1985) and these two amino acids could participate in aromatic 
stacking or in charge -transfer interactions. The indole nucleus of the Trp is electron 
rich and could feasibly interact with a protonated imidazole ring of histamine while the 
phenolic Tyr hydroxyl group could also be involved in hydrogen bonding (Janecka et 
al, 1994). 
Rivier and co- workers proposed that in its biologically active state GnRH binds to its 
receptor in a hairpin configuration with residues 4 -7 (Ser- Tyr- Gly -Leu) (Karten and 
Rivier, 1986), creating a ß turn. The alignment of the NH2 and COOH termini 
together (Monahan et al, 1973) ensures that only the ends of the GnRH peptide will 
interact directly with the receptor. Residues at the NH2 terminus of GnRH are thought 
to be important in receptor activation whilst those at the COOH end are crucial for high 
affinity binding (Nikolics et al, 1988). The role of amino acids at positions 4 -7 are 
probably structural. However, it is possible that certain residues participate in both 
receptor binding and functional activation and that individual amino acids do not act 
alone but as a structural unit. 
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2.7.6 Residues important in signal transduction 
Following ligand- receptor binding in GPCRs, a three -dimensional conformational 
change within the structure of the receptor activates a specific G- protein system located 
on the intracellular surface of the membrane. Like the amino acids involved in 
receptor binding function, both conserved and uniquely positioned receptor residues 
are likely to participate in G- protein activation. Site - directed mutagenesis and receptor 
chimera studies have implicated intracellular regions of GPCRs, especially the it 2, it 3 
and occasionally the COOH tail, in ligand- receptor activation processes (Caron and 
Lefkowitz, 1993; Probst et al, 1992; Savarese and Fraser, 1992). In particular, a 
conserved motif sequence Asp -Arg -Tyr (DRY), located at the TM III/il 2 interface, is 
thought to be involved in signal transduction mechanisms. Mutation of the Asp part of 
the sequence in the ß adrenergic, muscarinic M1 and a2 adrenergic receptors results in 
mutant receptors that display a high affinity binding site but, reduced or absent G- 
protein coupling (Savarese and Fraser, 1992). In rhodopsin, the corresponding Gln is 
also thought to be involved in signal transduction mechanisms (Savarese and Fraser, 
1992). 
In the muscarinic receptor, a Leu lying in close proximity to the DRY sequence in it 2 
has been implicated as an important residue in both signal transduction and receptor 
sequestration (Moro et al, 1993; 1994). A corresponding positioned Leu residue 
(Leu147) in the GnRH -R also appears important in G- protein activation and second 
messenger production. A study by Arora et al (1995) has demonstrated that 
substitution of Leu 147 to either Ala or Asp significantly alters second messenger 
production whilst retaining normal receptor binding function. However, in these 
studies some second messenger production was still detected implying that other 
receptor residues must also be involved. 
2.8 Unique features of the GnRH -R 
The GnRH -R exhibits unique features which make it distinct from other members of 
the GPCR family including the replacement of the Tyr residue in the conserved DRY 
motif in it 2, together with the interchange of a conserved Asp and Asn in helix 2 and 
helix 7 respectively. The most striking feature, however, is the total absence of a 
COOH tail making it the only GPCR cloned to date missing this structure. 
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2.8.1 Role of DRS sequence in the GnRH -R 
As highlighted in section 2.7.6, the DRY motif has been implicated in signal 
transduction mechanisms. In the GnRH -R this motif is altered to DRS thus generating 
a potential phosphorylation site. Site -directed mutagenesis studies, substituting a Tyr 
residue in place of Ser140 (the Ser residue in the DRS sequence) has shown that 
Ser140Tyr does not affect G- protein coupling but significantly increases receptor 
affinity and the rate of GnRH -R internalisation (Arora et al, 1995). 
2.8.2 Asp and Asn interchange 
An Asp in TM II and an Asn in TM VII are conserved in 98% and 95% of GPCRs 
respectively but in GnRH -R the positions of these two conserved amino acids are 
interchanged with Asn87 in TM II and Asp318 in TM VII. The role of the Asp in TM 
II has been examined in many neurotransmitter receptors. Site -directed mutagenesis 
studies replacing Asp with other amino acids has resulted in a wide variety of 
functional effects including reduced agonist/antagonist binding, diminished or loss of 
receptor activation and a loss of receptor modulation by pH, sodium, or GTP 
analogues (Zhou et al, 1993). The involvement of Asn in TM VII in ligand binding 
and receptor activation has not been so extensively studied. However, an 
experimental investigation in the 5 -HT1A receptor, substituting Asn396 (TM VII) to 
Ala/Phe/Val, has shown that this amino acid is essential for receptor binding (Chanda 
et al, 1993). 
The role of Asn87 in TM II and Asp318 in TM VII in the GnRH -R will be 
investigated in Chapter 6. 
2.8.3 Absence of COOH tail 
In other GPCRs the intracellular COOH domain is involved in the maintenance of 
receptor stability and phosphorylation -mediated receptor desensitisation (Savarese and 
Fraser, 1992). An increase in receptor stability occurs through palmitoylation of Cys 
residues, a process that facilitates interactions between the COOH tail and the 
membrane bilayer resulting in remodelling of the receptor structure to create another it 
(O'Dowd et al, 1989). As the GnRH -R lacks a COOH tail some of its functions 
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(stabilisation and receptor desensitisation) may be taken over by amino acids located in 
other parts of the receptor. Regions within the receptor involved in membrane 
stabilisation have yet to be identified but there are eight consensus phosphorylation 
sites (putative targets for protein kinases), at threonine (Thr) 64 and Ser 74 in the il 1, 
Ser140, Ser1S1, Ser153 and Ser158 in the il 2 and Thr238 and Thr264 in the il 3 in 
the rat GnRH -R. 
2.9 Receptor desensitisation and down -regulation 
mechanisms 
Desensitisation is generally defined as the attenuation of a biological response upon 
prolonged exposure to agonists. The ability to suppress the pituitary- gonadal axis 
through desensitisation of the GnRH -R underlies the clinical use of GnRH agonists 
and it is, therefore, vital to understand the mechanism by which such events arise. 
Exposure of the GnRH -R to its agonist induces a state of homologous desensitisation 
that results in a functional uncoupling of the receptor from its G- protein and effector 
system. Moreover, the responsiveness of other receptors utilising the same G- 
protein/effector system are unaffected by this desensitisation mechanism. In other 
GPCRs protein kinase dependent phosphorylation of Ser and Thr residues, in the il 3 
and COOH terminal tail, are important in G- protein uncoupling events. Specific 
receptor kinases in the ß adrenergic (Benovic et al, 1987) and rhodopsin (Hargrave 
and McDowell, 1992; Savarese and Fraser, 1992) systems have been shown to 
mediate these events. In the GnRH/GnRH -R system phosphorylation of Ser/Thr 
residues in the it 3 are also thought to be important but the mechanisms underlying 
receptor phosphorylation and the possible sites of action in the signal transduction 
cascade pathway are largely unknown. 
Studies in aT3 -1 cells have shown that rapid exposure of these cells to GnRH does 
not affect the production of the second messenger inositol 1,4,5 trisphosphate (InsP3), 
implying that agonist- induced G- protein uncoupling processes are mediated at sites 
down -stream of phospholipase C (PLC) membrane hydrolysis (Anderson et al, 1995) 
(see subsection 2.12). Further experiments in aT3 -1 cells have revealed that a single 
high dose pulse of GnRH rapidly desensitises GnRH- induced biphasic Cat+ release 
and, therefore, it is possible that G- protein uncoupling events are related to alterations 
in Calf. mobilisation (Anderson et al, 1995). Several other hypotheses have been put 
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forward with Milligan and co- workers suggesting that as multiple G- proteins can be 
stimulated by a single receptor type, G- protein uncoupling may result from preferential 
desensitisation of one G- protein over another (Milligan, 1993). 
The loss of G- protein coupling leads to the attenuation of gonadotrophin release from 
secretory granules. It has been further suggested that the decrease in LH secretion 
might result from a decrease in LH movement from non -releasable to releasable stores, 
with this movement being progressively diminished as agonist exposure time is 
increased, causing an eventual loss of gonadotrophin secretion (Janovick and Conn, 
1993). 
In addition to the influence on G- protein coupling and hormone secretion continuous 
agonist exposure directly affects the specific receptor that is responsible for the 
mediation of its actions. Continuous exposure of GnRH to the GnRH -R results in 
receptor sequestration, a process involving the removal of the receptor from the cell 
surface by internalisation. This loss in receptor number occurs in minutes to hours 
and is reversible on removal of GnRH. Arora and co- worker identified two sites 
within the GnRH -R that are involved in mediating receptor internalisation processes, 
Ser140 (part of the DRS motif) and Leu147. The substitution of these amino acids, 
Ser140 by Tyr and Leu147 by either Ala or Asp, affected levels of receptor 
internalisation. The Ser140Tyr mutation increased internalisation rates whilst both 
Leu 147Ala and Leu 147Asp mutations showed a 50% reduction in receptor 
internalisation compared to the wild -type (Arora et al, 1995). Chronic exposure to 
agonist, however, eventually results in the degradation of internalised receptors. This 
process is irreversible and thus, the restoration of receptor number must occur by de 
novo protein synthesis. 
It is clear from the studies highlighted in this section that a complex series of processes 
underlies receptor desensitisation and many of these issues still have to be explored. 
2.10 GnRH -R gene structure 
The GnRH -R belongs to a small subset of intron -containing GPCRs that include the 
glycoprotein, opsin and endothelin receptor families (Probst et al, 1992). Within this 
subset receptors can be further categorised by the position of their introns. However, 
the GnRH -R gene stands alone as no other GPCR has a gene structure with a similar 
Chapter 2 Literature Review 35 
intron/exon pattern. Both the mouse (Albarracin et al, 1994; Zhou and Sealfon, 1994) 
and human (Fan et al, 1994) GnRH -R genes have been cloned and consist of at least 
three exons and two introns, with the human gene localised as a single copy to 
chromosome 4 (Fan et al, 1994; Morrison et al, 1994). 
Analysis of the human gene structure shows that the first exon contains the 5' 
untranslated region and the open reading frame encoding for TM I -III and part of TM 
IV, the second exon codes for the remainder of TM IV and TM V and the third exon 
encodes the rest of the open reading frame and the 3' untranslated region. Of the two 
introns, the first (4.2 kb) is positioned between Gln174 and Leu175 (TM IV) and the 
second (5 kb) is between G1u248 and Leu 249 (il 3). The sequence of the mouse gene 
also appears to contain the same intron/exon pattern. Alternative spliced variants have 
been identified although these do not code for functional active receptors (Zhou and 
Sealfon, 1994). 
Albarracin et al (1994) have recently characterised part of the 5' flanking region of the 
mouse GnRH -R gene. A major transcription start site was identified 62 nucleotides 
upstream of the translational start site; however, the promoter region of the GnRH -R 
gene does not appear to contain a TATA box sequence. This TATA -less phenomenon 
has also been observed in the other GPCR genes including the LH, FSH (Huhtaniemi 
et al, 1992) and the somatostatin -1 (Hauser et al, 1994) receptors. Putative sites for 
the transactivation factor AP -1 and a 8 bp element, TGTCCTTG, homologous to part 
of the 30 bp GSE (Horn et al, 1992), were also identified (Albarracin et al, 1994). 
Additional studies analysing the mouse GnRH -R gene promoter region by Clay and 
co- workers have reported the presence of another transcription start site approximately 
200 bp in the 5' direction of the initiation codon. This more distal transcription 
initiation site appears to be associated with a consensus TATA motif. Further 
experiments have revealed the presence of putative cell specific regulatory elements 
between -400 and -500 bp relative to the translational ATG start site (Clay et al, 1995). 
2.11 Regulation of the GnRH -R 
Regulation of GnRH -R biosynthesis is dependent on mechanisms controlling gene 
transcription, mRNA production and stability along with translational /post 
translational processes. Receptor degradation, sequestration and recycling of 
receptors between accessible and non -accessible pools, together with the 
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responsiveness of the GnRH -R to its ligand, can also affect the outcome of ligand - 
receptor coupling mechanisms. 
2.11.1 GnRH regulation of the GnRH -R 
The action of GnRH on the GnRH -R can result in both up- and down -regulation of 
the receptor depending on the duration and level of GnRH exposure. In vitro 
experiments, using dispersed rat pituitary cells, have shown that administration of low 
doses of GnRH result in an initial loss of GnRH -Rs but after 6 hours the receptor 
number increases above basal levels (Conn et al, 1984). In contrast, exposure to high 
concentrations of GnRH only results in receptor down -regulation (Conn et al, 1984). 
Additional studies have indicated that, within this system, receptor down -regulation 
occurs via processes that do not require RNA or protein synthesis, whereas the 
ensuing up- regulation appears dependent on both synthesis of mRNA and receptor 
protein (Sealfon and Millar, 1995). The role of extracellular calcium ([Ca2 +]e) in 
receptor up- regulation events is controversial. Early studies highlighted the 
importance of Cat+ cell entry (Conn et al, 1984), but recent experiments suggest that 
[Ca2 +]e is not required for de novo receptor synthesis (Braden and Conn, 1990). 
Treatment of aT3 -1 cells with a low dose of GnRH (0.1 -10nM) results in an initial 
decrease followed by an increase in receptor number. However, receptor up- 
regulation is not accompanied by changes in GnRH -R mRNA levels or RNA stability 
(Tsutsumi et al, 1993). Chronic exposure of aT3 -1 cells to GnRH (11..1M) decreased 
the number of GnRH binding sites by 75% after 24 hours. In these studies GnRH -R 
mRNA levels were not altered but RNA translational efficiency was reduced, 
suggesting that receptor down -regulation in aT3 -1 cells is in part mediated by changes 
in receptor translation mechanisms (Tsutsumi et al, 1995). These results contrast with 
those obtained in pituitary cell culture studies which indicate that up- regulation of the 
GnRH -R, following pulsatile administration of GnRH, corresponds to an increase in 
receptor mRNA production (Kaiser et al, 1993). The reasons underlying these 
differences are at present unknown. 
Many in vivo studies have also been carried out to monitor the regulatory effects of 
GnRH and its analogues on GnRH -R levels. These experiments have highlighted that 
the mode of GnRH presentation to the GnRH -R is the most important determining 
factor. Katt and co- workers demonstrated that GnRH- induced GnRH -R up- regulation 
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is dependent on the frequency of GnRH pulses administered (Katt et al, 1985). Other 
experimental studies in sheep have indicated that pulsatile administration of a low dose 
of GnRH increases both mRNA levels and GnRH -R numbers (Turzillo et al, 1995). 
In contrast, administration of high doses of a potent GnRH agonist suppresses both 
GnRH -R mRNA and receptor levels in rats and sheep (Clayton and Catt, 1980; 
Lerrant et al, 1995; Wu et al, 1994). 
2.11.2 Regulation of GnRH -R levels during the estrous cycle 
The rate of gene transcription and the number of GnRH -Rs change during the estrous 
cycle. Northern Blot analysis of the rat GnRH -R mRNA has shown that transcription 
levels increase during diestrus I reaching a 3 -fold maximum increase at diestrus II and 
then decline to a 2 -fold increase by the late proestrus stage of the cycle (Kakar et al, 
1994). A similar pattern has also been seen during the estrous cycle of the sheep 
(Brooks et al, 1993) with changes in mRNA in accord with changes in receptor 
numbers (Clayton et al, 1980). The changes observed in mRNA and receptor levels 
throughout the estrous cycle probably reflect alterations in the hormonal milieu with 
the actions of both steroidal and non -steroidal factors having important regulatory 
roles. GnRH -R gene regulation has been well characterised in both rats and sheep. 
Removal of gonadal steroids by castration results in an increase in GnRH -R mRNA 
levels in the rat anterior pituitary, which can be reversed by the introduction of 
exogenous steroids (Kaiser et al, 1993; Kakar et al, 1994). Non -steroidal factors 
activin and inhibin are also important regulators with activin A increasing the rate of 
GnRH -R synthesis (as measured by density shift techniques) (Braden and Conn, 
1992) and inhibin decreasing receptor numbers in rat primary pituitary cultures (Wang 
et al, 1988). Studies in ovine pituitary cell cultures revealed that estradiol, 
progesterone and inhibin alter GnRH -R responsiveness, as determined by GnRH- 
stimulated LH release (Sealfon and Millar, 1995). These changes correspond to 
receptor content, with the lowest receptor number present during treatment with 
progesterone and the highest number observed following co- administration of 
estradiol with inhibin. Further studies have revealed that the changes in receptor 
number are linked to gene transcription (Wu et al, 1994). 
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2.12 Activation of the GnRH -R and signalling pathways in 
pituitary gonadotrophs and aT3 -1 cells 
The binding of GnRH to its pituitary receptor is associated with G- protein coupling, 
activation of PLC, followed by Cat+ mobilisation and finally exocytosis of secretory 
hormones from the cell. Many studies examining intracellular signalling events utilise 
aT3 -1 cells, a clonally derived cell line of gonadotroph lineage, as a representative 
model (Horn et al, 1991). aT3 -1 cells were established from embryonic cells before 
the development of the gonadotrophin ß subunit and are therefore unable to secrete 
gonadotrophins. This limits their use to the study of events leading up to exocytosis 
but not the mechanisms underlying exocytosis itself. Figure 2.4 illustrates signal 
transduction pathways activated by the interaction of GnRH with its receptor. 
2.12.1 G- protein coupling 
Ligand- receptor binding induces conformational changes in the GnRH -R which are 
responsible for the activation of a G- protein complex - a heterotrimeric structure 
located on the cytoplasmic surface of the plasma membrane. G- proteins are composed 
of three individual subunits. The a subunit is receptor specific, containing a receptor 
activation site whereas the ß and y subunits exist as a common pool interchangeable 
between the different a subunits. In the inactive state, G- proteins have guanosine 
diphosphate (GDP) bound to the a subunit. Receptor activation creates membrane 
perturbations and stimulates the replacement of GDP for guanosine triphosphate 
(GTP), resulting in the dissociation of the complex into a and ßy subunit components 
(Speigel et al, 1992). The free a subunit can now stimulate an appropriate second 
messenger system but this activation is only temporary as GTPase activity, intrinsic to 
the a subunit, rapidly leads to G- protein inactivation. a subunits are categorised by 
function and bacterial toxin sensitivity. GnRH -R ligand binding activates the pertussis 
toxin insensitive G- proteins, Gay and Gall (Anderson et al, 1993; Naor, 1990). 
Studies in aT3 -1 cells have shown that the GnRH- induced second messenger activity 
can be blocked with an antiserum raised against Gay and Gall (Hsieh and Martin, 
1992). A role for the dissociated fry subunits has also been implicated in GnRH -R 
activation in GGH3 -1 cells (GH3 cells stably transfected with the rat GnRH -R 
cDNA). GnRH- stimulated increases in second messenger production and hormone 
secretion in GGH3 cells can be attenuated by co- transfection of GnRH -R cDNA with 
part of the ß adrenergic receptor kinase (BARK) cDNA. 13ARK1 contains an 125 
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amino acid sequence that directly binds to the ßy subunits and thus allows the 
distinction between Ga and Gßy activated pathways (Guo et al, 1995). 
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Figure 2.4 Multiplicity of GnRH- induced intracellular signalling in pituitary 
gonadotrophs 
Illustration of 3 major interconnecting signal transduction pathways activated by GnRH in 
gonadotroph cells. GnRH interactions with its receptor activates a G- protein effector system. This 
results in the production of two major second messenger molecules InsP3 and DAG via the action of 
PLC. InsP3 is responsible for the mobilisation of Cat+ whilst DAG further activates PKC. DAG 
production may also arise from the stimulation of the PLD2 pathways and this alternative pathway 
prolongs the activation of PKC. PKC activation has a positive feedback effect on PLD2 and PLA2 
signalling pathways. The production of AA is thought to arise from the activation of PLA2. AA can 
be further metabolised by cycloxygenase (CO) and lipoxygenase (LO) to prostaglandins (PGs) and 
leukotrienes (LKs) respectively. 
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Gaq and Gall activates the 131 and 132 PLC isoforms promoting the hydrolysis of 
phosphatidylinositol 4,5 bisphosphate (PIP2). The activation of PIP2 results in the 
formation of two important signalling molecules inositol 1, 4, 5 trisphosphate (InsP3) 
and diacylgylcerol (DAG) (Limor et al, 1989) (Figure 2.4). 
2.1 2.2 Inositol Phosphate Production 
GnRH induces a biphasic elevation of InsP3 in cultured pituitary cells (Morgan et al, 
1987) and aT3 -1 gonadotroph cells (Anderson et al, 1992). This response is 
characterised by an early peak followed by a sustained rise in InsP3 production. InsP3 
acts at a high affinity binding site, forming part of a InsP3 receptor /Ca2+ channel 
complex, and InsP3- induced channel opening results in the release of [Ca2 +]i from 
Ca2+ stores (Guillemette et al, 1987). The InsP3 receptor /Ca2+ channel contains four 
potential InsP3 binding sites (Mignery et al, 1990) but it is thought that occupation of 
one site is sufficient for channel opening (Finch et al, 1991). Other regulatory 
domains for cAMP kinase, Ca2+ and protein kinase C (PKC) have also been identified 
on the complex (Mignery et al, 1990) and these may mediate the modulatory action of 
these factors on Ca2+ release. Regulation of Ca2+ channel opening is complex but 
studies indicate that it is sensitive to the level of [Ca2 +]i and the level of Ca2+ in the 
lumen of the ER (Stojilkovic et al, 1994b). The action of a Ca2 +ATPase, which 
functions to regulate cytoplasmic Ca2+ levels, is also thought to be involved 
(Stojilkovic et al, 1994b). However, whilst all InsP3 receptor /Ca2+ channels contain 
InsP3 binding sites not all of them are sensitive to InsP3 thus resulting in a large non - 
releasable Ca2+ pool. 
Once activated InsP3 is rapidly metabolised either by 5' phosphatase activity to inositol 
1,4 bisphosphate or by 3- kinase activity to inositol 1, 3, 4, 5 tetraphosphate (InsP4) 
(Shears, 1992). Dephosphorylation prevents any further activation of the system 
whereas phosphorylation may further propagate signal transduction via the production 
of InsP4. InsP4 is thought to control Ca2+ entry into the cell and may also act as a 
precursor for InsP5 or InsP6 production. Controversy surrounds the role of InsP4 
and the action of 'higher inositol phosphates', InsP5 and InsP6, in gonadotroph cell 
signalling. Nevertheless, it is clear that agonist- induced PLC activation is the main 
positive regulatory component of InsP3 production and the duration of signalling is 
dependent on its rate of activation compared to the action of its metabolising enzymes. 
Studies have revealed that 3- kinase activity is positively regulated by increasing 
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[Ca2 +]i and inhibited by PKC activity. Tyrosine kinase has also been implicated in its 
regulation (Johnson et al, 1989). The regulation of 5' phosphatase enzyme in 
gonadotrophs cells has been less well studied although in other systems it is thought to 
be receptor regulated (Stojilkovic et al, 1994b). 
2.12.3 Diacylglyceride signalling 
Receptor- induced PIP2 hydrolysis also results in the activation of DAG in both 
pituitary gonadotrophs and aT3 -1 cells, with an initial rapid stimulation followed by a 
sustained rise in DAG (Stojilkovic et al, 1994b). PLC activation is thought to account 
for the initial rapid increase in DAG formation although the sustained DAG response is 
thought to be mediated by PKC activation of another membrane phospholipase, 
phospholipase D2 (PLD2) (Zheng et al, 1994). PLD2 hydrolyses phosphatidylcholine 
(PC) to phosphatidic acid (PA) which can then be converted to DAG (see Figure 2.4). 
DAG can also be metabolised to arachidonic acids (AA) by DAG lipase and GnRH has 
been shown to stimulate AA release in pituitary cell cultures (Naor et al, 1985). AA 
formation can also occur through GnRH activation of another phopholipase, PLA2. 
Both AA and several of its metabolites, prostaglandins (PGs) and leukotrienes (LKs) 
have been shown to stimulate LH and FSH release from gonadotrophs in vitro 
(Hunting et al; 1985; Naor et al, 1985). 
2.12.4 Protein Kinase C activation 
The formation of DAG and the increase in [Ca2 +]i are primarily responsible for the 
activation of PKC isotypes a and ß II in pituitary gonadotroph cells. PKC acts in the 
membrane to modulate receptor number, ion channel function, phospholipase activity 
and endocytosis (Stojilkovic et al, 1994b). In the cytoplasm it is responsible for the 
control of Ca2+ signalling via its regulation of PLC, voltage sensitive Ca2+ channels 
(VSCC) and the InsP3 receptor /Ca2+ channel (Stojilkovic et al, 1994b) and in the 
nucleus PKC regulates cell growth and differentiation. The action of PKC in the 
nucleus involves the transcription of primary response genes which in turn regulate 
late response genes, required for cell growth and differentiation (MaMahon and 
Monroe, 1992). 
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2.12.5 Mechanism of exocytosis 
Secretion of LH and FSH from pituitary gonadotrophs is an energy dependent process 
requiring Ca2 +. In gonadotroph cells biphasic LH secretion occurs rapidly and can be 
correlated to changes in [Ca2 +]i (Stojilkovic and Catt, 1992). Despite the apparent link 
between changes in [Ca2 +]i and hormone secretion the underlying mechanisms are still 
unknown. Leong and Thorner (1991) devised a model to explain their relationship, 
and suggest that the GnRH- induced biphasic rise in [Ca2 +]i is associated with 
gonadotrophin secretion alongside an inhibition of LH ß subunit mRNA and a 
decrease in GnRH -R levels. This model also proposes that agonist- induced Ca2+ 
oscillations are responsible for increases in both LH ß subunit mRNA and GnRH -R 
levels but these actions are not sufficient to activate a secretory response. PKC and 
calmodulin have also been implicated in the modulation of exocytosis (Stojilkovic and 
Catt, 1992). 
2.12.6 Adenyl -cyclase signalling 
The role of GnRH- induced adenyl -cyclase activity in gonadotroph intracellular 
signalling processes is unclear. An increase in cAMP and cGMP levels has been 
observed in prolonged agonist stimulation of pituitary cell cultures (Naor et al, 19 79) 
but these factors do not appear to be involved in exocytosis. A role in the modulation 
of gonadotrophin synthesis (Lui and Jackson, 1981) has also been proposed. 
2.12.7 Plasma membrane oscillations 
Gonadotroph cells and aT3 -1 cells contain many different types of ion channels and 
the flow of various ions through these channels at any one time determines the 
membrane potential of the cell (Vm). Several different types of voltage gated K+ 
channels, T and L -type Ca2+ channels and tetrodotoxin- sensitive Na + channels have 
been identified in these cell types (Stojilkovic and Catt, 1992). Gonadotroph cells 
have a basal pace -maker activity (Stojilkovic and Catt, 1992) and the base line firing of 
action potentials (APs) is dependent on the magnitude and frequency of the transient 
hyperpolarisation which ensues after each AP. Non -stimulated pituitary gonadotrophs 
show fluctuations in [Ca2 +]i but these spontaneous [Ca2 +]i fluctuations are not 
sufficient to cause gonadotrophin secretion (Iida et al, 1991). 
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2.12.8 GnRH- induced Vm changes 
GnRH causes dramatic changes in the electrical activity of cultured pituitary 
gonadotroph cells with variations in voltage /current profiles largely dependent on 
agonist concentration. Administration of nanomolar concentrations of GnRH causes 
periodic hyperpolarisation of Vm, altering the resting Vm (-. -35 mV to -45 mV) to 
hyperpolarising values (- -75 mV to -95 mV) before returning to baseline levels. This 
slow depolarisation leads to the firing of multiple APs via the influx of Na + and Ca2+ 
ions through voltage dependent channels and these changes in Vm appear to be 
dependent on a rise in [Ca2 +]i. The periodic hyperpolarisation that follows 
depolarisation occurs as a result of continual opening and closing of small conductance 
Ca2 + -activated K+ channels and these ion sensitive channels are probably regulated by 
GnRH -induced [Ca2 +]i oscillations (Hille et al, 1995). 
2.12.9 GnRH- induced biphasic calcium response 
In pituitary gonadotrophs and aT3 -1 cells, treatment with GnRH results in a biphasic 
rise in [Ca2 +]i that is characterised by a rapid initial Ca2+ spike followed by a 
prolonged secondary plateau phase (Anderson et al, 1993). These non -oscillatory 
responses are dose -dependent, a sign indicative of an amplitude- modulated Ca2+ 
response i.e. increased receptor occupancy results in a Ca2+ response with an 
increased amplitude. The use of chemical agents that specifically modify different 
aspects of Ca2+ mobilisation, have allowed the differential contribution of [Ca2 +]i 
versus [Ca2 +]e to be studied during GnRH- induced biphasic Ca2+ responses. 
Thapsigargin, a sesquiterpene lactone, selectively inhibits ER Ca2 +ATPase activity, 
thereby depleting InsP3 regulated [Ca2 +]i stores, and can be used to indicate the 
importance of [Ca2 +]i release. The pretreatment of primary gonadotrophs and aT3 -1 
cells with thapsigargin abolishes the initial GnRH- induced Ca2+ spike phase 
(Anderson et al, 1992; Lida et al, 1991). This evidence, together with the observation 
that the rapid Ca2+ spike phase occurs independently of changes in the Vm and/or the 
activation of PKC in pituitary gonadotrophs, is consistent with the hypothesis that 
GnRH- induced fast Ca2+ transients are dependent on the release of Ca2+ from 
intracellular stores (Stojilkovic et al, 1994b). In addition, the close temporal 
relationship between InsP3 production and the rapid Ca2+ spike suggests it provides 
the trigger for the initial phase of the response (Anderson et al, 1993; 1995; Morgan et 
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al, 1987; Zheng et al, 1994). Following either the reduction of [Ca2 +]e by EGTA or 
the blockage of the L -type VSCC with nifedipine or cobalt, the secondary plateau 
phase in GnRH treated pituitary gonadotrophs is either substantially reduced or 
abolished (Anderson et al, 1992; McCardle and Poch, 1992). An influx of [Ca2 +]e via 
L -type VSCC therefore appears to be involved in the Ca2+ plateau phase. Further 
studies have shown that this secondary phase, which occurs at baseline levels of 
InsP3, is dependent on changes in the Vm, and can be modulated by PKC ( Stojilkovic 
et al, 1994b). However, Hille et al (1995) have provided a different model based on 
the observation that there is no sharp distinction between the two phases of GnRH- 
induced Ca2+ response. These authors suggest that InsP3 is continually synthesised 
during agonist exposure and that cyclic release of Ca2+ from intracellular stores is 
primarily responsible for [Ca2 +]i increases. They also propose that there is a 
concurrent slow entry of Ca2+ into the cell to replenish the loss from the intracellular 
stores. 
2.12.10 GnRH- induced Ca2+ oscillations 
Gonadotrophs are examples of excitable endocrine cells which exhibit both 
spontaneous and agonist- induced Ca2+ oscillations. However, no such oscillations 
have been reported in aT3 -1 cells although Anderson and co- workers have observed 
infrequent Ca2+ oscillation in these cells when treated with low concentrations of 
GnRH (unpublished observations). The pattern of these oscillations is known to be 
frequency modulated and increasing agonist concentrations cause a decrease in the 
response latency but an . increase in frequency of spiking (Iida et al, 1991). 
Continuous exposure to higher concentrations of GnRH (10nM) causes the amplitude 
of these spikes to wane and eventually reach a steady state plateau, an effect 
attributable to the gradual depletion of the agonist sensitive Ca2+ pool (Stojilkovic et 
al, 1993). The mobilisation of [Ca2 +]i and [Ca2 +]e appears to be responsible for these 
Ca2+ oscillations. 
2.12.11 Mechanism of Ca2+ oscillations 
In electrically excitable cells, Ca2+ oscillations can be divided into two classes 
depending on the primary Ca2+ source; namely via the plasma membrane [(Ca2 +]e) or 
cytoplasmic Ca2+ oscillators ([Ca2 +]i) (Berridge, 1988). In pituitary gonadotroph 
cells it is now generally regarded that cytoplasmic oscillations are of primary 
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importance in the generation of Ca2+ oscillations. Several different models have been 
proposed to explain GnRH- induced Ca2+ oscillations in pituitary cells. A currently 
favoured InsP3 controlled model involves the sequential positive and negative 
feedback of InsP3 on Ca2+ release (Finch et al, 1991; lino and Endo, 1992). Studies 
by Finch et al (1991) have shown that the InsP3 receptor /channel opening is sensitive 
to levels of [Ca2 +]i. The existence of a bell- shaped Ca2+ dependent sensitivity curve 
has been proposed whereby low levels of InsP3- induced [Ca2 +]i facilitates the opening 
of more InsP3 receptor /Ca2+ channels, but as the level of [Ca2 +]i continues to rise 
these channels close. The channel remains shut for several seconds to allow 
Ca2 +ATPases, located on the membranes of the intracellular ER stores, to pump the 
Ca2+ from the cytoplasm back into the stores. The concentration of Ca2+ within the 
lumen of the ER is also thought to modulate Ca2+ release for these vesicles (Nunn and 
Taylor, 1992). 
Stojilkovic and co- workers have developed a mathematical model to describe several 
aspects of agonist- induced Ca2+ signalling in GnRH- stimulated gonadotrophs (Li et 
al, 1994). This model is based upon rapid activation of the InsP3 receptor /Ca2+ 
channel at low [Ca2 +]i, and slow activation at high [Ca2 +]i levels. These gating 
properties, when combined with the action of the ER Ca2 +ATPase and the 
enhancement of channel opening in the presence of reduced ER luminal Ca2+ levels, 
predicts manyof the Ca2+ profiles seen during experimental procedures. 
2.13 Extrapituitary localisation of GnRH and its receptor 
GnRH and its specific receptor have been localised outside the hypothalamic- pituitary 
system in other brain regions and also in breast tissue, placenta, ovary, prostate and 
testes. Studies have documented a direct action of GnRH on extrapituitary tissues 
both in vivo and in vitro and GnRH has also been shown to have a regulatory effect 
on tumour cell proliferation (Prevost et al, 1993). The detection of local GnRH 
production or GnRH -like substances in these areas together with the expression of its 
receptor suggests that this hormone may have paracrine or autocrine functions. These 
potential actions, at tissues distal to the pituitary, may be mediated directly through 
receptor specific interactions or may operate indirectly through the modulation of other 
hormone systems. 
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2.13.1 GnRH and GnRH -Rs in the brain 
Autoradiographic studies using iodinated GnRH agonists Buserelin (Jennes et al, 
1988), [D -A1a6, Des, G1y10-NHEt] -GnRH (Le Blanc et al, 1988) and [D -A1a6, 
NaMeLeu7, Pro9, Des, Gly10-NHEt] -GnRH] (Reubi et al, 1987) have localised 
GnRH binding sites to a variety of regions in the rat brain. High affinity GnRH -R 
binding sites have been identified in rat olfactory regions, frontal cortex (sulcus 
rhinalis), lateral septum, arcuate nucleus, interpeduncular nucleus, central gray area, 
superior colliculus, cingulate cortex, amygdala, but the greatest number of receptors is 
found in the hippocampus. These regions correlate well with the localisation of 
immunoreactive GnRH (Jennes and Conn, 1994). The brain localisation of the rat 
GnRH -R mRNA has also been carried out and as expected its distribution closely 
follows that of the autoradiographic localisation of GnRH -R binding sites (Jennes and 
Conn, 1994). The only deviation from these dual localisation patterns is in the arcuate 
nucleus and ventromedial nucleus of the hypothalamus, along with the periventricular 
nucleus of the thalamus and the medial habenula of the epithalamus. These areas all 
contain GnRH -R mRNA but show no receptor binding sites. There are also a few 
areas that bind radiolabelled GnRH analogues but lack GnRH neurons to express the 
receptor mRNA and these sites include the interpeduncular nucleus and the central 
periaqueductual gray. In these areas it has been suggested that the receptors are 
synthesised in- another location and then transported to the required destination (Jennes 
and Conn, 1994). 
2.13.2 GnRH and Gz HRH -Rs in the placenta 
GnRH mRNA (Seeburg and Adelman, 1984) and peptide (Tan and Rousseau, 1982) 
together with GnRH -like peptides have all been identified in human placental tissue. 
In vitro studies using primary placental cultures have shown that GnRH stimulates 
hCG, ahCG, progesterone and estrogen production (Khodr and Siler -Khodr, 1978) 
but these responses are largely confined to the mid -term placenta. It has been 
suggested that these effects are receptor- mediated, as specific GnRH -Rs have been 
identified and characterised in placental cells using iodinated radiolabelled GnRH 
analogues. The receptor, unlike its pituitary equivalent, displays a low affinity 
binding site with a receptor dissociation constant in the µM range (Currie et al, 1981). 
The physiological significance of GnRH and its receptor in the foetal -placental unit 
together with any functional regulatory role they may play has yet to be established. 
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2.13.3 Breast tissue and human breast tumour cells 
Bovine and human milk contains an immunological substance similar to GnRH 
(Amarant et al, 1982). GnRH -like immunoreactive peptides and GnRH mRNA have 
also been identified in human breast cancer cell lines (Eidne et al, 1985; Harris et al, 
1991) but the action of GnRH agonists in these cell lines has yielded contradictory 
findings. In 1985, Miller et al reported that low doses of Buserelin could inhibit the 
growth of MCF -7 cells but later studies failed to reproduce these findings. Results 
from in vitro GnRH antagonist experiments have been clearer with the treatment of 
MCF -7 cells, ZR -75 -1 and MDA -MB -231 cell lines with GnRH antagonists resulting 
in either a decrease of 3[H] thymidine incorporation into DNA or an inhibition of cell 
growth (Eidne et al, 1987). The presence of both high (Baumann et al, 1993; Fekete 
et al, 1989; Milovanovic et al, 1992) and low affinity (Eidne et al, 1987; Fekete et al, 
1989; Milovanovic et al, 1992) GnRH -R binding sites in a variety of human breast 
cancer tumour tissue prompts the question of possible autocrine regulation of tumour 
cell growth. In addition, Kakar and co- workers PCR- amplified a product of 
comparable size to the GnRH -R from RNA derived from human breast tissue and 
MCF -7 breast cancer cell lines (Kakar et al, 1992). However, these GnRH -R mRNA 
transcripts appear to be expressed at very low levels as they could not be detected 
using Northern Blot analysis. 
2.13.4 Ovary 
GnRH has been shown to have a wide range of effects on rat ovarian tissue. In both 
hypophysectomised rats and in vitro culture systems, reported effects of GnRH are 
variable and appear dependent upon: (i) the gonadotrophin environment, (ii) the 
duration of exposure to GnRH analogues and (iii) the degree of follicular development 
(Fraser and Eidne, 1989). Acute responses to GnRH result in an increase in ovarian 
steroidogenesis, induction of meiosis and germinal vesicle breakdown, whilst chronic 
administration of GnRH has been shown to inhibit ovarian steroidogenesis (Fraser 
and Eidne, 1989). GnRH- induced cytodifferentiation in immature rat granulosa cells 
has also been described (Fraser and Eidne, 1989). The direct effects of GnRH on the 
ovary however vary between species and although distinct effects on rat ovarian 
physiology have been observed, these effects are less evident in other species. The 
presence of GnRH -like substances (Aten et al, 1986), a high affinity binding site 
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(Popkin et al, 1983) and GnRH -R mRNA (Whitelaw et al, 1995) in rat tissue provides 
additional evidence as to the importance of GnRH signalling in this species. 
In human epithelial ovarian cancer tissue and human ovarian cell lines both low and 
high affinity GnRH -R binding sites have been detected (Emons et al, 1993; Thompson 
et al, 1991). Although the biological significance of these binding sites is unclear, 
GnRH analogues have been reported to reduce cell proliferation in a number of 
ovarian tumour cell lines in vitro (Thompson et al, 1991). GnRH has also been 
shown to cause regression of human ovarian epithelial tumours transplanted into nude 
mice (Schally et al, 1984). 
2.13.5 Prostate 
Both GnRH -like peptides (Quyam et al, 1990a) and GnRH -Rs (Quyam et al, 1990b) 
have been identified in the prostate and prostatic cancer tissue. Once again, GnRH has 
been implicated in prostatic epithelial cell growth and it has been suggested that the 
effects of GnRH analogues in these cancers are mediated by specific GnRH tumour 
receptors. 
2.13.6 GnRH and apoptosis 
A current theory put forward to explain the presence of GnRH in extrapituitary tissue 
is its possible involvement in apoptosis. Hormone -sensitive tissue, implicated in 
apoptosis, has been shown to produce both GnRH (or GnRH -like peptides) along 
with the GnRH -R. In addition, apoptotic tumour regression has been observed in 
female mice bearing mammary carcinomas following treatment with GnRH and the 
GnRH antagonist Cetrorelix (SB -75) (Redding et al, 1992). These effects in animal 
models may be indirect due to suppression of the pituitary -gonadal axis and may not 
be a direct result of a receptor mediated process. However, Billing et al (1994) have 
recently shown that GnRH can directly induce apoptotic death in ovaries from 
hypophysectomised rats, further suggesting that GnRH may be involved in 
programmed cell death. 
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2.14 Summary 
This chapter has examined the physiological actions of GnRH, and highlighted its 
importance as the key regulatory element in mammalian reproduction. The isolation of 
the GnRH peptide by Burgus and Guillemin in 1971, initiated many investigations 
into the mechanisms underlying the function of this hypothalamic- releasing hormone. 
Since the 1970s, a great deal of information has been assimilated and this knowledge, 
in turn, has been exploited for use in reproductive medicine. GnRH is now widely 
used in the treatment of a variety of reproductive endocrine conditions /disorders 
ranging from contraception to hormone -dependent breast and prostate cancer. 
However, a lot remains unknown especially about the interaction of GnRH with its 
target pituitary receptor, the GnRH -R. 
It was only recently, in 1992, that the GnRH -R cDNA structure was identified and 
characterised. With the cloning of the receptor, it is now possible to study structure - 
function relationships within the GnRH -R and identify specific areas important for 
ligand- receptor interactions. Such investigations will aid in further understanding the 
molecular mechanisms governing the action of GnRH at the pituitary. Moreover, this 
information can be used in rational design of novel GnRH analogues. 
This study has utilised a technique known as site -directed mutagenesis. Using this 
procedure, the receptor cDNA sequence can be altered, and the properties of 
genetically engineered 'mutant' receptors analysed. This approach therefore allows 
the comparison of wild -type receptor properties (receptor binding function, receptor 
expression and second messenger coupling) with those of the mutant receptors. 
Moreover, alterations in the normal receptor function, displayed by receptor mutants, 
provides important information about possible structure -function relationships. For 
example, if a mutant receptor shows a decrease in ligand- receptor binding, then this 
implies that the normally positioned amino acid is an important mediator of receptor 
function. In this way, the properties of the mutant receptors can be related back to the 
function of the receptor residues initially altered to create the mutation. With this 
strategy, the role of specifically targeted amino acids in the rat GnRH -R, isolated and 
characterised by Eidne et al (1992) have been investigated. The methodology utilised 
to generate mutant GnRH -Rs and analyse their functional properties is described in the 
following chapter. 
3 Materials and methods 
3.1 Introduction 
The techniques described in this chapter include general molecular biology 
techniques and specific methods used to (i) generate point mutations in receptor 
DNA, (ii) express these 'mutant' constructs in eukaryotic cells, (iii) monitor ensuing 
RNA transcription levels and (iv) assess the functional properties of the translated 
mutant proteins. 
Site -directed mutagenesis is commonly used to examine structure -function 
relationships in DNA and its encoded proteins. This technique allows small 
alterations to be introduced in the wild -type receptor (TRH - R/GnRH -R) cDNA and 
thus into its translated protein. Following mutagenesis, the receptor cDNA was 
expressed in a mammalian cell culture system using either a transient or stable 
expression system. In the transient method, the cDNA is localised in the cytoplasm 
and expressed episomally for 48 -72 hours post transfection, whereas in the stable 
expression system the cDNA is incorporated into the cell genome. Stable 
transfection systems have the advantage that DNA expression is maintained as the 
cell divides. The functional properties of the receptor mutants were subsequently 
analysed and compared to the wild -type receptor. The effects of receptor mutants on 
RNA transcription levels were monitored using Northern Blot analysis. The ligand 
binding and second messenger activational properties of the mutant receptors were 
assessed using receptor binding assays and ligand- stimulated total inositol phosphate 
measurements respectively. 
A detailed list of buffers and chemical suppliers is included in Appendix I and 
Appendix II respectively and additional methodology is detailed in Appendix III. 
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3.2 DNA preparation and purification 
3.2.1 Plasmid DNA preparation 
A single bacterial colony was used to inoculate 10m1 of LB broth containing 
antibiotics. The E.Coli culture was grown overnight with shaking at 37 °C and the 
DNA extracted using a Promega WizardTM Mini -prep DNA purification system as 
follows. Bacterial cells were pelleted by centrifugation at 12000 rpm for 5 minutes, 
resuspended, lysed and neutralised with 3001.t1 of resuspension, lysis and 
neutralisation solutions respectively. Following further centrifugation at 12000 rpm 
for 5 minutes, the clear supernatant was removed, divided into 2x 0.4ml aliquots and 
0.5ml of Mini -prep DNA purification resin added to each tube. The DNA/resin 
mixture was then incubated at room temperature for 5 minutes and subsequently 
filtered through Miniprep columns using a vacuum manifold. Finally, the columns 
were washed with ethanol, dried, and the DNA eluted with l00111 of TE buffer by 
centrifugation at 12000 rpm for 1 minute. Approximately 30µg of plasmid DNA 
was obtained from a 10m1 E. Coli bacterial culture. Larger scale plasmid DNA 
preparations were carried out using a Promega WizardTM Maxi -prep kit. Using this 
procedure, a 10m1 E. Coli starter culture was used to inoculate 300m1 of antibiotic - 
containing LB broth and the DNA extracted using a similar but scaled up version of 
the Mini -prep procedure described above. Approximately 6001.tg of DNA was 
obtained using this method. 
3.2.2 Agarose gel electrophoresis 
Agarose gel electrophoresis is a method of separating, identifying and purifying 
DNA fragments. A 0.9% agarose gel (Boehringer Mannheim) was routinely used to 
analyse DNA samples, as this gives high resolution of DNA fragments between 500 
bp and 7 kb. The agarose was melted in 1xTBE buffer, 0.3µg /m1 ethidium bromide 
added and when hand hot, the gel was cast into a casting tray and allowed to set. 
Meantime, samples containing 50ng to 11.tg of DNA were prepared in sterile water, 
electrophoresis loading dye added, to approximately 10% of the total volume, and 
the samples loaded into the wells. In addition, DNA markers, HindIII/EcoR1 and 
pGEM (Promega), were prepared and run alongside the samples so as to ascertain 
the size of the DNA fragments. The gel was run in 1xTBE buffer at a constant 
voltage of 50V for several hours until the dye front reached the bottom of the gel. 
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DNA visualisation was carried out under ultra violet (u /v) light using a u/v 
transluminator (Vilber Lourmat). 
Low melting point agarose (Sea Plaque agarose, Flowgen) gels were used to extract 
DNA samples for further purification. This method is similar to the protocol 
described above except that the 1% low melting point agarose gels were set and run 
at 4 °C. In addition, to prevent any damage to the DNA, ethidium bromide staining 
occurred following electrophoresis. The DNA fragments were then viewed under 
u/v light, the position of the required fragment(s) ascertained and the correct DNA 
bands excised with a scalpel blade for further purification. 
3.2.3 Phenol/chloroform DNA purification 
Phenol /chloroform extraction separates nucleic acids from proteins, and is a widely 
used technique for the removal /inactivation of enzymes or the purification of DNA 
from agarose gels. The excised agarose fragment was melted at 65 °C in 5 volumes 
of 20mM Tris -HCI pH 8.0. An equal volume of TE- saturated phenol was added and 
the sample vortexed for 1 minute followed by centrifugation at 10000 rpm for 5 
minutes. The upper aqueous phase was removed into a separate tube and the 
vortexing and centrifugation procedure repeated, first with an equal volume of 
phenol /chloroform and finally with an equal volume of chloroform. The DNA was 
extracted from the chloroform phase using a salt/ethanol precipitation method. 
3.2.4 DNA/ RNA salt and ethanol precipitation methods 
Nucleic acids were concentrated by precipitation, with ethanol, in the presence of 
monovalent cations. Ammonium acetate (10M) or sodium acetate (3M, pH 5.4) was 
added to a final concentration of 2.5M or 0.3M respectively, together with 3 volumes 
of 100% ethanol. The samples were precipitated at -70 °C for 30 minutes and 
centrifuged at 12000 rpm for 20 minutes at 4 °C. The liquid was then removed, the 
DNA pellet washed in 75% ethanol and resuspended in TE buffer /water. 
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3.2.5 Sphectrophotometric DNA/RNA quantitation 
The concentration of a 1:200 dilution of a DNA/RNA preparation was determined by 
measuring the optical density (OD) at 260 nm and 280 nm in a Kontron Analytical 
spectrophotometer. An OD 260 reading equivalent to one corresponds to 50µg /ml 
for double- stranded DNA, 401.1g /m1 for either single- stranded DNA or RNA and 
20µg /ml for single- stranded oligonucleotides. An OD 260:280 ratio of 1.8 for DNA 
and 2.0 for RNA indicates good sample purity. 
3.2.6 Restriction enzyme digestion 
Restriction digests were used to release cDNA receptor inserts from plasmids or to 
linearise circular plasmid DNA. Restriction enzymes (Boehringer Mannheim) bind 
to, and cleave, specific sequences in double- stranded DNA; for example, EcoR1 (a 
commonly used enzyme) recognises the five nucleotide sequence G /AATTC. 1 -5µg 
of purified DNA was digested with 10 units of restriction enzyme, in lx enzyme 
buffer at 37 °C for 1 hour, and the digestion products subsequently analysed by gel 
electrophoresis. 
3.3 Site -directed mutagenesis 
3.3.1 General methodology 
DNA mutations were introduced in the GnRH -R and TRH -R using a method adapted 
from Kunkel (Kunkel, 1987) and performed using a Muta- GeneTM phagemid in vitro 
mutagenesis kit (Bio -Rad). The gene of interest was cloned into a eukaryotic 
expression vector and the DNA replicated within a dut, ung double mutant E. Coli 
bacterium. The dut mutation inactivates dUTPase whereas the ung mutation 
inactivates the enzyme uracil -N- glycosylase. Together these mutations result in the 
incorporation of uracils into the DNA. This 'parental' DNA strand was then used as 
a template to anneal an oligonucleotide with the desired mutation. A 
complementary non -uracil containing DNA strand, identical except that it carried the 
mutation, was subsequently synthesised. The double -stranded DNA construct was 
transformed into cells containing an efficient uracil -N- glycosylase enzyme system 
and this resulted in the inactivation of the parental DNA strand, thus permitting only 
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the DNA strand carrying the mutation to replicate. The basic principle of this 
specific site -directed mutagenesis protocol is summarised in Figure 3.1 
3.3.2 Isolation of receptor cDNA 
The rat TRH -R, a 3.3 kb clone, was isolated from a rat anterior pituitary cDNA 
library (lamba Zap) and cloned into the EcoR 1 polylinker site in the eukaryotic 
expression vector pcDNA 1(Sellar et al, 1993). The rat GnRH -R, a 2.2 kb clone, 
isolated from the same library, was also cloned into pcDNA 1 as well as into another 
eukaryotic expression vector pcDNA 3, again at the EcoRl polylinker site (Eidne et 
al, 1992). 
3.3.3 Eukaryotic expression vectors 
The plasmid pcDNA 1 (Invitrogen) is a 4.0 kb vector derived from pCDM8. The 
vector contains a CMV promoter and enhancer, splice segments and a 
polyadenylation signal, together with SV40 and polyoma virus eukaryotic origins of 
replication. It also includes an M13 origin for the rescue of single- stranded DNA, 
essential for this mutagenesis protocol, SP6 and T7 promoters for the production of 
sense /antisense RNA transcripts and an phiVX (ColE1 like) high copy plasmid 
origin. The presence of the Sup F gene confers ampicillin (Amp) and tetracycline 
(Tet) resistance in the E.Coli strain MC 1061/P3. 
The plasmid pcDNA 3 (Invitrogen) is a 5.4 kb vector derived from pRc /CMV. The 
vector contains a CMV promoter and enhancer, SV40 origin for transient episomal 
replication of cells expressing the SV40 large T antigen, and a bovine growth 
hormone polyadenylation signal. It also contains an fl origin for the rescue of 
single- stranded DNA, T7 and SP6 promoters for the production of sense /antisense 
RNA transcripts, and a ColE 1(from pUC 19) high copy number origin. The 13- 
lactamase gene confers Amp resistance in the E.Coli strain TOP 10F'. In addition, 
this vector has the advantage of a neomycin resistance marker, expressed from the 
SV40 early promoter, for the selection of stable transformants in the presence of 
G418. 
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3.3.4 E.Coli bacterial strains (Table 3.1) 
MC106IJP3 is a bacterial strain designed to support the replication of plasmid DNA 
encoding the tyrosine tRNA suppressor (Synthetic Sup F gene). The P3 plasmid 
carries kanamycin (Kan), Amp and Tet drug resistance markers but these genes are 
inactivated, during normal bacterial growth, by the presence of amber mutations 
carried on the P3 plasmid. Tet and Amp resistance properties are, however, restored 
upon the introduction of pcDNA 1 plasmids carrying the Sup F gene. 
TOP 10F' is a recombinant negative strain for stable replication of high copy 
number plasmids. It carries the F' episome which is required for pili formation and 
thus for single -stranded DNA rescue by helper phage superinfection. The F' 
episome carries the Tet resistance gene marker and cells can therefore be selected 
with this antibiotic. 
CJ263/P3 is a strain used for uracil incorporation. The dut and ung phenotypes 
result in the occasional substitution of thymidine by uracil. This strain carries the F' 
episome and therefore can be used for the isolation of single -stranded DNA. It also 
contains the P3 gene. 
CJ263 has the same features as CJ263/P3 except that it does not contain the P3 
gene. 
Figure 3.1 Site -directed mutagenesis method (following page) 
The rat GnRH -Rand TRH -R were electroporated into a dut ung E. Coli bacterial strain and this 
resulted in the incorporation of uracils into the DNA. A mutagenic oligonucleotide was designed and 
annealed to this uracil- containing template, with the complementary strand generated incorporating 
the desired mutation. The double -stranded DNA construct was transformed into cells containing an 
efficient uracil -N- glycosylase enzyme system which resulted in the inactivation of the parental DNA 
strand, permitting only the DNA strand carrying the mutation to replicate. 
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3.3.5 Helper phage 
M13KO7 (Invitrogen) is a single- stranded interference resistance helper phage 
carrying the mutant gene II. Phage infection of plasmids containing either an fl or 
M13 origin- (for the rescue of single- stranded DNA) results in the preferential 
replication, packaging and extrusion of single -stranded plasmid DNA. M13KO7 had 
a titre of 2.6x1010 plaque forming units (pfu) /m1 and was added at a multiplicity of 
infection of 20:1 (phage:cells) to a cell culture containing 1x108 colony forming 
units (cfu) /ml. Kan was used to select for cells infected with helper phage. 
E. Coli Strain Genotype Antibiotic 
LB agar/broth 
CJ263/P3 Dut -1, ung -1, th/ -1, relA -1, deoR +, 
pCJ105(camR, F'), {p3: amber 





CJ263 Dut -1, ung -1, th/ -1, rel 
Al /pCJ105(cmR), F' 
Chl 
15 /30µg /m1 
MC1061/P3 AraD139, D (araABC -leu), 7696, 
galU, galK, DlacX74, (rk,m +k), 
strA, deoR +, rpsL, thi, mcrB, { p3: 
amber ampR, amber tetR, KmR } 
Kan 
701.tg /m1 
Top 10F' mcrA, D(mrr- hsddRMS -mcrBC), 
F'800D1acZDM15, DlacX74, deoR, 
recAl, ara D 139, D(ara,leu). 7697, 




Table 3.1 E.Coli bacterial strains used in the site -directed mutagenesis procedure 
E.ColI cell stains (Invitrogen), CJ263/P3 and MC1061/P3 were used in the site -directed mutagenesis 
procedure to construct mutant receptors expressed in the eukaryotic expression vector pcDNA 1. 
CJ263 and Top 10F' cells were used to generate mutant receptors in pcDNA3. The individual cell 
genotypes and their corresponding antibiotic growing conditions are also highlighted. 
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3.3.6 Preparation of uracil containing template 
CJ263 cells were streaked onto LB agar plates containing 301.1g /ml chloramphenicol 
(Chl) and single colonies selected for further use. In contrast, CJ263/P3 cells were 
streaked onto LB agar plates containing 3014/ml Chl and 701.1g /ml Kan, then single 
colonies were picked and subsequently replated on separate plates containing either 
15µg /m1 Tet, 5011g /m1 Amp or 3011g /ml Chl plus 7011g /ml Kan. Only colonies that 
grew on the Chl plus Kan plates were picked for further use. Individual colonies 
were subsequently grown in an appropriate antibiotic environment and 
electrocompetent cells prepared as follows. Cells in mid -log phase (200m1) were 
chilled on ice, pelleted by centrifugation at 4000 rpm for 5 minutes, washed twice 
with ice cold sterile water and twice with ice cold 10% glycerol. Following 
production of the final pellet, 400µl of ice cold 10% glycerol was added to yield 
approximately 1.1m1 of electrocompetent cells. These cells were stored in 100111 
aliquots at -70 °C. Electrocompetent CJ263P3/CJ263 cells (4Oµ1) were 
electroporated, using a Gene PulserTM (Bio -Rad), with 2111 of DNA and incubated in 
SOC media, containing Chl, Amp and Tet, for 45 minutes to allow antibiotic 
resistance to develop. The transformed cells were plated onto LB agar plates, 
containing appropriate antibiotics, incubated overnight at 37 °C and single colonies 
picked. The DNA plasmids were then extracted and the presence of inserts checked 
by EcoR 1 restriction digests. 
3.3.7 Single- stranded DNA preparation 
Selected colonies were grown in 2xYT broth, containing appropriate concentrations 
of Chl, Amp and Tet, for 4 hours until an OD reading (at 600 nm) of 0.3 was 
reached. M13KO7 helper phage was added, the incubation continued for 1 hour 
prior to the addition of Kan (7011g /ml) and then continued overnight. The E Coli 
cells were pelleted by centrifugation and the supernatant treated with 1011g /ml 
RNase and 1011g /ml DNase at 37 °C for 10 minutes. One quarter of the total volume 
of 3.5M ammonium acetate /20% polyethylene glycol was added, the solution 
precipitated on ice for 10 minutes, and the DNA repelleted by centrifugation at 
12000 rpm for 20 minutes. The DNA was resuspended in TE buffer and purified 
using a phenol /chloroform extracted method. The single -stranded uracil- containing 
DNA was then used as a template to anneal mutagenic oligonucleotides. 
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3.3.8 Oligonucleotide design 
Mutagenic oligonucleotides, complementary to the receptor DNA except containing 
internal base mismatches, were designed to the targeted area of the receptor (Table 
3.2 and 3.3)-and synthesised on an Applied Biosystems PCR Mate synthesiser. The 
oligonucleotides were deprotected in lml of ammonia solution at 55 °C overnight, 
purified by salt/ethanol precipitation, and subsequently phosphorylated using T4 
polynucleotide kinase. These phosphorylated oligos were then annealed to a uracil- 
containing template in a 25:1 primer to template ratio. A complementary strand of 
DNA was synthesised from dNTPs using T7 DNA polymerase and the ends of this 
de novo DNA strand ligated together with T4 DNA ligase. 
Mutation . TRH -R 
Wild- Type /mutagenic 
DNA sequence 
TRH -R 





Cys98Ser ATGTTGGCTGCCTCTGC Val -Gly- Cys -Leu -Cys 17 
ATGTTGGCAGCCTCTGC Val -Gly- Ser -Leu -Cys 284 -300 
Cys179Ser TGATATCCTGTGGCTAC Ile- Ser -Cys -Gly -Tyr 17 
TGATATCCAGTGGCTAC Ile- Ser -Ser -Gly -Tyr 527 -543 
Cys 100Ser GCTGCCTCTGCATCACG Cys -Leu- Cys -Ile -Thr 17 
GCTGCCTCAGCATCACG Cys -Leu- Ser- Leu -Thr 290 -306 
Cys98Ala TGTTGGCTGCCTCTGCA Val -Gly- Cys -Leu -Cys 17 
TGTTGGCGCCCTCTGCA Val -Gly- Ala -Leu -Cys 285 -301 
Cys 179A1a' GATATCCTGTGGCTACAA Ile- Ser - Cys -Gly -Tyr 18 
GATATCCGCTGGCTACAA Ile -Ser -Ala -Gly -Tyr 528 -545 
Cys 100Ala CTGCCTCTGCATCACGT Cys -Leu -Cys -Ile -Thr 17 
CTGCCTCGCCATCACGT Cys -Leu- Ala- Leu -Thr 291 -307 
Table 3.2 TRH -R mutant constructs 
Oligo- directed mutagenesis of the rat TRH -R showing the location of the mutation(s) in the DNA and 
amino acid sequence. The design and length of the oligonucleotides are also highlighted. These 
mutations were generated in the eukaryotic expression vector pcDNA 1. 
Table 3.3 GnRH -R mutant constructs (following page) 
Oligo- directed mutagenesis of the rat GnRH -R showing the location of the mutation(s) in the DNA 
and amino acid sequence. The design and length of the oligonucleotides are also highlighted. These 
mutations were generated in the expression vector pcDNA 3 with the exception of mutations 
highlighted ( *) which were made in pcDNA 1. Mutations created in both expression vectors are 
indicated (). 
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Mutation GnRH -R Wild- Type /mutagenic 
DNA sequence 




Cysl4Ser AAAATCACTGCTCAGCC Asn- His -Cys- Ser -Ala 17 
* AAAATCACAGCTCAGCC Asn -His- Ser- Ser -Ala 32 -48 
Cys114Ser AGTTCCTTTGCAAAGTT Phe- Leu -Cys- Lys -Val 17 
* AGTTCCTTAGCAAAGTT Phe- Leu -Ser- Lys -Val 332 -348 
Cys195Ser TCTCGCAATGTGTGACC Ser -Gln- Cys - Val -Thr 17 
* TCTCGCAAAGTGTGACC Ser- Gln -Ser- Val -Thr 575 -591 
Cys199Ser TGACCCACTGCAGCTTT Thr- His - Cys -Ser -Phe 17 
* TGACCCACAGCAGCTIT Thr- His- Ser -Ser -Phe 587 -603 
Asn87Asp ACCTTAGCCAACCTCCTTG Thr- Leu -Ala -Asn- Leu -Leu 19 
ACCTTAGCCGACCTCCTTG Thr- Leu- Ala -Asp- Leu -Leu 250 -268 
Asp318Asn CCGTGCTTCGACCCACTT Thr- Leu -Ala -Asn- Leu -Leu 18 
CCGTGCTTCAACCCACTT Thr- Leu- Ala -Asp- Leu -Leu 943 -960 
Asn87Asp ACCTTAGCCAACCTCCTTG Thr- Leu -Ala -Asn- Leu -Leu 18 
Asp318Asn ACCTTAGCCGACCTCCTTG Thr- Leu- Ala -Asp- Leu -Leu 943 -960 
' CCGTGCTTCGACCCACTT Thr- Leu -Ala -Asn- Leu -Leu 
CCGTGCTTCAACCCACTT Thr- Leu- Ala -Asp- Leu -Leu 
Glu90Gln ACCTCCTTGAGACTCTA Leu -Leu - Glu -Thr -Leu 17 
ACCTCCTTGAGACTCTA Leu -Leu- Gln -Thr -Leu 260 -276 
Lys115Arg CCTTTGCAAAGTTCTCA Leu -Cys- Lys -Val -Leu 17 
CCTTTGCAGAGTTCTCA Leu -Cys- Arg -Val -Leu 336 -352 
Lys121Arg CTATCTGAAGCTCTTCT Tyr- Leu - Lys -Phe -Ser 17 
CTATCTGAGGCTCTTCT Tyr- Leu -Arg -Phe -Ser 354 -370 
Gln174Glu CGGGACCAÇAGTTATAT Gly- Pro -Gln- Leu -Tyr 17 
CGGGACCAGAGTTATAT Gly -Pro- lu- Leu -Tyr 512 -528 
Asn211Asp ÇCTTCTACAACI"1"1"1"1'C Phe- Tyr -Mn- Phe -Phe . 17 
Phe- Tyr -Asp- Phe -Phe 623 -639 CCTTCTACGAC riTri'C 
Asn304Asp AGCCAGTCAATCACTTC Pro -Val- Asn -His -Phe 17 
AGCCAGTCGATCACTTC Pro -Val -Asp -His -Phe 902 -918 
His305Arg AGTCAATCACTTGTTGT Val -Asn- His -Phe -Phe 17 
AGTCAATCGCTTCTTCT Val- Asn -A jg- Phe -Phe 906 -922 
Asn314Asp GGTTTCTAAACCCGTGC Phe- Leu -Asn -Pro -Cys 17 
GG.TTTCTAGACCCGTGC Phe- Leu -Asp -Pro -Cys 932 -948 
Phe312Tyr TCTTTGGTTTTCTAAAC Phe -Gly -Phe- Leu -Asn 17 
Phe -Gly- Tyr- Leu -Asn 926 -939 TC'1 ET'GGTTATCTAAAC 
Phe312AIa TCTTTGGTTTTCTAAAC Phe -Gly -Phe- Leu -Asn 17 
TCTTTGGTGCTCTAAAC Phe- Gly -Ala- Leu -Asn 926 -942 
Phe312Arg TCTTTGGTTTTCTAAAC Phe -Gly -Phe- Leu -Asn 17 
TCTTTGGTCGTCTAAAC Phe -Gly- Arg- Leu -Asn 926 -942 
Leu83Val TTAAAGCATTTGACCTTAGCC Leu -Lys -His- Leu -Thr- Leu -Ma -Asn 21 
TTAAAGCATGTGACCTTAGCC Leu -Lys- His- Val-Thr- Leu -Ala -Asn 238 -258 
Leu83Ala TTAAAGCATTTGACCTTAGCC Leu -Lys- His -Leu -Thr- Leu -Ala -Asn 21 
TTAAAGCATGCGACCTTAGCC Leu -Lys- His- Ala -Thr- Leu -Ala -Asn 238 -258 
Leu83Arg TTAAAGCATTTGACCTTAGCC Leu -Lys- His -Leu -Thr- Leu -Ala -Asn 21 
TTAAAGCATAAGACCTTAGCC Leu -Lys- His - Lys -Thr- Leu -Ala -Asn 238 -258 
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3.4 Tissue Culture Procedures 
3.4.1 Cell lines and reagents 
Tissue culture reagents were purchased from Gibco BRL and Advanced Protein 
Products Ltd. COS -1 cells (Monkey kidney, SV40 transformed fibroblasts) and 
HEK -293 cells (Human embryonic kidney epithelial cells) were obtained from the 
American Type Culture Collection and aT3 -1 cells (immortalised anterior pituitary 
cells of gonadotroph lineage) were a gift from Dr. Pamela Mellon (The Salk 
Institute, La Jolla, CA, USA). Cells were routinely maintained and passaged in 
complete Dulbecco's modified Eagle's medium (DMEM), containing 10% (v /v) heat 
inactivated foetal calf serum (HIFCS), glutamine (0.3mg /m1), penicillin (100IU /m1) 
and streptomycin (1001.tg /ml), and incubated at 37 °C in a humidified atmosphere of 
5% (v /v) CO2 in air. COS -1 cells were used for the transient tranfection procedures 
and HEK -293 cells for the generation of stably expressing rat GnRH -R WT or 
mutant cell lines. 
3.5 Transfection Procedures 
3.5.1 Liposome- mediated transfections 
Liposome- mediated transient transfection protocols using lipofectinTM (Gibco BRL), 
N- [1- (2,3- dioleyloxy) propyl] -N, N, N- trimethylammonium chloride 
(DOTMA) /dioleoyl phosphatidylethanolamine (DOPE) and TransfectamTM 
(Promega), a synthetic lipopolyamine, are described below. Both these compounds 
have a high affinity for DNA, forming an outer cationic lipid layer to facilitate DNA 
entry into the cell. 
3.5.2 Preparation of cells for transfection 
COS -1 cells in 175cm2 flasks were trypsinised with 0.5% Trypsin -EDTA solution 
and plated into 60mm/100mm culture dishes at concentrations of 0.5/2x106 cells per 
dish. 
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3.5.3 LipofectinTM 
DNA (1241g) was diluted into 50111 of sterile water, mixed gently with 501.1.1 of 
lipofectin and incubated for 15 minutes at room temperature. 100mm culture dishes, 
approximately 80% confluent, were washed twice with DMEM and the 
lipofectin /DNA mixture added dropwise to dishes containing 3m1 of media. The 
plates were gently swirled and incubated for 16 hours overnight. The following day 
the transfection solution was removed and replaced with complete DMEM media. 
3.5.4 TransfectamTM 
60mm culture dishes, approximately 60% confluent, were washed twice with 
DMEM. DNA (31.1g) was diluted in 0.5ml DMEM, combined with 101.t1 of 
transfectam in 0.5ml DMEM and pipetted dropwise into dishes containing 0.5mí 
media. The plates were incubated for 6 hours, washed and replaced with complete 
DMEM media. 
3.5.5 ß-galactosidase transfections 
To monitor the efficiency of the transfection procedure, COS -1 cells were 
transfected with 3µg of pSV -ß galactosidase control vector (Promega) using l0111 of 
transfectam per 60mm culture plate, and stained in -situ for ß- galactosidase activity 
72 hours later. The cells were washed twice in PBS, fixed with 2ml of 0.25% 
glutaraldehyde solution and incubated at 37 °C for 15 minutes. This solution was 
removed by washing with PBS, followed by the addition of lml of X -gal (5- bromo- 
4- chlor-3- indolyl -ß -D- galactopyranoside) {3-galactosidase substrate. The incubation 
was continued for a further 4 -6 hours, with cells expressing the 13-galactosidase 
enzyme appearing blue under an Olympus CK2 inverted microscope. Figure 3.2 
highlights the number of COS -1 cells incorporating the pSV -ß galactosidase control 
vector. 
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Figure 3.2 Photomicrographs of 0-galactosidase transfections using Transfectam reagent 
COS -1 cells transiently transfected with (a) 314 of control pSV -ß galactosidase vector (b) 3µg of 
control pSV -13 galactosidase vector + 314 GnRH -R (pcDNA 3) and (c) sham untransfected COS -1 
cells. The uptake of DNA is represented by the blue coloration and approximately 25 -35% of the 
cells incorporate and express the transfected DNA. 
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3.5.6 Stable transfection procedure 
Stable cell lines of the rat GnRH -R WT and mutants were generated in HEK -293 
cells. The receptor DNA (600ng) was linearised using the Not 1 restriction enzyme 
(Boehringer Mannheim) and transfected in HEK -293 cells, plated into 6 well dishes, 
(Falcon) using 3O111 of lipofectin. Once the cells were approximately 90% confluent, 
they were trypsinised and transferred first into 75cm2 flasks (Costar) and 
subsequently into 175cm2 flasks. The pcDNA 3 expression vector contains a 
neomycin resistance gene marker and thus cells incorporating DNA, expressed in 
this vector, were selected through antibiotic resistance. When cells in the 175cm2 
flasks were 50% confluent, Geneticin G418 sulphate (Gibco BRL) was added at a 
concentration of lmg /ml. Individual receptor- expressing clones were isolated, 
expanded from single cell colonies and maintained in complete DMEM media 
containing 800ng /ml G418. 
3.6 Northern Blot Analysis 
3.6.1 Isolation of total RNA from mammalian cells 
Total RNA was extracted from confluent 2x 60mm cell culture dishes using TRI 
reagent (Molecular Research Centre). Cells were initially lysed with 6m1 of TRI 
reagent and left for 5 minutes at room temperature to allow nuclear protein 
dissociation. Lysed cells were then mixed vigorously with 1.2ml chloroform, 
incubated at room temperature for 15 minutes, centrifuged at 12000 rpm for a 
further 15 minutes at 4 °C and the RNA- containing upper aqueous phase removed. 
RNA was precipitated with 4m1 of isopropanol for 30 minutes at -70 °C, again 
pelleted by centrifugation at 12000 rpm for 15 minutes at 4 °C, washed with 75% 
ethanol, and resuspended in DEPC treated water. Approximately 2- 611g /µl of total 
RNA was obtained from 2x 60mM dishes using this method. 
3.6.2 Analysis of RNA by formaldehyde gel electrophoresis 
A 1.5% agarose gel was prepared by dissolving agarose in H20, cooling to 60 °C, and 
then adding 5xformaldehyde gel running buffer (RB), together with formaldehyde to 
final concentrations of lx and 2.2M respectively. The gel was cast in a chemical 
fume hood and allowed to set for 30 minutes. Meantime, the samples were prepared 
by adding l0111 formamide, 3.5111 of a 37% formaldehyde solution and 5xRB to 
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151.ig of RNA. The mixture was then denatured by heating at 65 °C for 10 minutes. 
Following sample cooling, on ice, 8111 of sample loading buffer was added and the 
samples loaded onto the gel. The gel was run in 1 x RB, at a low voltage of 50 V 
overnight, and stained with ethidium bromide. The position of the 18S and 28S 
RNA bands were noted and the RNA blotted onto a Hybond -N (Amersham) nylon 
membrane as described in section 3.6.3. 
3.6.3 RNA transfer to nylon membrane 
The apparatus is depicted in Figure 3.3. Two pieces of 3mm Whatman filter paper 
were cut, soaked in 20xSSC, and laid over a glass plate raised on rubber bungs. The 
gel was placed on top of the wicks and the air bubbles removed with a glass rod. 
Hybond -N nylon membrane (Amersham), cut to size, was placed over the gel, 
autoradiographic film inserted beneath the sides, to ensure buffer transfer through 
the gel, and 4 pieces of filter paper positioned on top. Paper towels and a heavy 
weight were finally placed over the filter paper and the blot left overnight. After 
RNA transfer, the positions of the wells were marked with a needle, the RNA fixed 
by u/v cross linking, and the blot stored at 4 °C until hybridisation. 
3.6.4 Preparation of radiolabelled probes 
Plasmid GnRH -R and TRH -R cDNA was digested with EcoRl restriction enzyme, 
to release a 2.2 kb and a 3.3 kb DNA insert respectively. The inserts were separated 
from the plasmids on a low melting point gel, excised, placed in eppendorf tubes 
with 5 volumes of 20mM Tris pH 8.0 /1mM EDTA and melted by heating at 65 °C 
for 5 minutes. When cool, an equal volume of TE- saturated phenol was added to the 
tubes, they were vortexed for 2 minutes, and then centrifuged at 10000 rpm for 1 
minute. The clear supernatant was removed and transferred to a fresh tube, where an 
equal volume of phenol /chloroform was added and the tubes vortexed, centrifuged 
and the supernatant extracted. Finally, an equal volume of chloroform was added 
and following vortexing and centrifugation, the supernatant was collected and 
precipitated with 0.2 volumes of 10M ammonium acetate and 2 volumes of 100% 
ethanol at -70 °C for 30 minutes. The purified DNA was pelleted by centrifugation at 
12000 rpm for 20 minutes and resuspended in TE buffer. 
















Figure 3.3 Northern Blot apparatus 
Capillary transfer of RNA from agarose /formaldehyde gel to a nylon membrane. Transfer buffer is 
drawn from the reservoir through the gel, via the wick, and into a stack of paper towels. The RNA is 
eluted from the gel by the moving stream of buffer and is deposited onto the nylon membrane. The 
weight applied to the top of the paper towels ensures a tight connection between the layers of material 
used in the transfer system. 
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The purified cDNA insert was labelled with [a32P]dCTP (Amersham) by the random 
primer method (Feinburg and Vogelstein, 1983; Feinburg and Vogelstein, 1984), 
using a random primer DNA labelling kit (Boehringer Mannheim). DNA (100ng) 
was denatured by boiling for 5 minutes and placed on ice to prevent renaturation. 
Label mix containing 1111 of dGTP, dATP, dCTP and dTTP was added to the DNA 
together with 5011Ci of radiolabelled dCTP and 211 of Klenow enzyme (in a total 
volume of 20µ1). The reaction was incubated for 1 hour at 37 °C and finally stopped 
by the addition of 0.5111 of 0.5M EDTA, pH 8.0. The unincorporated label was 
separated out using a NuTrap Push Column (Stratagene) and the specific activity of 
the probe measured using a 1209 Rackbeta liquid LKB Wallac scintillation counter 
(Pharmacia). 
3.6.5 Hybridisation and washing 
The membrane was transferred into a polythene bag, 7m1 of hybridisation buffer 
added, the bag sealed and then incubated in a water bath for 4 hours at 42 °C. The 
liquid was removed from the bag, hybridisation buffer containing lx106cpm/ml of 
denatured probe added, the bag resealed and returned to the shaking water bath for 16 
hours. The following day, the radiolabelled probe was removed, the membrane 
rinsed in 4xSSC and washed in 4xSSC, 2xSSC, 1xSSC, 0.5xSSC for 30 minutes at 
each buffer concentration. 
3.6.6 Autoradiography 
The plastic enclosed membranes were placed in cassettes with two intensifying 
screens, overlaid with two X -OMATTm S scientific imaging films (Kodak), and 
exposed for 24 hours at -70 °C. The first film was developed with LX 24 X -ray 
developer (Kodak), fixed with FX -40 X -ray liquid fixer (Kodak) (according to the 
manufacturer's instructions), and left to dry. If the positive signals were not visible 
at this time point then the second film was left for a longer exposure period. 
3.6.7 RNA loading 
To check for even RNA sample loading, the membranes were stripped by boiling in 
0.1% SDS and reprobed using an end -labelled anti -18S RNA oligonucleotide probe 
(Chang et al, 1984). The oligonucleotide was labelled with [y32P]dATP using T4 
polynucleotide kinase for 45 minutes at 37 °C (in a total volume of 100. The 
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unincorporated radiolabelled nucleotides were then removed through a NuTrap 
column and the probe's specific activity measured. The membrane was transferred 
into a polythene bag, 7ml of hybridisation buffer added, sealed and incubated for 4 
hours at 65 °C. The liquid was removed from the bag, hybridisation buffer 
containing Ix 106 cpm/ml of probe added and the bag resealed prior to returning to 
the shaking water bath for 16 hours. The following day, the radiolabelled probe was 
removed, the membrane rinsed in oligonucleotide hybridisation washing buffer and 
washed twice for 30 minutes before exposing to autoradiographic film. 
Details of the composition of hybridisation buffers and washing solutions for the 
cDNA and oligonucleotide labelled probes are given in Appendix I. 
3.7 Receptor Binding Assays 
3.7.1 Radiolabelled ligands 
3- methyl -his2, [L- his -4 -3H, L- pro -3, 4 -3H] TRH (3H[3- Me- His2]TRH) was 
purchased from NEN Dupont. The specific activity of 3H[3- Me- His2]TRH (TRH - 
A) was 62.8Ci/mmol. In contrast, the GnRH -R binding assays were carried out 
using an iodinated radiolabelled GnRH agonist (GnRH -A, [des G1y10, D -Trp6, Pro9 
NEt] -GnRH) and antagonist (GnRH -An, [Ac- 3,4- dehydro- ProlD- p- F -Phe2, D- 
Trp3'6]- GnRH). These GnRH analogues (Sigma) were labelled with I125 using the 
lactoperoxidase- glucose oxidase method, chromatographed on a lx 60cm Sephadex 
G -25 column and eluted with 0.O1N acetic acid /0.1% BSA (Sharpe and Fraser, 
1980). Fractions corresponding to the monoiodinated hormone peaks were pooled 
and frozen in 2m1 aliquots at -20 °C. Preparations of radiolabelled tracer were tested 
for high affinity binding on membranes prepared from HEK -293 cells stably 
expressing the rat GnRH -R. 
3.7.2 Preparation of cell membranes 
Seventy -two hours post -transfection, cells were washed twice with PBS, scraped 
from 60mM culture dishes using cell scrapers (Falcon) and pelleted by centrifugation 
at 1000 rpm for 5 minutes. The cell pellets were resuspended in 20mM Tris, pH 7.2, 
and left to lyse on ice for 10 minutes. The cell suspensions were homogenised using 
a glass homogeniser (BDH) and centrifuged at 14000 rpm for 20 minutes at 4 °C. The 
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buffer was removed by aspiration and the cell membranes aliquoted and stored at 
-70 °C until further use. 
3.7.3 TRH -R (displacement) binding assays 
Displacement curves were generated using 500pM 3H -[3 -Me -His2] -TRH and [3 -Me- 
His2] -TRH (Peninsula) at concentrations ranging from 0.1nM to 101.1M (Lee et al, 
1995). Glass test tubes containing l00111 of 3H[3 -Me -His2] -TRH, l00111 [3 -Me- 
His2] -TRH, 100111 of membrane preparation (20 -50µg of total protein resuspended in 
TRH RBA buffer) and 200µ1 TRH RBA buffer, were incubated for 2 hours at 4 °C. 
The samples were filtered onto Whatman GFB glass filters (pre- treated in 0.5% 
polyethylenimine) using a Brandell cell harvester (Semat), washed three times with 
TRH RBA buffer, and the filter papers shaken overnight in EcoScint scintillant 
(Pharmacia) before counting. Maximum binding (Bo) was measured from tubes 
containing no displacing [3 -Me -His2] -TRH, non -specific binding from tubes 
containing 10-5M [3 -Me -His2] -TRH and blank values from tubes with no 
membranes. 
3.7.4 TRH -R saturation binding assays 
Saturation assays were performed using concentrations of 3H[3- Me- His2] -TRH 
between 40pM- 40000pM. Glass test tubes containing 200µl of 3H[3 -Me -His2] -TRH, 
l00111 of membrane preparation (2014 total protein resuspended in TRH RBA buffer) 
and 200111 TRH RBA buffer, were incubated for 2 hours at 4 °C prior to filtration. 
Non -specific binding was calculated in the presence of 10µg of [3 -Me -His2] -TRH 
and blank values in tubes incubated without membranes. Saturation assays were also 
performed in the presence of the cysteine- modifying compounds dithiothreitol (DTT) 
and p- chloromercuribenzoic acid (p -CMB). These chemicals, obtained from Sigma, 
were added to final concentrations of 20mM and 0.05mM respectively for DTT and 
p -CMB. 
3.7.5 Pre -equilibrium TRH -R binding assays 
Cell membrane preparations were preincubated with DTT at concentrations of 1mM, 
2.5mM, 5mM, 10mM and 20mM or p -CMB at concentrations of 0.01mM, 0.05mM, 
0.1mM, 0.2mM and 0.5mM, on ice for 30 minutes. l00111 of membrane preparation 
(20µg total protein resuspended in TRH RBA buffer) were added to tubes containing 
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l00111 (2nM) 3H[3 -Me -His2] -TRH, 300111 TRH assay buffer and ± lµg [3- Me- His2]- 
TRH (Bo or NSB values). The assay was incubated for 2 hours at 40C. Specific 
binding was calculated as Bo -NSB and expressed per µg of protein. 
3.7.6 Post -equilibrium TRH binding studies 
Glass tubes containing l00111 of membranes (2014 total protein resuspended in TRH 
RBA buffer), 10011l (2nM) 3H -[3 -Me -His2] -TRH, 30011.1 TRH assay buffer and ± 1µg 
[3 -Me -His2] -TRH (Bo or NSB values) were incubated for 2 hours at 4 °C. Chemical 
modifying agents, DTT or p -CMB, were then added at concentrations of 1mM, 
2.5mM, 5mM, 10mM and 20mM for DTT and 0.01mM, 0.05mM, 0.1mM, 0.2mM 
and 0.5mM for p -CMB, for a further 30 minutes. The assays were then filtered and 
counted. Specific binding was calculated as Bo -NSB and expressed per µg of 
protein. 
3.7.7 Specific activity of GnRH -A/An tracers 
Specific activities of the radiolabelled tracers were calculated from self displacement 
assays using either female rat pituitary homogenates or cell membrane preparations 
from either HEK -293 cells stably expressing the WT GnRH -R or COS -1 cells 
transiently expressing the receptor. Specific activities ranged from 16 to 7511.Ci /µg. 
3.7.8 GnRH saturation binding assays 
GnRH receptor binding assays were set up on ice, in order to minimise degradation 
of the unbound tracer and dissociation of the tracer bound to the membranes. Glass 
tubes containing between 200µ1 of 125I GnRH tracer (5000 cpm to 200000 cpm), 
S0111 of 1% BSA solution, 150111 GnRH RBA buffer and l00111 of membranes (20- 
50µg of total protein resuspended in GnRH RBA buffer) were incubated for 2 hours 
at 40C (Bramley et al, 1985). The samples were filtered onto Whatman GFB glass 
filters (pre- treated in 0.5% polyethylenimine) using a Brandell cell harvester (Semat) 
and washed three times with 5m1 of GnRH RBA buffer containing 0.1% BSA. The 
filter papers were counted on a LBK Wallac y counter at 75% efficiency. Non- 
specific binding was calculated in the presence of 10µg of GnRH -A and blank 
values from tubes incubated without membranes. 
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3.7.9 GnRH displacement binding assays 
Glass tubes containing l00111 of 125I GnRH tracer (100000 cpm), 100µ1 of unlabelled 
GnRH -A at final concentrations of between 10-11M to 10-5M, 50111 of 1% BSA 
solution, 150R1 GnRH RBA buffer and l00µ1 of membranes (20 -5014 of total protein 
resuspended in GnRH RBA buffer) were incubated for 2 hours at 40C. These tubes 
were filtered and counted. Specific binding was measured from tubes containing no 
unlabelled GnRH -A, non -specific binding from tubes containing 10-5M GnRH -A and 
blank values from tubes with no membranes. 
3.7.10 Protein assays 
To determine the concentration of protein in each sample, protein assays were 
carried out in 96 well microtitre plates (Nunc). A protein BSA standard (Biorad) 
was diluted to concentrations of 71.tg /ml, 14µg /ml, 211.tg /ml, 351.1,g /ml, 70µg /ml, 
1051.tg /m1, 140µg /ml for standard curve measurements. The samples were diluted 
accordingly (1:5 and 1:10) in sterile water and 50µ1 of standard or sample added into 
the individual wells of the microtitre plates. In addition, 1501.t1 of sterile water, 
100111 of 0.2M NaOH and 501x1 of Farbstoff -Konzentrat dye reagent (Biorad) were 
added to the plates. The plates were mixed for 20 minutes and the colour absorbance 
measured at 620 nm in a Labsystems plate reader. Data was analysed using the 
computer program Assay Zap. 
3.7.11 Data analysis 
Receptor dissociation constant (Kd) and receptor number (B max) were calculated 
from Scatchard analysis or Cheng and Prussoff analysis (DeBlasi et al, 1989) using 
Sigma Plot. Scatchard analysis involves the calculation of the amount of 
radioactivity bound (B) to cell membranes versus the non -bound amount, or free (F), 
radioactivity. A Scatchard plot involves the plotting of B/F verses B. A linear 
relationship indicates a single affinity binding site with a Kd value calculated from 
the slope of this line and a B max value from its x- intercept. Cheng and Prussoff 
analysis involves the calculation of Kd and B max from measurements of the 
concentration of unlabelled ligand required to displace half the specific binding 
(IC50 values). This analysis is only appropriate when the same compound is used as 
both the radioligand and competitor. Assays were carried out on a minimum of three 
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independent occasions, unless otherwise specified, with individual assay points 
representing the mean of triplicate or duplicate samples. 
3.8 Total Inositol Phosphate (IP) Production 
3.8.1 General methodology 
Total IPs, containing inositol monophosphates -InsPi, inositol bisphosphates -InsP2 
and inositol trisphosphates- InsP3, were extracted and separated according to the 
method developed by Pelvin and Boarder (1988). Cells expressing the receptor were 
labelled with myo [3H]- inositol and then stimulated with ligand. The assays were 
carried out in the presence of lithium ions in order to prevent the recycling of 
monophosphates to inositol. Total IPs produced were extracted, using perchloric 
acid (PCA), and separated on a column containing an anion exchange resin. Water 
was used to elute off free inositol, followed by elution of any 
glycerophosphoinositols with sodium tetraborate /ammonium formate. Finally, the 
total IPs were retrieved by elution with formic acid/ammonium formate solution and 
counted with liquid scintillation counting. 
3.8.2 Incubation with radiolabelled myo -inositol 
Twenty -four hours post -transfection, COS -1 cells were trypsinised from 60mm 
dishes and transferred into 12 well plates. Cells were labelled with 3[H]myo-inositol 
(1.511Ci/well, Amersham) in inositol -free DMEM containing 1% dialysed HIFCS, 
glutamine (0.3mg /m1), penicillin (100IÚ /ml) and streptomycin (10011g /ml), then 
incubated for a further 48 hours (Anderson et al, 1993). 
3.8.3 Total IP Extraction 
COS -1 cells were washed with Buffer A (Appendix I F) and incubated for 20 minutes 
in Buffer A containing 20mM LiCl. Cells were subsequently stimulated with ligand, 
at final concentrations between 10-11M and 10 -2M, for 45 minutes at 37 °C. The 
peptides were purchased from Cambridge Research Biochemicals (TRH), Peninsula 
(GnRH) or Sigma (GnRH). The buffer was then aspirated off, 500111 of 2% 
PCA/5mM EDTA and 501.t1 of 1.8mg /m1 phytic acid solution added, and the plates 
incubated for a further 10 minutes at 4 °C. This solution containing IPs was 
transferred into polystyrene tubes, neutralised with 450111 of neutralisation solution 
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and centrifuged at 3000 rpm for 10 minutes at 4 °C. The supernatant was then 
transferred into a fresh tube containing 5O0111 Ag 1 -X8 anion exchange resin 
(Biorad), vortexed, the resin allowed to settle and the clear upper liquid aspirated off. 
The resin was washed with 1ml of sterile water, vortexed, and the supernatant again 
removed. This procedure was repeated with 1ml 60mM ammonium formate /5mM 
sodium tetraborate solution. Finally, the total IPs were released into solution 
following the addition of 1ml of 1M ammonium formate /0.1M formic acid. An 
800111 aliquot was removed, dissolved in 4m1 Optiphase Hisafe scintillant 
(Pharmacia) and counted using a 1209 Rackbeta liquid scintillation counter. 
3.8.4 Total Counts 
The total incorporation of 3[H]myo- inositol into COS -1 cells was measured to allow 
standardisation of the number of cells in each well. Cells in the 12 well plates were 
washed twice with 2% PCA /5mM EDTA solution, solubilised with 5O0111 0.2M 
NaOH and then neutralised with 400µ1 of 0.66% acetic acid. Optiphase Hisafe 
scintillant was added and total radioactivity in the cells counted as in section 3.8.3. 
3.8.5 Expression of results 
Results are expressed either as dpm or dpm/100000 Total Counts (Tc) with assay 
points representing the mean of triplicate or duplicate samples. Assays were carried 
out on at least three independent occasions unless otherwise stated. 
3.9 Computer and statistical analysis of experimental data 
3.9.1 Computer hardware and software packages 
All the computer software programmes were run on a Power Macintosh 6100/66 
except were otherwise stated. Individual software packages are specified in the text 
as relevant. 
3.9.2 Analytical techniques and significance levels 
The statistical significance of experimental data was analysed by Student's t test 
using Statview. Significance of the calculated t values was assessed against the 
Student t distribution tabulated values at the 95% probability level (p values < 0.05). 
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This chapter has outlined the specific methodology used during the course of this 
study. Chapter 4 now considers the use of molecular models as a means of targeting 
amino acids for site -directed mutagenesis procedures. 
4 Molecular modelling of the GnRH -R and 
GnRH ligand 
4.1 Introduction 
To assist in the understanding of the construction of the three -dimensional molecular 
models, a brief review of the recent developments in this area has been included at the 
beginning of the chapter. This background information is considered vital in order 
that the generation of the_models used in this study can be viewed against other GPCR 
molecular modelling approaches. The introductory section encompasses a synopsis of 
the structural determination of bacteriorhodopsin and rhodopsin, together with the 
advantages and disadvantages of their use as templates in GPCR molecular modelling 
studies. The results section deals with the construction of the GnRH ligand and 
receptor models. 
The information derived from these studies was critical in analysing results obtained 
from site -directed mutagenesis studies carried out in Chapters 6 and 7, and in the 
targeting of potentially important GnRH -R amino acids involved in ligand- receptor 
function in Chapter 8. 
4.1.1 Structural determination of heptahelical proteins 
A wealth of data on structure -function relationships in GPCRs has been derived from 
biochemical studies, but it is increasingly important to view this information within a 
three -dimensional structural framework. Bacteriorhodopsin was the first heptahelical 
protein structure to be determined (Henderson et al, 1990), and the structural 
elucidation of a closely related protein, halorhodopsin (Havelka et al, 1995) has 
subsequently followed. Both these proteins are similar in structure to GPCRs but do 
not couple to G- proteins. The first major breakthrough in the structural determination 
of a GPCR was the low resolution 9A projection map of bovine rhodopsin reported by 
Schertler and colleagues (1993). Rhodopsin still remains the only GPCR for which 
hard structural data has been obtained. Two -dimensional crystals of frog rhodopsin 
have also now been purified and 6A and 7A resolution projection maps, generated 
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from these crystals, have provided further insight into the arrangement and tilts of TM 
domains (Schertler and Hargrave, 1995). To date, the structural determination of 
these heptahelical proteins has been limited to the TM domains, primarily due to the 
use of two -dimensional crystals for crystallography. Further advances in 
crystallográphy techniques, however, should permit the development of three - 
dimensional crystals and hence provide the necessary starting material to determine the 
entire GPCR structure. 
Bacteriorhodopsin functions as a light -driven proton pump and is found naturally as a 
two- dimensional crystalline protein in the membrane of the Halobacterium halobium. 
In 1990, Henderson and co- workers constructed a high resolution (3.5 A), three - 
dimensional map, using electron cryo -microscopy techniques (Henderson et al, 1990). 
The model of bacteriorhodopsin revealed the importance of kink- inducing Pro residues 
and highlighted the tilted positions of the helices relative to each other and to the 
membrane. With such a high degree of resolution it was possible to visualise the 
amino acids involved in chromophore binding and proton pump activation. A total of 
21 amino acids constituted the retinal binding pocket and the binding of the 
chromophore, perpendicular to the plane of the helices, was localised to a position 
approximately half way down the central channel. The structural information derived 
from the model was in accord with earlier bacteriorhodopsin site -directed mutagenesis 
studies, and many of these characteristic features have now been extrapolated to 
encompass the entire GPCR family. 
More recently, a three- dimensional structure of the a helices of halorhodopsin, a light - 
driven chloride pump, has been determined from two -dimensional crystals. The 7A 
resolution map generated by Hevelka and co- workers (Havelka et al, 1995), revealed 
that the arrangement of the seven TM helices was similar to bacteriorhodopsin 
although the orientation of the protein framework within the membrane appeared 
rotated by approximately three degrees. 
The low resolution (9A) projection map of bovine rhodopsin reported by Schertler et 
al (1993) revealed that each rhodopsin molecule displayed an elongated arc- shaped 
feature together with four resolved density peaks. Each high density peak was 
thought to represent a TM domain orientated perpendicular to the membrane (helices 
IV, V, VI, VII) with the arc -like feature corresponding to the tilted arrangement of the 
remaining three a helices (helices I, II and III). Comparative structural analysis of 
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bacteriorhodopsin and rhodopsin indicates that whilst both proteins share a common 
heptahelical structure, they differ with respect to the position and tilts of the individual 
helices, as illustrated in Figure 4.1. In bovine rhodopsin, the protein structure appears 
less elongated and- slightly wider relative to bacteriorhodopsin, with helix III deeply 
buried between helix II, IV, V and VII. Helix IV and VII are parallel in orientation 
and occupy a position approximately equidistant from helix III. In bacteriorhodopsin, 
helix IV appears roughly parallel to helix II and III, whilst helix III lies closer to helix 
IV than to helix VII (Donnelly and Findlay, 1994). Two projection maps of frog 
rhodopsin at significantly higher resolution have since been reported (Schertler and 
Hargrave, 1995). The 6A and 7A resolution projection maps closely resembled the 
9A bovine rhodopsin structure but show that helix V carries a much stronger tilt than 
previously realised (Figure 4.1). This information further supports the distinct 
structural differences between rhodopsin and bacteriorhodopsin. 
4.1.2 Molecular Modelling of GPCRs 
The availability of structures for bacteriorhodopsin and rhodopsin together with 
biochemical/biophysical data regarding G- protein structure -function relationships, and 
the technical developments in molecular modelling software has lead to rapid 
advancements in receptor modelling. Many three- dimensional models of GPCRs have 
been constructed, but their degree of adherence to the bacteriorhodopsin/rhodopsin 
template structures varies enormously thus producing markedly different results. 
Homology modelling is now a widely used approach in molecular modelling. This 
technique relies on identifying a known protein sequence that bears a common three - 
dimensional structure with an unknown protein and can, therefore, be used as a 
suitable template. Bacteriorhodopsin provides the basic structural framework for the 
construction of many GPCR models, but these models tend to vary in their degree of 
adherence to its structure. GPCR models, including those of the ß2 adrenergic 
receptor, adenosine Al receptor, muscarinic M1 receptor and thromboxane A2 receptor 
(Yamamoto et al, 1993) have closely followed the co- ordinates of bacteriorhodopsin 
whereas other models, including those for the dopamine D2 receptor, the C5a receptor 
and the opsin receptor, have only utilised the overall topology of the seven TM helices 
(Grotzinger et al, 1991). In this latter receptor group, additional information on the 
structure of other membrane bound proteins together with biochemical data has been 
amalgamated in order to optimise the model's structure. 
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Figure 4.1 Structural comparison of frog and bovine rhodopsin with 
bacteriorhodopsin 
Projection density maps of bovine rhodopsin (9A) and frog rhodopsin (7A and 6A) compared to 
bacteriorhodopsin (BR, 9A, 7A and 6A) (Schertler and Hargrave, 1995). These projection maps 
highlight the structural differences between rhodopsin and bacteriorhodopsin. This figures is printed 
with the permission of Dr G F X Schertler. 
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Bacteriorhodopsin, however, may not prove an ideal template as although structurally 
similar to GPCRs, it does not couple to a G- protein effector system, and has little 
sequence homology with other GPCRs. Many sequence analysis methods fail to 
show any significant alignment between bacteriorhodopsin and GPCRs but use of the 
Clustal algorithm (Thompson et al, 1994) reveals that whilst the homology is low, it is 
sufficient to align GPCR amino acid sequences to bacteriorhodopsin. Molecular 
models of GPCRs using bacteriorhodopsin as a template will clearly differ if 
alternative analysis methods are used to align the GPCR to bacteriorhodopsin. This 
problem has been demonstrated in ß adrenergic models where, despite similarities in 
modelling techniques, different models have been constructed due to variations in their 
alignment with the bacteriorhodopsin template. 
The differences between the electron diffraction patterns obtained for 
bacteriorhodopsin and rhodopsin have also lead to speculation that it is a model of 
limited value on which to base predications about GPCRs. Others groups have argued 
that bacteriorhodopsin and rhodopsin have the same TM three -dimensional structure 
and that differences in their electron diffraction patterns result from altered tilting in the 
protein structures of the two -dimensional crystals (Hoflack et al, 1994) or differences 
in crystal formation per se. This however, now seems unlikely as two different 
crystals of frog rhodopsin have generated a similar electron density map (Schertler and 
Hargrave, 1995). 
Not all GPCR models have been based on the structure of bacteriorhodopsin. 
Alternative models of the dopamine D2 receptor and the ß2 adrenergic receptor have 
also been constructed and both models appear as the mirror image of 
bacteriorhodopsin (Donnelly and Findlay, 1994). Zhang and Weinstein, initially 
favoured a model of the 5HT receptor, derived from molecular dynamic studies, that 
displayed a non -sequential order rather than a clockwise or anticlockwise arrangement 
of the helices: however, they have now adopted the more conventional sequential 
arrangement (Zhang and Weinstein, 1993; 1994). 
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4.1.3 The Baldwin model of GPCRs 
The Baldwin model of GPCRs was based on structural information derived from 
detailed sequence analysis of 204 members of the GPCR family (Baldwin, 1993). 
This model predicts that each TM domain is spatially close to its neighbour in 
sequence and that helix III is deeply buried in the membrane, whereas helices I, IV 
and V are most exposed to the lipid. The observations on helix positioning were 
deduced from the knowledge that certain GPCRs contain very short interhelical loops. 
If all members have an identical helical arrangement, the only feasible structure must 
position helix I beside helix II and helix II beside helix III and so on. The predications 
concerning the relative exposure of each helix to the surrounding lipid surfaces were 
derived from analysis of the hydrophobic nature of the amino acid side chains. By 
assigning each residue -into a class, non -lipid interacting polar residues or lipid 
interacting non -polar residues, and then viewing the structure of the helices in a wheel 
shaped model, it was apparent that helices I, IV, V and VI had a large surface area 
without polar residues whereas helices II, III and VII had a much smaller non -polar 
surface area. This information, in conjunction with the position of conserved amino 
acids and positional differences between closely related sequences, has lead to 
speculation that helices I, IV and V are the most exposed to the lipid and that helix III 
is buried deep in the membrane. 
Baldwin's analysis has allowed a tentative assignment of the order of the helices to the 
peaks observed in the rhodopsin projection map. This proposed arrangement 
appeared similar to the middle region of the membrane -embedded part of 
bacteriorhodopsin, although further analysis revealed differences in the helical tilts. 
These structural differences have been postulated to arise from the presence of a 
disulphide bridge, between a conserved Cys residue in the el 1 and el 2, and the 
altered positions of Pro residues in GPCRs relative to bacteriorhodopsin. Additional 
evidence supporting these findings has been provided from the binding of small amine 
peptides. In these receptors, the helical residues that interact with the ligand, as 
identified by site - directed mutagenesis, are not in an appropriate position in 
bacteriorhodopsin to permit such an interaction. However, the potential mobility of 
the protein must also be taken into consideration and whilst in their unbound state the 
receptors may adopt different orientations, upon ligand- receptor binding there may be 
a high degree of internal conformational change. Receptor mobility, together with the 
different nature of the ligands in GPCRs, suggests that every receptor will have a 
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certain degree of structural diversity and that no one model will accurately predict the 
nature of the binding site. 
A model of rhodopsin, in agreement with Baldwin's model, has been constructed by 
Donnelly using a method that detects helical periodicity in sequence alignments from 
known protein structures (Donnelly et al, 1994). Zhang and Weinstein have used the 
alternative approach of polarity- conserved positioning to determine the orientation of 
GPCR TM helices. Whilst their results are not identical to Baldwin's, they do predict 
that helices III and VII are buried deep within the membrane (Zhang and Weinstein, 
1994). 
4.2 Results 
4.2.1 Structure of the Baldwin model of the GnRH -R 
The Baldwin model of the GnRH -R consists of three cross -sectional wheel diagrams 
through different regions of the TM domains (Figure 4.2). The first diagram depicts 
the position of amino acids located nearest to the TM/intracellular interface (Figure 
4.2a), the second is a view of residues in the middle regions of the a helices (Figure 
4.2b) and the third represents amino acids positioned proximal to the TM/extracellular 
interface (Figure 4.2c). 
Figure 4.2 The Baldwin model of the GnRH -R (following page) 
(a) The Baldwin wheel diagrams of the rat GnRH -R amino acid sequence, viewed from the intracellular 
surface of the receptor. The model shows a cross -sectional view through (a) the intracellular face 11 
amino acids (b) the middle TM domain 12 amino acids and (c) the extracellular surface 11 amino acids. 
Each large circle represents a TM domain with the position of the a carbon atoms represented as dots 
around the periphery and numbered in accordance with the protein sequence of the GnRH -R. The size 
of the dot indicates its depth within the TM domain with the largest dots closest to the intracellular 
face and the smallest dots closest to the extracellular face. These templates were generated by Dr J M 
Baldwin. 
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b rat Gi middl 
c 
1? amino acids 
a) rat GnM -R intracellniar 11 amino acids 
Legend: 
® A 70 Location and number of residue (size of circle indicates depth). 
Polar residue conserved in more than 10% of GPCRs 
Bars indicate non -conserved residues. More bars = more variable. 
Solid triangle indicates residue conserved in > 85% of cases. 
-.0141 Shaded triangle indicates residue conserved in > 75% of cases 
Shaded bar indicates residue conserved in > 65% of cases 
A Broken bar indicates one of a pair of related residues, conserved 
in > 75% of cases. 
(b) rat GnRH -R middle 12 amino acids 
e) rat GnRH -R extracellular 1 I amino acids 
Legend: 
® h 70 Location and number of residue (size of circle indicates depth). 
Polar residue conserved in more than 10% of GPCRs 
Bars indicate non -conserved residues. More bars = more variable. 
Solid triangle indicates residue conserved in > 85% of cases. 
Shaded triangle indicates residue conserved in > 75% of cases 
® Shaded bar indicates residue conserved in > 65% of cases 
01111 NMI Broken bar indicates one of a pair of related residues, conserved 
in > 75% of cases. 
Nf4 
(c) rat GnRH -R extracellular 11 amino acids 
Legend: 
® A 70 Location and number of residue (size of circle indicates 
depth). 
Polar residue conserved in more than 10% of GPCRs 
Bars indicate non -conserved residues. More bars = more variable. 
Solid triangle indicates residue conserved in > 85% of cases. 
Shaded triangle indicates residue conserved in > 75% 
of cases 
am= Shaded bar indicates residue conserved in > 65% of cases 
1111111 Broken bar indicates one of a pair of related residues, 
conserved 
in > 75% of cases. 
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To generate a three- dimensional GnRH -R model, further modulations of the wheel 
diagrams were carried out.- Initially, the individual diagrams were superimposed in 
order to calculate the tilt angles of each TM helix. The TM helices were subsequently 
flipped to obtain -a .view of the receptor from the extracellular surface. Figure 4.3 
illustrates the composite GnRH -R model, as viewed from the extracellular surface, 
and highlights the relative positions of the TM domains as they transverse the 
membrane. A noticeable feature of this model is the markedly different tilt displayed 
by each helix. Helix I, helix II and helix III show dramatic tilts, helix IV, helix V and 
helix VII have only slight tilts whereas helix VI is relatively straight. The amino acids 
targeted for study using the Baldwin model of the GnRH -R are described in Chapter 
7. 
4.2.2 Structure of the computer- derived three -dimensional model(s) 
of the GnRH -R 
The GnRH -R model was constructed using information derived from the structure of 
bacteriorhodopsin and the Baldwin model of GPCRs (Figure 4.4a and 4.4b). The 
bacteriorhodopsin co- ordinates were used as an initial template and the amino acid side 
chains removed to leave the peptide backbone. The skeleton model was then 
reassembled using the modelling computer programme MacMimic and each helix 
rotated and,translated into the position predicted by the Baldwin model. Sequence 
alignment of bacteriorhodopsin and the GnRH -R, as illustrated in Table 4.1, allowed 
the position of the individual amino acids in each GnRH -R helix to be located relative 
to their position in bacteriorhodopsin. Amino acid side chains were then assigned to 
the appropriate Ca atom in the model. The model was then transferred to a Silicon 
Graphics workstation where further manipulations were performed using Sybyl 
(Tripos Associates). The configuration of the Pro residues were adjusted according to 
the main -chain torsion angle as suggested by Sankararamakrishnan, 1991 
( Sankararamakrishnan et al, 1991). The initial locations of the helices left large gaps, 
and these were closed by manually condensing the model, rotating and translating the 
helices to obtain the best fit between the amino acid side chains. The model was 
finally subjected to energy minimisation using the Kollman all -atom energy model. 
An initial round of ten iterations of steepest- descent energy minimisation was followed 
by repeated conjugate -gradient minimisation, to a final energy gradient of 0.05 
kCaUmol. 
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Figure 4.3 The composite Baldwin model of the GnRH -R 
Structural model of the TM domains of the rat GnRH -R as predicted by the Baldwin model. The 
model has been flipped and is a view from the extracellular surface of the receptor, looking inwards 
down the central receptor pore, towards the intracellular face. The TM domains are represented as 
cylinders and the amino acids have been removed in order to give a clear three dimensional view of 
TM domain tilts. 




Figure 4.4 Computer -derived model of the GnRH -R 
Computer model of the TM domains of the GnRH -R with GnRH inserted into a putative binding 
location. (a) side view from within the membrane (b) plan view looking into the pore from outside 
the cell. The TM domains are represented as ribbons so that the individual tilts of the helices and 
their positions relative to other helices can be observed. 
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Table 4.1 Sequence alignment of the rat GnRH -R and bacteriorhodopsin 
Identical amino acids are represented as and conserved homologous residues represented I. 
Sequence homology was analysed using the Clustal algorithm on Gene jockey II. 
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4.2.3 The GnRH computer- derived model 
A model of the GnRH peptide in its biologically active state has been constructed by 
Gupta et al (1993) using an homology modelling approach. Twenty protein templates 
containing at least 5 consecutive amino acids in the GnRH peptide were identified, 
energy minimised models constructed, and the protein segments further categorised 
based on their broad conformational features. Two classes of structure emerged either 
folded or extended, and whilst the extended category displayed structural diversity, 
many of the folded structures contained a common ß -III type turn motif around the 
Trp -Ser- Tyr -Gly segment - a prediction that has also been made for the structure of 
GnRH. Utilising bochemical GnRH structure -function information, one molecular 
structure from Streptomyces griseus proteinase A (Sielecki et al, 1979) had an 
appropriate conformation and was used as the basis for the GnRH model. This 
molecule appeared folded bringing the N- and C- termini close together in a hairpin 
configuration. It is known that a D- amino acid following a ß -III turn stabilises the 
turn and an extensive family of GnRH super -agonists incorporate a D -amino acid at 
position 6, serving to confirm the model. The location of the Gly at position 6 in the 
Gupta model, in close proximity to the ß -III turn, would allow such a substitution. 
The side chains of Trp3 and Arg8 are exposed suggesting their importance for receptor 
interactions. Arg8 has a high positive electrostatic potential in keeping with the 
hypothesis that it is the critical residue involved in species -specific GnRH binding. In 
addition, analogues substituted at position 8 with the amino acids, Lys, Orn or Leu 
showed a reduced positive electrostatic potential in agreement with their decrease in 
biological activity. The Gupta model was used as the basis for the computer- derived 
model of GnRH (MRC, Reproductive Unit, Edinburgh) and this computer model is 
illustrated in Figure 4.5 
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Gly Gly 
Figure 4.5 The computer- derived GnRH model 
A model of the GnRH ligand derived from the Gupta model. This is a stereo pair and can be seen as 
a three -dimensional image if the GnRH structure is viewed cross eyed. The position of the 13-turn 
around the Trp3- Ser4- Tyr5 -Gly6 amino acids can be clearly seen. 
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4.2.4 GnRH ligand and receptor interactions 
The GnRH model was docked into the computer- derived model of the receptor. It 
was immediately apparent that there was only one possible location within the receptor 
structure, between TM II, TM III and TM VII, where GnRH could be located (Figure 
4.4a and 4.4b). However, at this site it is possible to orientate the GnRH decapeptide 
either with the ends of the hairpin configuration or with the Tyr at position 5 going in 
first. Based on the design of GnRH analogues, and the biochemical evidence linking 
the C- and N- termini with receptor binding and activation, it is likely that GnRH 
binds to the receptor with the ends of the molecule entering the receptor pore first. 
Energy minimisation was carried out with the ligand located in this position as 
previously describid in section 4.2.2. A space -filling model showing the position of 
the ligand within the receptor structure is illustrated in Figure 4.6. 
As yet it is uncertain as to how far down the pore the ligand will penetrate but based 
on the observation of retinal binding in rhodopsin and bacteriorhodopsin, it is 
reasonable to presume that the binding and activation sites are roughly in the middle of 
the TM regions. Using the simulated model structures, two amino acids in the 
receptor appear in appropriate positions to interact with GnRH. Leu at position 83 
(Leu83) and Phe at position 312 (Phe312) occupy positions allowing potential 
interactions with Leu? and Trp3 respectively in the GnRH ligand. To test the potential 
importance of these highlighted residues they were mutated either to amino acids of 
similar hydropathicity, different hydropathicity or the small hydrophobic residue Ala 
(see Chapter 8). 
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Figure 4.6 Space -filling model of GnRH- R/GnRH 
Space filling model of the GnRH -R showing a possible arrangement between the TM domains of the 
GnRH -R (blue) and GnRH (yellow). GnRH is in a hairpin configuration with the ß turn nearest Tyr5. 
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4.3 Discussion 
During the course of this study, three -dimensional models of the GnRH -R, the 
Baldwin model and a computer- derived model, together with a computer model of the 
GnRH ligännd were constructed and utilised to predict potential amino acids involved in 
ligand- receptor interactions. 
The Baldwin model of the GnRH -R was constructed from the helical wheel diagrams 
generated by Dr. Joyce Baldwin. A three -dimensional model of the GnRH -R was 
generated by superimposing the three individual wheel diagrams together. This 
provided the first spatial view of the GnRH -R structure and was subsequently used to 
aid in the targeting:of polar amino acids for site -directed mutagenesis (Chapter 7). In 
addition, this model allowed the tentative calculation of the TM domain tilt angles, 
information utilised in the development of the computer- derived model of the receptor. 
In order to construct a three -dimensional computer model of the GnRH -R, it was 
necessary to collate and interpret all the information currently available on GPCR 
molecular modelling techniques. The co- ordinates of bacteriorhodopsin were used as 
a starting point as this is the only heptahelical protein whose structure has been 
determined to near atomical resolution. In addition, as recent evidence suggests that 
the structure of the GPCR rhodopsin provides a more suitable template structure 
(relative to bacteriorhodopsin) (Hoflack et al, 1994), the TM domain tilt angles derived 
from the Baldwin model were also incorporated into the bacteriorhodopsin 
framework. The amino acid side chains of bacteriorhodopsin were stripped off the 
template and those of the GnRH -R subsequently superimposed. Further adjustments 
were then carried out with the Pro residues altered in accordance with the angles 
suggested by Sankararamakrishnan and the TM domains rotated into an optimal 
minimum energy position. 
A computer model of the GnRH ligand was also generated based on the structure 
proposed by Gupta and co- workers. With computer models of both the ligand and 
receptor, it was possible to combine these models and hence predict possible 
interacting sites. From these studies, two amino acids in the GnRH -R, Leu83 in TM 
II and Phe312 in TM VII were targeted for site -directed mutagenesis study, discussed 
in Chapter 8. The ligand- receptor simulation studies were carried out with the NH2 
and COOH ends of the hairpin GnRH structure penetrating furthest into the receptor 
pore. This particular ligand orientation was adopted as the chromophore ligand in 
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bacteriorhodopsin binds in the middle regions of the TM domains (Henderson et al, 
1990). Furthermore, it has been postulated that the COOH and NH2 termini of GnRH 
are principally involved in receptor binding and activation respectively (Nikolics et al, 
1988) and, therefore, it is likely that the ends of the ligand penetrate deepest into the 
receptor pore. However, it is also possible that GnRH is orientated in the opposite 
direction with the residues clustered around the hairpin (Ser4 -Leu7) entering the 
receptor TM domains first. This arrangement seems more unlikely and to date no 
simulation studies have been carried out with GnRH orientated in this alternative 
configuration. 
The computer- derived GnRH -R model has evolved through many different stages 
from the original template structure. The initial position of the TM helices have been 
re- orientated and rotated and the a helices now occupy different positions when 
compared to the starting framework. These alterations are largely as a result of the 
change in the torsion angle of the kink- inducing Pro residues, together with the 
extensive energy minimisation procedures carried out. The present space -filling model 
of the GnRH -R is illustrated in Figure 4.6. 
The modelling approach has proved extremely useful in this study as it has enabled 
structural alterations of the model, based on the information derived from site -directed 
mutagenesis experiments. Furthermore, this permits the reciprocal exchange of 
information, whereby the model can be used to predict amino acids potentially 
important in ligand- receptor binding and the site -directed mutagenesis studies then 
used to assess the accuracy of the model and subsequently redefine its structure 
accordingly. 
The computer modelling and subsequent ligand- receptor simulation studies have 
provided a good framework from which to base predictions about putative ligand- 
receptor amino acid interactions. This approach helped to localise sites within the 
receptor structure where the ligand is most likely to bind, thereby eliminating the 
necessity to mutate every individual receptor residue. Together the molecular 
modelling and site- directed mutagenesis studies create a very powerful targeting 
approach, whereby the models can be used as hypothetical indicators of amino acid 
function and the site -directed mutagenesis data used to provide hard biochemical 
evidence for these predications. 
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Molecular models of the GnRH -R TM domains have been utilised in Chapters 6, 7 
and 8 to predict amino acids involved in ligand- receptor interactions and to analyse 
site -directed mutagenesis data. However, no molecular models of the extracellular and 
intracellular loop structures of GPCRs have been generated and, therefore, examining 
the role of such residues must be carried out without the use of these models. Chapter 
5 has focused on the function of extracellular Cys residues in disulphide bond 
formation and this study is based on comparative sequence information from other 
GPCRs. 
5 Role of extracellular Cys residues in 
the GnRH -R and the TRH -R 
5.1 Introduction 
Sequence analysis of many GPCRs has identified the presence of two conserved Cys 
residues in the extracellular domain. Cys residues contain sulfhydryl groups ( -SH) 
which are involved in the formation of disulphide bridges (Figure 5.1). Furthermore, 
it has been postulated that these disulphide bonds function to stabilise the three 
dimensional intra- helical receptor structure (Baldwin, 1994). The orientation and 
folding of the receptor within the membrane is vital so that the ligand can gain entry 
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Figure 5.1 Structure of cysteine residues and the formation of disulphide bonds 
(a) Chemical structure of Cys residues showing their free sulfhydryl (SH) groups and (b) the formation 
of a disulphide bond ( *) between closely positioned extracellular Cys residues. 
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The rat GnRH -R contains 4 extracellular Cys residues with two conserved residues 
positioned at Cys 114 in the el between TM II and TM III (el 1) and Cys 195 in the el 
between TM IV and TM V (el 2). The other two extracellular Cys residues occupy 
non -conserved positions at Cys 14 and Cys 199 in the NH2 terminus and el 2 
respectively. In order to investigate the role of extracellular Cys residues in the 
GnRH -R and examine their potential involvement in disulphide bond formation, all the 
GnRH -R extracellular Cys residues were replaced by Ser. The amino acids targeted 
for study are illustrated in Table 5.1. Figure 5.2 shows a schematic diagram of the 
GnRH -R highlighting the position of these four Cys residues together with their 
potential involvement in disulphide bond formation. 
GnRH -R Mutant TM Position Amino acid modification 
Cysl4Ser 
Cys114Ser 






C to S 
C to S 
C to S 
C to S 
Table 5.1 GnRH -R Cys /Ser mutations 
Amino acids in the GnRH -R targeted for site -directed mutagenesis and their corresponding amino acid 
substitutions. 
To assess the functional role of these GnRH -R mutants, the mutant DNA was 
expressed in an in vitro culture system. COS -1 cells, a monkey kidney fibroblast cell 
line, were transiently transfected, with either the WT or mutant GnRH -R constructs 
and subsequently tested for their ability to bind a radiolabelled GnRH agonist (GnRH- 
A), and elicit an appropriate GnRH- induced second messenger response. Following 
the failure of the GnRH -R Cys to Ser mutations to produce any ligand binding 
response (see Results 5.2.1) it was decided, for comparison, to conduct a similar 
study in another pituitary peptide receptor, the TRH -R. 
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Figure 5.2 Structure of the rat pituitary GnRH -R 
Schematic representation of the rat pituitary GnRH -R showing the classical heptahelical structure of a 
GPCR. Conserved extracellular Cys114 and Cys195 and non -conserved extracellular Cys14 and 
Cys199 are shown in putative disulphide bond formations. 
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The TRH -R provides a good comparative model as it has many similarities to the 
GnRH -R. TRH -R regulates the action of TRH, a hypothalamic neuropeptide, 
responsible for controlling the synthesis and release of TSH and PRL from the 
anterior pituitary gland (Metcalf and Jackson, 1989). Like the GnRH -R, ligand - 
induced activation of the TRH -R is mediated through the G- proteins, Gq and G11 
(Aragay et al, 1992; Hsieh and Martin, 1992). 
The rat TRH -R contains two conserved extracellular Cys residues, Cys98 (el 1) and 
Cys179 (el 2). In addition, another extracellular Cys residue lies in close proximity to 
Cys98 at position Cys100 at the el 1/TM III interface (Sellar et al, 1993). To assess 
the disulphide bonding role of TRH -R Cys residues, these amino acids were mutated 
to Ser (Cys98Ser, Cys 179Ser and Cys 100Ser). Furthermore, these sites were also 
mutated to Ala (Cys98Ala, Cys 179Ala and Cys 100A1a) as studies in rhodopsin 
revealed that substitution of extracellular Cys residues with non -polar amino acids 
maintains normal levels of receptor expression (Davidson et al, 1994). The amino 
acids targeted for study are summarised in Table 5.2 and their positions within the 
TRH -R are illustrated in Figure 5.3. A putative disulphide bonding interaction 
between the two conserved Cys residues, Cys98 and Cys 179, together with the 
position of Cys100 at the el 1/TM III interface is highlighted (Figure 5.3). 









el 1/TM III 
el 1 
el 2 
el 1/TM III 
C to S 
C to S 
C to S 
C to A 
C to A 
C to A 
Table 5.2 TRH -R Cys /Ser and Cys /Ala mutations 
Amino acids in the TRH -R targeted for site -directed mutagenesis and their corresponding amino acid 
substitutions. 
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Figure 5.3 Structure of the rat pituitary TRH -R 
Schematic representation of the rat pituitary TRH -R (the 411 amino acid long form) (Sellar et al, 
1993) showing the classical heptahelical structure of a GPCR. Conserved extracellular Cys98 and 
Cys179 are highlighted in a putative disulphide bond formation. The position of the non -conserved 
extracellular Cys 100 at the extracellular/ TM interface is also highlighted. 
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To complement the site -directed mutagenesis data, a further investigation into the role 
of extracellular Cys residues in TRH -R disulphide bonding interactions was carried out 
using the disulphide- reducing chemical agent dithiothreitol (DTT). In addition, as 
evidence suggests_ that Cys residues carrying free sulfhydryl groups (i.e. those not 
involved in disulphide bond formation) may also participate in receptor binding 
processes, parallel studies were conducted using p- chloromercuribenzoic acid (p- 
CMB) - a chemical compound that reacts with Cys residues carrying free sulfhydryl 
groups (Lu et al, 1993). The aim of these chemical modification studies was to 
investigate the effects of specific reagents on Cys residues, either those involved in 
disulphide bonding (using DTT) or Cys residues carrying free sulfhydryl groups 
(using p -CMB), and to determine how chemical modification interferes with normal 
receptor binding mechanisms. 
5.2 Results 
5.2.1 Cys residues in the GnRH -R 
Scatchard analysis of competitive receptor binding assays revealed that the GnRH -R 
WT had a Kd (± SEM) value of 3.8 ± 0.38 nM and a B max (± SEM) value of 1.60 ± 
0.49 pmol/mg protein (Figure 5.4). 
Ligand- induced total IP production measurements, in COS -1 cells transiently 
expressing the GnRH -R WT, showed a two fold increase when stimulated with 111M 
GnRH (Figure 5.5). In contrast, GnRH -R mutants Cysl4Ser, Cys 114Ser, 
Cys195Ser and Cys199Ser exhibited no receptor binding when compared to the WT 
and hence failed to display a ligand- induced second messenger response as shown in 
Figure 5.5. 
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Figure 5.4 WT GnRH -R agonist binding data 
Scatchard analysis of GnRH -A binding to COS -1 cells transiently expressing the WT GnRH -R. 
Competition receptor binding assays were performed using an iodinated GnRH -A [des Glyl °, D -Trp6, 
Pro9 NEt] -GnRH on membrane preparations. Data points are the mean of duplicate /triplicate samples 
and the graph is a representative example from n =4 experiments. 
Figure 5.5 GnRH -R WT and Cys /Ser mutants total inositol phosphate 
production (following page) 
Total IP production in COS -1 cells transiently expressing the GnRH -R WT and mutants Cysl4Ser, 
Cys114Ser, Cys195Ser and Cys199Ser. The open bars represent the basal stimulation following the 
addition of Buffer A only whilst the hatched bars represent IP production with 1RM GnRH. Each bar 
is the mean of duplicate /triplicate samples (± SEM) and the graph is an average of n =3 experiments. 
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Wild -type Cys 14Ser Cys 114Ser Cys 195Ser Cys 199Ser 
The Cys to Ser substitutions prevented ligand binding and receptor activation, 
indicating that extracellular Cys residues have an important role in receptor function. 
The loss of ligand- receptor binding displayed by GnRH -R mutants Cys 14Ser, 
Cys 114Ser, Cys 195Ser and Cys 199Ser probably arises from alterations in disulphide 
bonding patterns, resulting in destabilisation of the receptor's three dimensional 
extracellular structure. ,. 
In rhodopsin, substitution of Cys residues with hydrophilic Ser residues decreased 
levels of receptor expression (Karnik et al, 1988). Therefore, it is possible that the 
loss of receptor binding and second messenger coupling in the GnRH -R Cys /Ser 
mutations may reflect a lack of functionally active cell surface GnRH -Rs. The next 
logical step was hence to measure mutant GnRH -R expression levels, but at this stage 
a receptor specific antibody was unavailable. To overcome this problem it was 
decided to generate GnRH -R antibodies (see section 9.2.1). However, this proved 
more difficult then initially perceived and is still an ongoing project. 
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5.2.2 Cys residues in the TRH -R 
The Kd and B max of TRH -R mutants CyslOOSer and Cys 100Ala, calculated from 
displacement curves (Figure 5.6), were comparable to WT (Table 5.3) and both these 
mutants showed WT levels of ligand- induced total IP production (Figure 5.7 a and b). 
TRH -R mutants Cys98Ser, Cys 179Ser, Cys98Ala and Cys 179Ala expressed in COS - 
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Figure 5.6 TRH -R WT and Cys100 mutants agonist binding data 
Displacement of 3H[3 -Me -His2] -TRH (500pM) binding to COS -1 cell membranes transiently 
expressing the TRH -R wild -type or mutants CyslOOSer and Cys100Ala by unlabelled [3- Me- His2]- 
TRH (0.1 nM to 1 µM). Data points represent the mean of duplicate /triplicate samples and the graph is 
a representative example from n =3 individual experiments. 
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TRH -R Construct Kd ± SEM (nM) B max ± SEM 
(pmol /mg protein ) 
Wild -Type 2.73 ± 0.68 2.13 ± 0.80 
Cys98Ser no binding - 
Cys98Ala no binding - 
Cys 179Ser no binding 
Cys 179Ala no binding - 
Cys 100Ser 2.23 ± 0.22 1.79 ± 0.75 
Cys100Ala 3.56 ± 0.42 
_ 
1.40 ± 0.55 
Table 5.3 Summary of TRH -R WT, Cys /Ser and Cys /Ala mutant binding data 
Table summarising TRH -R binding assay data. Receptor dissociation constant (Kd) and receptor 
number (B max) were calculated from Scatchard analysis of competition receptor binding assays. Kd 
and B max values are the average ± SEM of at least n =3 individual experiments. 
Figure 5.7 TRH -R WT, Cys /Ser and Cys /Ala mutants total inositol phosphate 
production (following page) 
Total IP production in COS -1 cells transiently expressing the TRH -R WT or mutant receptors 
following stimulation with TRH (100pM -10mM) (a) TRH -R WT and mutants Cys98Ser, Cys179Ser, 
and CyslOOSer (b) TRH -R WT and mutants Cys98Ala, Cys 179Ala and Cys 100Ala. Untransfected 
COS -1 cells Ave used as a negative control. Data points represent the mean of duplicate/triplicate 
samples and the graph is a representative example from n =3 individual experiments. 
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These results were similar to those obtained for the GnRH -R, but again the lack of 
receptor -specific antibodies hindered the measurement of receptor expression levels. 
However, experiments by Gershengorn and co- workers have overcome these 
problems by measuring TRH -R mutant IP responses in the presence of high 
concentrations of TRH (Perlman et al, 1994a,b; 1995). Their results have shown that 
it is possible to elicit a functional response in some mutant receptors, with non - 
detectable levels of receptor binding, using concentrations of stimulating ligand 
between 1µM and 10mM. Furthermore, from these experiments the potency of mutant 
receptors can be estimated. A similar experiment was thus conducted in the six TRH -R 
mutant constructs, The EC50 values of total IP stimulation by TRH for cells 
expressing WT, Cys98Ser, Cys98Ala and Cys 179Ala were 0.0041.1,M, 100011M, 
60µM and 60µM -respectively. Maximum levels of IP stimulation were 70% for 
Cys98Ser, 100% for Cys98Ala and 70% for Cys179Ala when compared to WT 
(Figure 5.7 a and b). In contrast, Cys 179Ser showed no IP stimulation with TRH at 
any of the concentrations used (Figure 5.7a). 
The chemical modification studies (with DU and p -CMB) were conducted using cell 
membranes prepared from either COS -1 cells transiently expressing the TRH -R or 
from a stably expressing cell line, HEK -293 E2 cells (as both cell types gave similar 
results in receptor binding experiments). Cell membranes were either pre- treated with 
each of thé reagents for 30 minutes on ice (pre -equilibrium), or added to the receptor 
binding assay after equilibrium had been reached (post -equilibrium). Pre- incubation of 
membranes with DU resulted in a dose -dependent partial decrease of radiolabelled 
TRH -A binding and inhibition was about 20% at a concentration of 20mM DTT 
(Figure 5.8a). The effects of DTT were fully reversible as WT values were restored 
after membranes were washed with assay buffer. Addition of DTT for 30 minutes to 
the receptor binding assay, post -equilibrium, did not alter the dose -dependent decrease 
in TRH -A receptor binding when compared to membrane pre -treatment (Figure 5.8a). 
Following pre- treatment of membranes with p -CMB, a dose -dependent decrease in 
specific binding of TRH -A was observed (Figure 5.8b). The action of p -CMB was 
irreversible as removal of the chemical agent, by washing membranes twice in assay 
buffer, did not significantly alter the dose response profile. However, addition of p- 
CMB for 30 minutes, post -equilibrium, at concentrations of 0.1mM and higher was 
significantly less effective in reducing specific binding relative to the pre- incubated 
membrane treatment (Figure 5.8b). Non -specific binding was not affected in these 
experiments. 
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Figure 5.8 Chemical modification of the rat TRH -R WT (following page) 
(a) The effect of DTT on 3H[3- Me -His2] -TRH (250pM) binding to HEK -293 E2 cell membranes (20- 
50µg total protein) expressing the rat TRH -R. Membranes were pre -treated for 30 minutes on ice with 
DTT (1mM to 20mM ) _ (open bars) before addition to the assay or the DTT added for 30 minutes after 
the assay had reached equilibrium (hatched bars). Assays were incubated for 2 hours at 4 °C and the data 
points represent the mean of duplicate /triplicate samples ± SEM. 
(b) The effect of p -CMB on 3H[3- Me -His2] -TRH (250pM) binding to HEK -293 E2 cell membranes 
(20 -5014 total protein) expressing the rat TRH -R. Membranes were pre- treated for 30 minutes on ice 
with p -CMB (0.01mM to 0.5mM ) (open bars) before addition to the assay or the p -CMB added for 
30 minutes after the assay had reached equilibrium (hatched bars). Assays were incubated for 2 hours at 
4 °C and the data points represent the mean of duplicate /triplicate samples ± SEM. 
p values represent * p<0.05 and ** p <0.01. 
Saturation analysis of TRH -A binding was conducted in the absence or presence of p- 
CMB (0.05mM) or DTT (20mM). Membranes were incubated with buffer (control) or 
in the presence of these reagents for 30 minutes before the addition of radiolabelled 
TRH -A in the range 40- 8000pM. Receptor number for DTT- treated membranes was 
significantly reduced (B max ± SEM of 3.8 ± 0.2 pmol/mg protein, p <0.05), while 
receptor affinity (Kd ± SEM = 4.5 ± 1.0) was comparable to control values. The 
presence of p -CMB decreased receptor number values (B max ± SEM of 2.3 ± 0.2 
pmol/mg protein, p< 0.01) compared to control values (B max ± SEM of 4.8 ± 0.6 
pmol/mg protein). Receptor affinity (Kd ± SEM = 5.0 ± 0.7) was not significantly 
different when compared to the control (Kd ± SEM = 3.8 ± 0.5). 
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Northern Blot analysis was used to compare the expression of TRH -R mutant RNA 
with WT RNA. Figure 5.9 shows a Northern Blot of total RNA extracted from COS -1 
cells transiently expressing the WT and mutant TRH -Rs. RNA extracted from HEK - 
293 E2 cells is a positive control and RNA from untransfected HEK -293 and COS -1 
cells are negative controls. The size of the TRH -R mRNA transcript is approximately 
4 kb (Figure 5.9a). Hybridisation of a radiolabelled 18S oligonucleotide probe with a 
1.9 kb band corresponding to 18S RNA showed equivalent amounts of RNA were 
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Figure 5.9 Northern Blot of TRH -R WT, Cys /Ser and Cys /Ala mutants 
(a)Northern blot probed with a [32P]adCTP labelled 2.5 kb rat TRH -R insert showing RNA 
expression levels in total RNA (151.1g) from COS -1 cells transiently expressing TRH -R Cys 
mutations (Cys100Ala, Cys179Ala, Cys98Ala, CyslOOSer, Cys179Ser, Cys98Ser) (lane 1 -6), wild - 
type (lane 7), untransfected COS -1 cells (lane 8), and HEK -293 cells (lane 9), and HEK -293E2 cells 
(lane 10). 
(b) Northern Blot probed with [32Pty dATP labelled anti -18S oligonucleotide to check for the 
presence of even RNA loading in the corresponding wells. 
Experiments were carried out on at least n =3 independent occasions using different batches of RNA. 
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5.3 Discussion 
Sequence alignment of over 200 members of the GPCR family show that there are two 
conserved Cys fesidues found in el 1 and el 2 of 92% of these receptors (Baldwin, 
1994; Probst et al, 1992). In the GnRH -R, these conserved Cys residues are found at 
Cys 114 in el 1 and Cys 195 in el 2. Another pair of non -conserved Cys residues are 
also present in the el domains at Cys 14 in the NH2 terminus and Cys 199 in the el 2 
(Eidne et al, 1992). Extracellular GPCR Cys residues, potentially involved in 
disulphide bridge formation, are thought to be important in stabilising three 
dimensional receptor conformation and facilitating ligand- induced receptor activation 
(Baldwin, 1994). Substitution of these Cys residues with other amino acids should 
prevent disulphide bqnd formation and therefore destabilise the tertiary receptor 
structure. This receptor destabilisation may alter the path of the ligand to its 
recognition site within the TM domain or disrupt the recognition site itself, resulting in 
a loss of binding activity. 
In the GnRH -R, substitution of Cys 14, Cys 114, Cys 195 and Cys 199 with Ser 
residues resulted in a loss of measurable 125I GnRH -A binding and this may be due to 
prevention of disulphide bridge formation. Furthermore, the failure of all four 
Cys /Ser mutations to bind GnRH suggests the presence of at least two disulphide 
bonds. 
The loss of receptor binding activity displayed by the GnRH -R Cys to Ser mutants 
may also reflect a deciéase in mutant receptor expression. To address this possibility, 
GnRH -R antibodies were developed. However, the initial antibodies raised against 
the GnRH -R, in the rabbit, proved non -specific. A different strategy using epitope 
tagging has now been adopted. A hemagglutinin (HA) epitope tag sequence has been 
positioned at the amino acid terminus of the GnRH -R WT sequence. The receptor 
binding and second messenger properties of the HA- tagged GnRH -R have been 
characterised and suitable detection methods established. Presently, this tag construct 
is being incorporated into the GnRH -R Cys /Ser mutations to monitor levels of cell 
surface GnRH -R protein (see section 9.2.3). 
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The role of extracellular Cys residues in the TRH -R was also examined using site - 
directed mutagenesis and chemical modification studies. The decision to investigate 
the function of these residues was based on the following. Firstly, the majority of 
work regarding GPÇR extracellular Cys residues, and their role in disulphide bridge 
formation, has been carried out on catecholamine receptors and rhodopsin, with very 
few studies in peptide receptors. The TRH -R is a pituitary peptide receptor, 
displaying similar receptor coupling properties to the GnRH -R, and hence makes an 
ideal comparative model. Secondly, receptor expression levels can be monitored in 
TRH -R mutants lacking receptor binding function by measuring second messenger 
production in the presence of high concentrations of stimulating ligand. A method of 
monitoring levels of mutant receptor expression, in the absence of a specific TRH -R 
antibody, has been, described by Gershengorn and co- workers (Perlman et al, 1994a, 
b; 1995). These workers have mutated a number of sites within the ligand binding 
pocket of the TRH -R. Some of these mutant receptors exhibit very low affinities for 
TRH analogues and thus are difficult to measure in binding experiments. For such 
mutants, relative affinities were assessed by measuring potencies of second messenger 
stimulation, and the magnitude of the TRH -stimulated IP responses directly correlated 
to levels of TRH -R expression. Attempts to utilise this experimental approach in the 
GnRH -R Cys to Ser mutants was hampered due to low levels of receptor expression. 
For this reason, GnRH- stimulated IP responses could not be correlated to levels of 
GnRH -R éxpression. 
In the TRH -R, conserved extracellular Cys residues are found at Cys98 in el 1 and 
Cys179 in el 2.` Another Cys, Cys100, is located at the el 1/TM III interface (Sellar et 
al, 1993). Substitution of Cys98 and Cys179 to either Ser or Ala resulted in a loss of 
measurable TRH -A binding. The relative affinity of Cys98Ser, Cys179Ser, Cys98Ala 
and Cys 179Ala TRH -R mutants was assessed by measuring the potencies of TRH - 
stimulated IP second messenger production. The potency of these mutants was shown 
to decrease by 4 -5 orders of magnitude. Cys 179Ser showed no IP production at any 
of the concentrations used and this may be representative of a loss of receptor 
expression. Alternatively, as Cys179 is located in the middle of the el 2 any structural 
alterations in this region may affect the three dimensional folding of the receptor. 
Substitution of Cys98 and Cys 179 to Ser showed a decrease in maximum TRH - 
induced IP formation compared to their Cys to Ala counterparts. This may result from 
the hydrophilic nature of the Ser residue. The choice of substituting residue appears 
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critical in site -directed mutagenesis studies. Extracellular Cys residues are commonly 
replaced with hydrophilic-Ser residues and these have been shown to impair receptor 
expression in the muscarinic receptor (Savarese et al, 1992) and in rhodopsin (Karnik 
et al, 1988). A further study in rhodopsin (Davidson et al, 1994), mutating the Cys 
residues to non -polar Ala, demonstrated a protein with normal expression levels but a 
defective signal transduction pathway. The function of disulphide bridge formation in 
rhodopsin therefore appears to be the stabilisation of the active receptor state. In this 
study, both extracellular Cys to Ala substitutions resulted in higher expression levels of 
the receptor protein when compared to Cys to Ser mutations. Northern Blot analysis 
of Cys to Ser and. Cys to Ala TRH -R mutants showed similar expression of all these i 
mutants at the RNA level, indicating that translational and/or post -translational factors 
could be responsible for the observed results. The level of protein cell surface receptor 
expression displayed by these mutant receptors has now also been carried out (See 
Appendix V). 
TRH -R mutants at the extracellular /membrane interface, Cys l00Ser and Cys 100Ala, 
did not affect the receptor binding site as receptor binding parameters and signal 
transduction measurements were similar to the WT receptor. Although Cys 100 lies in 
close proximity to Cys98, its position close to the TM domain makes it an unlikely 
candidate for extracellular disulphide bridge formation. 
Covalent chemical modification of proteins with reagents specific for Cys residues can 
be a useful approach to examine structure -function relationships in GPCRs. DTT, a 
disulphide -reducing agent, and p -CMB, a sulfhydryl- modifying agent, were used to 
further investigate the role of extracellular disulphide bond formation and free 
sulfhydryl groups respectively (Fonseca et al, 1991; Lu et al, 1993). The effects of 
DTT in both pre- and post -equilibrium studies resulted in a small reduction in binding 
which was due to an apparent loss in receptor numbers. These effects were fully 
reversible following removal of DTT. The modest effect of DTT suggests that the 
disulphide bridge could be buried within the TM domain and therefore not fully 
accessible to the action of this reducing reagent. Studies carried out with rhodopsin 
(Karnik and Khorana, 1990) and the a2 adrenergic receptor (Parini et al, 1987) have 
showed that prior treatment with denaturants could greatly enhance the effects of DTT. 
Modification of sulfhydryl groups in the TRH -R with p -CMB resulted in a loss of 
specific receptor binding. Scatchard analysis carried out in the presence of 0.05M p- 
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CMB revealed that there was a loss of available receptor binding sites. Both pre- and 
post -equilibrium incubations with p -CMB resulted in an irreversible reduction of TRH 
analogue binding, in a dose -dependent manner. However, there was a greater loss of 
specific binding fóllowing pre -equilibrium incubations with p -CMB at concentrations 
of 0.1mM and above. Incubation of the membranes with [3- Me -His2] -TRH therefore 
conveys some protection against the action of p -CMB. In the rat TRH -R there are a 
total of 16 Cys residues, 14 of which are potentially available for modification by p- 
CMB (the Cys residues involved in disulphide bridge formation would be unavailable) 
and 7 lie within the TM domains. If the ligand is bound to the receptor prior to the 
addition of p -CMB, the receptor will have adopted a ligand- activated conformational 
state and therefore not all these Cys residues may be available for modification. A 
model of the ligand binding pocket within the TM domains, involving Tyr106, 
Asn110, Arg283 and Arg306 has been proposed by Perlman et al, 1994a, b; 1995. 
TRH binding within this site could conceivably block the action of p -CMB on the free 
sulfhydryl groups of Cys residues lying in close proximity to the active site. 
In summary, site -directed mutagenesis evidence suggests that disulphide bonding 
interactions occur between the extracellular Cys residues Cys 14, Cys 114, Cys 195 and 
Cys 199 in the GnRH -R. Site -directed mutagenesis and chemical modification studies 
in the TRH -R provide further evidence that extracellular Cys residues (Cys98 and 
Cys 179) Are involved in a disulphide bonding interaction. Extracellular disulphide 
bridges appear important in maintaining the correct tertiary structure of the receptor and 
therefore hold the receptor in a conformational state to permit ligand- receptor 
interactions. Chemical modification of other TRH -R Cys residues suggests that some 
of the TM located residues may lie in close proximity to the TRH recognition site. 
This chapter has investigated the role of conserved extracellular Cys residues in 
GPCRs. The following chapter (Chapter 6) focuses on the role of two uniquely 
positioned TM domain residues, Asn87 and Asp318, in GnRH ligand binding and 
receptor activation mechanisms. 
6 Role of amino acids Asn87 and Asp318 in 
the GnRH -R 
6.1 Introduction 
The rat GnRH -R despite its structural homology to other GPCRs exhibits some 
unique features. These differences include the replacement of a highly conserved Asp 
residue in TM II with an Asn, Asn87. This charged residue has been shown to be 
important in mediating receptor binding in monoamine receptors (Strader et al, 1988) 
as well as in receptor coupling (Probst et al, 1994). The reverse substitution occurs in 
TM VII where a highly conserved Asn residue is replaced by an Asp, Asp318, 
suggesting that the function performed by these residues is transposed. Therefore to 
investigate the role of these amino acids and determine whether this apparent amino 
acid inversion has a specific functional role, site -directed mutagenesis experiments 
were carried out. Two single mutations substituting Asn87 to Asp (Asn87Asp) and 
Asp318 to Asn (Asp318Asn) were generated together with a double mutation in which 
both these sites were substituted simultaneously to recreate the situation observed in 
the majority of other GPCRs (Asn87AspAsp318Asn). The amino acids targeted are 
summarised in Table 6.1. 






TM II and TM VII 
N to D 
D to N 
N to D and D to N 
Table 6.1 GnRH -R Asp /Asn mutations 
Amino acids targeted for site -directed mutagenesis and their corresponding amino acid substitutions. 
113 
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6.2 Results 
6.2.1 GnRH -R Asp /Asn mutations 
Alignment between various GPCRs shows the GnRH -R to be virtually unique in its 
possession of an Asn87 residue in TM II and an Asp318 residue in TM VII (Table 
6.2). 
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CYLVSLAVA D LMVLVAAGLP 
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YFITSLACA D LVMGLAVVPF 
YFITSLACA D LVMGLAVVPF 
YFITSLACA D LVMGLAVVPF 
YFLVNLAFA E ACMAAFNTVV 
YFIVNLALA D LCMAAFNAAA 
HFIGSLAVA D LLGSVIFVYS 
ILIASLALG D LLHIIIDIPI 
ALIASLALG D LIYVVIDLPI 
LFISSLALG D LLLLVTCAPV 
-NSAI N PVIYNLM 
-NSAI N PVIYNLM 
ANSSL N PIIYAF- 
VNSGF N PLIYCR- 
VNSAF N PLIYCR- 
VNSAF N PLIYCR- 
SSTMY N PIIYCCL 
SSTMY N PIIYCCL 
LNSTV N PIIYALR 
LNSCI N PIAL-YL 
MNSCI N PIAL-YF 
TNSCV N PFAL-YL 
Table 6.2 Position of conserved TM II Asp residue and TM VII Asn residue in 
GPCRs 
Alignment of the amino acid sequences in TM II and TM VII regions of members of the GPCR 
family. The position of Asn87 (N) in TM II and Asp318 (D) in TM VII is virtually unique to the 
GnRH -R. 
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Scatchard analysis of competition receptor binding assays revealed that the GnRH -R 
WT and mutant Asp318Asn have similar receptor affinities with Kd values (± SEM) 
of 3.8 ± 0.38 nM and 3.9 ± 0.03 nM respectively (Table 6.3). The B max value (± 
SEM) of mutant Asp318Asn was 1.65 ± 0.63 pmol/mg protein, similar to the 1.60 ± 
0.49 pmol /mg protein value calculated for the WT receptor. The displacement of 
radiolabelled GnRH -A with unlabelled GnRH -A is illustrated in Figure 6.1. 
Unlabelled native GnRH peptide was also used to displace the iodinated GnRH -A 
(Figure 6.1) and a ratio of the ED50 values (ED50 GnRH : ED50 GnRH -A) of 10.1 
and 13.4 were calculated for the WT (Figure 6.1a) and Asp318Asn (Figure 6.1b) 
respectively. 
GnRH -R Construct Kd ± SEM (nM) B max ± SEM 
(pmol /mg protein ) 
Wild -Type 3.8 ± 0.38 1.60 ± 0.49 
Asn87Asp no binding 
Asp318Asn 3.9 ± 0.03 1.65 ± 0.63 
Asn87AspAsp318Asn no binding 
Table 6.3 Summary of GnRH -R WT and Asp /Asn mutant agonist binding data 
Table summarising receptor binding assay data. Receptor dissociation constant (Kd) and receptor 
number (B max) were calculated from Scatchard analysis of competitive receptor binding assays. Kd 
and B max values are the average ± SEM of at least n =3 individual experiments. 
Figure 6.1 GnRH -R WT and Asp318Asn mutant agonist binding data 
(following page) 
Displacement curves of GnRH -A binding to (a) GnRH -R WT and (b) mutant Asp318Asn. 
Competitive binding assays were performed using an iodinated GnRH -A [des Glyl0, D -Trp6, Pro9 
NEt} -GnRH, in the presence of different concentrations of either cold GnRH -A or GnRH, on 
membrane preparations from COS -1 cells transiently expressing the GnRH WT or Asp318Asn. 
Specific binding is expressed as a % of the maximum binding (Bo) minus the non -specific binding 
(NSB). Data points are the mean of triplicate samples and the graphs are representative examples 
from at least n =3 individual experiments. 
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Both the WT GnRH -R and Asp318Asn also showed similar levels of specific binding 
when membrane preparations were incubated with the radiolabelled GnRH antagonist 
125I [Ac -3,4- dehydro- Prol- D- p- F- Phe2,D- Trp3'6] -GnRH as illustrated in Figure 6.2. 
In contrast, COS -1 cells transiently expressing the GnRH -R single mutant Asn87Asp 
and the double mutation, Asn87AspAsp318Asn, exhibited no GnRH -A binding 
(Figure 6.2). These mutants also showed no significant GnRH -An binding compared 
to WT. Table 6.3 summarises the GnRH -R agonist binding data for the WT and 
receptor mutants. 
1200' 
Wild -type Asn87Asp Asp318Asn Double 
Mutant 
Figure 6.2 GnRH -R WT and Asp /Asn mutants antagonist binding data 
Specific binding of the GnRH -An 125I [Ac -3,4- dehydro- Prol- D- p- F- Phe2,D- Trp3'6] -GnRH to 
membrane preparations of COS -1 cells transiently transfected with GnRH -R WT or mutants 
Asn87Asp, Asp318Asn and Asn87AspAsp3l8Asn. Specific binding is expressed as maximum 
binding (Bo) minus non -specific binding (NSB). Data points are the mean of triplicate samples and 
the graph represents the average of n =2 individual experiments. 
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Second messenger function of the WT and mutant receptors was ascertained through 
the measurement of GnRH- stimulated total IP production (Figure 6.3). COS -1 cells 
transiently expressing the WT receptor displayed a GnRH- induced dose -dependent 
increase in total IP accumulation. However, both single mutants, Asn87Asp and 
Asp318Asn, together with the double mutation failed to produce an IP response when 
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Figure 6.3 GnRH -R WT and Asp /Asn mutants total inositol phosphate 
production 
Total IP production in COS -1 cells transiently expressing the GnRH -R WT or mutants Asn87Asp, 
Asp318Asn and Asn87AspAsp318Asn following stimulation with GnRH (10 pM -1 .tM). 
Untransfected COS -1 cells used as a negative control (data omitted for clarity) showed only basal 
stimulation at all concentrations of GnRH. Data points are the mean of triplicate samples (± SEM) 
and the graph is a representative example from n =3 individual experiments. 
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6.2.2 Improving expression levels in GnRH -R Asn /Asp mutant 
In general the maximum levels of receptor binding and second messenger total IP 
production observed in the WT GnRH -R were quite low. To improve the transfection 
efficiency séveral alternative chemical transient transfection methods were tested. 
These included CaPO4 (Sambrook et al, 1989), DEAE -Dextran (Sambrook et al, 
1989) and lipofectamine (GIBCO BRL). In addition, pilot studies utilising a non - 
chemical method of DNA incorporation, electroporation, (Andreason and Evans, 
1988) were also carried out. All of the above DNA transfer methods proved 
ineffective in increasing receptor expression levels and therefore attention was focused 
on an alternative vector expression system. Studies this far, utilised the eukaryotic 
expression vector;_pcDNA 1. The WT, Asp318Asn and the double mutant were 
subsequently subcIoned into a new vector, pcDNA 3 (Invitrogen), with a reportedly 
stronger promoter activity and hence potentially higher expression levels. 
Furthermore, a new transfection reagent, Transfectam (Promega), when used together 
with the pcDNA 3 expression system resulted in a three -fold increase in receptor 
expression levels. 
The results using the new expression system were largely similar to those described in 
section 6.2.1. The binding properties of the WT receptor and the Asp318Asn mutant 
were comparable to those observed using pcDNA 1 (see Figure 6.4). However, with 
the improved expression system a small amount of specific receptor binding was 
detectable in the double reciprocal mutation and this equated to approximately 5% of 
WT activity (Figure 6.4). Second messenger activation of the pcDNA 3 WT receptor 
again showed a dose -dependent increase in total IP production with the maximum 
level of stimulation at 1µM approximately seven -fold that of the basal value (compared 
with the 2 -3 fold stimulation above basal levels seen in the WT receptor in pcDNA 1). 
None of the receptor mutants showed a GnRH- induced total IP production (Figure 
6.5). 
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40 - 
Wild -Type Asp3 1 8Asn Double 
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Figure 6.4 GnRH -R WT and Asp /Asn (pcDNA 3) mutants receptor agonist 
binding data 
Specific binding of iodinated GnRH -A [des Glyl0, D -Trp6, Pro9 NEt] -GnRH in COS -1 cells 
transiently expressing the WT and mutants Asp318Asn and Asn87AspAsp318Asn expressed in the 
eukaryotic expression vector pcDNA 3. Specific binding is expressed as maximum binding (Bo) 
minus non specific binding (NSB) ± SEM per µg of total protein. Binding assays were performed 
using an iodinated GnRH -A on membrane preparations. Data points are the mean of triplicate 
samples and the graph represents an average of n =2 individual experiments. 
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Figure 6.5 GnRH -R WT and Asn/Asn (pcDNA3) mutants total inositol 
phosphate production 
Total IP production in COS -1 cells transiently expressing the GnRH -R WT and mutants Asp318Asn 
and Asn87AspAsp318Asn (subcloned into the eukaryotic expression vector pcDNA 3) following 
stimulation with GnRH (10 pM to 1µM). Untransfected COS -1 cells used as a negative control (data 
omitted for clarity) showed only basal stimulation at all concentrations of GnRH. Data points are 
thé mean of triplicate samples and the graph is a representative example from n =2 individual 
experiments. 
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6.3 Discussion 
These results suggest that Asn87 is essential for GnRH ligand binding whereas 
Asp318 is not required for binding, but is necessary for signal transduction. The data 
also indicates that these two amino acids must be located in their natural positions to 
maintain full receptor binding and second messenger coupling activity. However, 
caution must be exercised in the interpretation of results obtained for receptors using 
site -directed mutagenesis studies, since a mutant which abolishes receptor binding 
may do so for any one of several reasons. Activity may be lost because the mutation 
is located in a site which is in contact with the ligand and directly involved with 
binding, or because it is in a remote site which nonetheless affects the size or shape of 
the ligand binding pocket. In addition, the mutation may interfere with post - 
translational processing or the insertion of the receptor into the cell membrane. In this 
study, indirect distortions of the ligand binding pocket are likely to be low as Asp and 
Asn are of similar size and their high frequency of evolutionary substitution would 
suggest that they are readily interchangeable. Furthermore, the near universal 
occurrence of Asp87 in TM H of other GPCRs, implies that there is no reason to 
expect this substitution will interfere with protein processing and/or membrane 
assembly. 
These experiments highlight the necessity for the presence of Asn87 in TM II to 
mediate ligand binding functions of the GnRH -R. Site -directed mutagenesis studies in 
other GPCRs have shown that the Asp residue, normally located in the homologous 
TM II position, is also. a crucial mediator of receptor binding and function. In the ß 
adrenergic receptor it has been suggested that the negative charge carried by the TM II 
Asp residue is involved in both ligand binding and the transfer of information across 
the cell membrane (Chung et al, 1988; Strader et al, 1988). Clearly any potential ionic 
interactions, similar to those observed in the ß adrenergic receptor, are unlikely in the 
GnRH -R as the Asn in this position is uncharged. However, in other GPCRs the 
modification of the Asp residue, through site -directed mutagenesis, has been 
associated with reduced agonist affinity (Chung et al, 1988; Fraser, 1989; Strader et 
al, 1987), altered receptor binding properties in response to pH (Neve et al, 1991), 
sodium (Hortsman et al, 1992; Neve et al, 1991) and GTP analogues (Chung et al, 
1988) together with alterations in receptor coupling activity (Chung et al, 1988; 
Fraser, 1989). 
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In the GnRH -R, Asp318 is important in second messenger G- protein coupling. Site - 
directed mutagenesis studies in the 5HT1A receptor have also highlighted a role for the 
equivalently positioned Asn residue in receptor binding. In the 5HT1A receptor study, 
carried out by Chanda et al (1993) substitution of the TM VII conserved Asn residue 
to either Ala, Phe or Val resulted in a loss of agonist binding, but agonist binding was 
maintained when Gln was introduced at this site. 
The reciprocal mutant was constructed on the rationale that if other GPCRs normally 
contain an Asp in TM II and an Asn in TM VII, then functional activity of the GnRH- 
R single mutant Asn87Asp might be restored on incorporation of an Asn in TM VII. 
However, the findings of this study do not support this hypothesis, as the maximum 
levels of GnRH -A binding in the double mutation (expressed in pcDNA 3) reached 
only 5% of the WT value. Although the double mutation failed to restore WT ligand 
binding properties, the small amount of receptor binding activity suggests that the 
mutation is unlikely to affect receptor membrane assembly or tertiary protein folding. 
The Baldwin model of the GnRH -R structure predicts that conserved TM- located 
hydrophilic amino acids are positioned with their side chains orientated in towards the 
central pore of the receptor. The positions of Asn87 in TM II and Asp318 in TM VII 
in this model are illustrated in Figure 6.6 and whilst both amino acids are inwardly 
facing their side chains lie positioned at right angles, some distance apart. The failure 
of the double mutant to restore significant binding function to the receptor implies that 
the amino acid function is not transposable between the two residues. Furthermore, if 
Asn87 interacts directly with GnRH then the stereochemical configuration of the 
GnRH ligand is unable to support this crucial interaction when Asn is symmetrically 
located on the opposite side of the channel. In contrast to the results obtained for the ß 
adrenergic receptor both Asn87Asp and the double mutation also failed to bind GnRH 
antagonist, implying that Asn87 may be important in the binding of both agonist and 
antagonist analogues. 
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Figure 6.6 Position of Asn87 and Asp318 in the Baldwin GnRH -R model 
Structural model of the TM domains of the rat GnRH -R as predicted by the Baldwin model. The 
model is a view from the extracellular surface of the receptor, looking inwards down the central pore, 
towards the intracellular face. The TM domains are represented by cylinders and the individual tilts 
and relative positions of the helices can be observed. Mutated amino acids are highlighted. 
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These experimental results have been largely substantiated by a similar study carried 
out by Zhou and co- workers (Zhou et al, 1993). This research group also constructed 
two single mutants, Asn87Asp and Asp318Asn, together with a double reciprocal 
mutation in ,the mouse GnRH -R. Again, similar observations regarding the receptor 
binding and functional activation of the single mutants were reported but the double 
reciprocal mutation appeared to have receptor binding activity of between 10% and 
40% of the WT, depending on the efficiency of transfection (Dr James Davidson, 
personal communications). Zhou et al, have suggested that Asn87 is unlikely to be 
directly involved in ligand binding as (i) Asn87 is located at an amino acid position 
generally conserved throughout the GPCR family, (ii) the residue lies too far down the 
receptor channel and (iii) no differential agonist and antagonist binding was observed 
between the WT receptor and the double mutant. They have concluded that "the loss 
of binding of Asp87 mutant must be due a structural perturbation of the receptor that 
either distorts the binding site or disrupts the proper membrane insertion of the mutant 
receptor ". 
These conclusions differ from the interpretation of the results presented in this study. 
Firstly, Asn87 is in a unique position compared to other GPCRs and therefore could 
mediate ligand- induced receptor specificity. Secondly, the position of the TM regions 
has not been absolutely defined and may in fact be quite flexible. In the Baldwin 
model the'TM domains are represented by 26 amino acids and a value of between 20- 
25 amino acids is usually considered as a plausible TM domain length (Baldwin, 
1993). Moreover, there is no information as to how far the ligand penetrates into the 
receptor pore. Thirdly; experiments have suggested that the agonist and antagonist 
sites are different (Janovick et al, 1993) but there is no reason why the failure to 
observe differential binding of both analogues should preclude Asn87 as a direct 
mediator of-receptor binding function. For these three reasons it is possible that 
Asn87 has a direct functional role in GnRH- specific binding. Additional evidence 
supporting a putative role for Asn87 in GnRH -R binding also comes from analysis of 
the computer simulated model of the GnRH ligand and receptor (Figure 6.7). When 
GnRH is positioned in an optimal binding position, the COOH terminus of the 
decapeptide, implicated as an important mediator of receptor binding function, comes 
in close proximity to Asn87. 
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Figure 6.7 Position of Asn87 and Asp318 in the computer -derived GnRH -R model 
Computer model of the TM domains of the GnRH -R with GnRH inserted in a putative binding 
location. The position of Asn87 in TM II and Asp318 in TM VII are highlighted. The close 
proximity of Asn87 and Asp318 to the GnRH ligand indicates that possible ligand- receptor 
interactions may be crucial for GnRH binding and receptor activation. The position of Arg8 in GnRH 
is marked with an *. 
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Zhou and colleagues also suggested that the double mutation retains functional activity 
through the restoration of H -bonds between the Asn and Asp residues (Zhou et al, 
1993). They predicted a close spatial arrangement between TM II and TM VII, 
permitting a H -bonding interaction between Asn87 and Asp318. Although this 
bonding pattern is lost in the Asn87Asp single mutation the concurrent introduction of 
an Asn at the TM VII locus recreated this bonding pattern, and therefore restored the 
agonist binding properties of the receptor. However, in this study only 5% of WT 
receptor binding activity was observed for the double mutation. According to the 
proposed model (Figure 6.7), the distances between Asn87 and Asp318 are too great 
for H -bond formation. In addition, H- bonding between these amino acid residues 
would not be feasible if the ligand binds in the position shown between TM II, TM III 
and TM VII. 
The differences between the findings obtained by Zhou and co- workers and this study 
may be due to variations in experimental procedures used. For example; (i) the use of 
different species of GnRH -R cDNA (rat verses mouse) (ii) alternative eukaryotic 
expression vectors or (iii) alternative methods of transfection. 
In summary, mutant Asn87Asp prevented agonist -stimulated receptor binding activity 
and hence second messenger function, whilst Asp318Asn displayed normal WT 
receptor binding properties but was functionally uncoupled from its effector G- 
protein. The generation of a double reciprocal mutation did not restore full receptor 
binding activity and, in fact, this mutation displayed a very low level of receptor 
binding. The double mutation, like Asp318Asn, was also functionally uncoupled. 
These results indicate that Asp318 is important in receptor activation whereas Asn87 
appears important in receptor binding. The position of the Asn87 residue from the 
molecular modelling studies locates this residue in an ideal position to make direct 
contact with the ligand. 
Analysis of the GnRH -R amino acid sequence, relative to the sequences of other 
GPCRs, has provided invaluable information on the potential role of specific residues 
in structure -function relationships. However, an alternative molecular modelling 
approach has been used in the remaining experimental chapters (Chapter 7 and 8) to 
target amino acids potentially involved in GnRH -R ligand binding interactions. 
7 Role of polar amino acids in the TM helices 
of the GnRH -R 
7.1 Introduction 
In this chapter a different approach has been utilised to target potentially important 
residues involved in GnRH -R binding. This strategy involved the analysis of site - 
directed mutagenesis data alongside information derived from the three -dimensional 
Baldwin model of the`GnRH -R (see Chapter 4). 
To predict amino acids in the receptor structure that are likely to be involved in 
ligand binding, both the nature and location of any putative interactions must be 
examined. There are three different types of bonding patterns likely to occur 
between a ligand and its receptor. The first type are ionic interactions, either ionic 
bonds between residues with opposite charges or ionic repulsion between like 
charged groups. The second type of interactions are hydrogen bonds (H- bonds), 
formed between -NH or -OH groups and the C =0 groups in the peptide backbone or 
the -COO- group in Asp /Glu residues. Finally, hydrophobic interactions may also be 
important in ligand- receptor binding mechanisms (this aspect is dealt with in Chapter 
8). Analysis of the 
1 
ligand structure reveals the presence of a highly basic Arg 
residue at position 8 and therefore it is feasible that ionic interactions (either ionic 
bonds or repulsion forces) might play an important part in ligand binding. In 
addition, H bonds may also be involved in ligand- receptor interactions. 
Having established possible types of bonding interactions, attention focused on 
putative sites within the GnRH -R where such interactions might occur. The 
structural elucidation of bacteriorhodopsin /rhodopsin indicated that the retinal 
chromophore binds in the middle regions of the TM domains (Henderson et al, 
1990), hence this region of the GnRH -R was examined for potentially important 
ligand binding sites. Analysis of the middle cross -sectional view of the Baldwin 
GnRH -R model reveals the presence of polar residues G1u90, Lys 121, Glu 174 and 
Asn314, in the centre of TM II, TM III, TM IV and TM VII respectively. These 
residues have been highlighted in the Baldwin model as they represent TM sites 
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occupied by polar amino acids (either a Asn, Asp, Glu, Gln, His or Lys) in at least 
10% of receptor sequences analysed. The presence of hydrophilic TM residues is 
unusual as the TM helices, by definition, are composed of hydrophobic amino acids. 
Therefore, it is- possible that polar amino acids may have an important role in 
mediating receptor functions, as their hydrophilic nature would allow interactions 
with the GnRH ligand. For example, an ionic bond is possible between G1u90 and 
Arg8 in the ligand, ionic repulsions between Lys115 and Lys121 and Arg8, and H- 
bonds between G1n174 /Asn314 and the carbonyl groups of the peptide backbone. In 
addition, these residues are ideally positioned to interact with the ligand as their side 
chains are directed into the centre of the receptor pore. Furthermore, GnRH -R 
residue Lys121 corresponds to Glul 13 in rhodopsin - an amino acid important in 
ligand- receptor activation (Savarese and Fraser, 1992; Zhou et al, 1995). Glul 13 
acts as the counterion for the protonated Schiff base Lys296 and its substitution to 
Gln impairs ligand- receptor signal transduction mechanisms resulting in a change in 
the absorbance spectrum of rhodopsin from 498 nm to 380 nm (Sakmar et al, 1989). 
Studies in the GnRH -R have also indicated that residues located in the 
TM/extracellular interface may also have a functional role in receptor binding 
mechanisms (Davidson et al, 1994). Therefore, the extracellular cross -sectional view 
of the GnRH -R Baldwin model was also examined for any suitably positioned 
residues. This view of the receptor highlights a further three polar amino acids, 
Lys115 in TM III/el 1 together with Asn304 and His305 in TM VII/el 3, which are 
orientated with their side chains pointing in towards the receptor pore. Furthermore, 
the nature of these residues would also permit suitable bonding interactions with the 
ligand. 
In total seven amino acids were targeted, G1u90, Lys115, Lys121, G1n174, Asn304, 
His305 and Asn314. The position of these residues in the Baldwin GnRH -R model 
is illustrated in Figure 7.1 and the mutants generated summarised in Table 7.1. 
Following site -directed mutagenesis, the mutant GnRH -Rs were transiently 
expressed in COS -1 cells and their role in GnRH -R binding and second messenger 
activation tested. In addition, mutants that failed to show any ligand binding 
function using this system were then stably expressed in HEK -293 cells for further 
study. 
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Figure 7.1 Position of TM located polar amino acids in the Baldwin GnRH -R model 
Structural model of the TM domains of the rat GnRH -R as predicted by the Baldwin model. The 
model is a view from the extracellular surface of the receptor, looking inwards down the central pore, 
towards the intracellular face. The TM domains are represented by cylinders and the individual tilts 
and relative positions of the helices can be observed. Mutated amino acids are highlighted. 
Chapter 7 Role of polar amino acids in the TM helices of the GnRH -R 131 
GnRH-R Mutant TM Position Amino acid modification 
Glu90Gln TM II E to Q 
Lys 115Arg TM III/el 1 K to R 
- Lys 1-2 fArg TM III K to R 
Gin 174G1u TM IV Q to E 
Asn304Asp TM VII/e13 N to D 
His305Arg TM VII/e13 H to R 
Asn314Asp TM VII N to D 
Table 7.1 GnRH -R TM- located polar mutations 
Amino acids in the GnRE`I -R targeted for site -directed mutagenesis and their corresponding amino 
acid substitutions. 
7.2 Results 
COS -1 cells transiently expressing the GnRH -R mutants Glu90Gln (TM II), 
Lys115Arg (TM III/el 1), Lys121Arg (TM III), Gln174Glu (TM IV) and Asn304Asp 
(TM VIl/el 3) showed GnRH -A receptor binding properties similar to WT. The 
displacement of radiolabelled GnRH -A with unlabelled GnRH -A is illustrated in 
Figure 7.2. Analysis of displacement curves generated IC50 values of 3.3 nM, 4.1 
nM, 3.6 nM 4.5 nM 4.7 nM and 5.5 nM for the GnRH -R WT and mutants Glu9OGln, 
Lys 115Arg, Lyys 121Arg, Gln 174Glu and Asn304Asp respectively. In contrast, COS - 
1 cells transiently expressing the mutants His305Arg (TM Vil/el 3) and Asn314Asp 
(TM VII) showed no receptor binding with either the GnRH -A or GnRH peptide. 
The WT and mutant GnRH -R binding data is summarised in Table 7.2. 
Figure 7.2 GnRH -R WT and TM polar mutants agonist binding data (following page) 
Displacement curves of GnRH -A binding to GnRH -R WT and mutants. Competitive binding assays 
were performed using an iodinated GnRH -A [des Glyl °, D -Trp6, Prop NEt] -GnRH (100 000 cpm), in 
the presence of different concentrations of cold GnRH -A, on membrane preparations from COS -1 
cells transiently expressing the GnRH -R WT and mutants. Specific binding is expressed as % of the 
maximum binding (Bo) minus the non -specific binding (NSB). Data points are the mean of 
duplicate /triplicate samples and the graph is a representative example from at least n =4 individual 
experiments. 
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GnRH -R mutants G1u90G1n, Lys115Arg, Lys121Arg and G1n174Glu showed similar 
GnRH -stimulated IP production profiles to WT. The ED50 values of WT and GnRH 
mutant receptors Glu90Gln, Lys115Arg, Lys121Arg and Gln174Glu were 7.0 nM, 
10.1 nM, 6.2 nM, 13.0 nM and 6.4 nM respectively (see Figure 7.3). Overall, the 
maximum levels of IP production between GnRH -R mutants and WT were 
comparable, although a considerable interassay variation was observed with mutants 
displaying maximum IP production ranging from 50% to 150% of WT activity. In 
general, the individual transfection efficiencies observed in second messenger 
activation were also displayed in the maximum receptor binding (Bo) values of the 
mutants. By contrast, mutant Asn304Asp, despite a similar WT IC 50 receptor 
binding value, showed a 10 fold increase in the GnRH concentration required to 
stimulate half maximal levels of total IPs (ED50 of 64 nM, Figure 7.3). In addition, 
this mutant showed a slight but significant decrease in maximal WT total IP 
production (p< 0.05). As expected the transiently expressing GnRH -R mutants 
His305Arg and Asn314Asp showed no GnRH ligand- stimulated IP response. WT 
and mutant GnRH -R stimulated second messenger activity is summarised in Table 
7.3. 
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Figure 7.3 GnRH -R WT and TM polar mutants total inositol phosphate production 
Total IP production in COS -1 cells transiently expressing the GnRH -R WT or mutants Glu90G1n, 
Lys115Arg, Lys121Arg, Gln174G1u, Asn304Asp, His305Arg and Asn314Asp following stimulation 
with GnRH (100pM -lp.M). Untransfected COS -1 cells, negative controls, (data omitted for clarity) 
showed only basal stimulation at all GnRH concentrations. Data points are the mean of 
duplicate /triplicate samples and the graph is a representative example from n =3 individual 
experiments. 
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GnRH -R Construct IC50 (nM) ± SEM 
Wild -Type 3.3 ± 0.5 
Glu90Gln 4.1 ± 0.6 
Lys115Arg 3.6 ±0.7 
Lys121Arg 4.5 ± 1.0 
Gln l 74Glu 4.7 ± 1.2 
Asn304Asp 5.5 ± 1.3 
His305Arg no binding 
Asn314Asp no binding 
Table 7.2 Summary of GnRH -R WT and TM polar mutant binding data 
Table summarising receptor binding assay data. IC50 values were calculated from competitive 
binding assays, with iodinated GnRH -A displaced with cold GnRH -A. IC50 values are the average (± 
SEM) of at least n =3 individual experiments. 
GnRH -R Construct ED50 GnRH 
± SEM (nM) 
Maximum IP production 
(% WT) 
Wild -Type 7.0 ± 0.5 100% 
Glu90Gln 10.1 ± 0.1 95.8 ± 20.3 
Lys 115Arg 6.2 ± 1.7 100.2 ± 13.2 
Lys121Arg 13.0± 0.3 89.2± 15.6 
Gin 174Glu 6.3 ± 2.7 96.1 ± 19.8 
Asn304Asp 64 ± 20.0 75.1 ± 14.2 
His305Arg no IP stimulation - 
Asn314Asp no IP stimulation - 
Table 7.3 Summary of GnRH -R WT and TM polar mutant total inositol phosphate data 
Table summarising total IP production. The ED50 values were calculated from GnRH (100pM- l µM) 
stimulated IP production dose response curves. ED50 values are the average (± SEM) of at least n =3 
individual experiments. 
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To establish whether GnRH -R mutants His305Arg and Asn314Asp completely 
abolished receptor binding or whether receptor binding was simply reduced to non- 
detectable levels, stable cell lines of both the WT and these specific mutants were 
constructed in HEK -293 cells. In total, two WT clones (HEK -WT clone 1 and 2), 
two His305Arg clones (HEK- His305Arg clone 1 and 2) and five Asn314Asp clones 
(HEK- Asn314Asp clone 1, 2, 3, 4 and 5) were expanded and screened for ligand 
binding and second messenger properties. In general, different clonal cell lines of 
the same mutation behaved in a similar fashion (the HEK- Asn314Asp clones were 
slightly more variable) and therefore, one representative example of the WT (HEK - 
WT clone 1) and each mutant (HEK- His305Arg clone 1 and HEK- Asn314Asp clone 
3) was chosen f& in -depth study. These clones were subsequently examined for 
GnRH -A receptor, binding parameters and GnRH- stimulated total IP production. In 
addition, GnRH -induced single cell Cat+ responses were also studied in the WT 
clone using dual fluorescent microscopy combined with dynamic video imaging. In 
order to determine any possible effects of the site -directed mutagenesis procedure on 
RNA transcription levels Northern Blot analysis was also carried out. 
Receptor binding parameters, Kd and B max were calculated from Scatchard analysis 
of saturation binding data. HEK -WT cells showed a Kd (± SEM) value of 0.20 ± 
0.14 nM and a B max (± SEM) value of 3.10 ± 0.63 pmol/mg protein (Figure 7.4). 
Saturation binding experiments on cell membrane preparations of HEK- His305Arg 
and HEK- Asn314Asp revealed that both these mutants exhibited a small degree of 
receptor binding but the level was insufficient for Scatchard analysis. To further 
characterise these mutants, receptor binding studies were performed using different 
concentrations of mutant membrane preparations. Total protein concentrations of 20, 
40, 60 and 801.tg were added to each tube and the specific binding calculated. Figure 
7.5a shows that the receptor binding activity of these mutants is markedly reduced 
compared to WT, but that the linear increase in specific binding corresponds to a rise 
in total protein concentration (Figure 7.5a and b). At the maximum total protein 
concentration of 80µg per tube, the specific binding of HEK- His305Arg and HEK - 
Asn314Asp was approximately 1% and 6% respectively of that observed for the WT. 
This is an important finding as it shows that functionally active proteins are 
expressed at the cell surface. 
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Figure 7.4 HEK -WT GnRH -R agonist binding data 
Scatchard analysis of GnRH -A binding to HEK -WT -R. 
performed using an iodinated GnRH -A [des Gly10, D -Trp6, Pro9 NEt] -GnRH on membrane 
preparations from HEK -293 cells stably expressing the rat GnRH -R WT. Data points are the mean of 
duplicate /triplicate samples and the graph is a representative example from n =4 individual 
experiments. 
Figure 7.5 HEK -WT, HEK- His305Arg and HEK- Asn314Asp agonist binding data 
(following page) 
Specific binding of GnRH -A [des Gly10, D -Trp6, Pro9 NEt] -GnRH in the presence of increasing 
concentrations of total protein per tube of (a) HEK -WT GnRH and mutants HEK- His305Arg and 
HEK- Asn314Asp (b) mutants HEK- His305Arg and HEK- Asn314Asp only. Specific binding is 
expressed as maximum binding (Bo) minus non specific binding (NSB) ± SEM. Binding assays were 
performed using the iodinated GnRH -A on membrane preparations. Data points represent the mean 
of triplicate samples from n =2 individual experiments 
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GnRH -stimulated second messenger production in the HEK -WT cells showed a 
dose -dependent increase in total IP production (Figure 7.6) with an ED50 (± SEM) 
value of 5.16 ± 1.0 nM. Again the two receptor mutants showed markedly reduced 
levels of receptpr activation with the maximum level of IP stimulation at 11.1M GnRH 
corresponding tä10% for HEK- His305Arg and 20% for HEK- Asn314Asp compared 
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Figure 7.6 HEK -WT, HEK- His305Arg and HEK- Asn314Asp total inositol phosphate 
production 
Total IP production in HEK -293 cells stably expressing the HEK -WT, HEK- His305Arg and HEK - 
Asn314Asp mutant GnRH -Rs following stimulation with GnRH (100pM -11.1M). Untransfected 
HEK -293 cells, used as a negative control (omitted for clarity), showed only basal stimulation at all 
concentrations of GnRH. Data points represent the mean of duplicate /triplicate samples and the graph 
is a representative example from n =3 individual experiments. 
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In addition to monitoring GnRH induced total IP production, changes in [Ca2 +]i were 
also measured in individual HEK -WT cells using fluorescent microscopy combined 
with dynamic video imaging (Figure 7.7). HEK -WT cells showed a monophasic rise 
in [Ca2 +]i when stimulated with a concentration of 100nM GnRH. See Appendix 
HIA for a description of additional methodology used. 
Figure 7.7 Dynamic calcium imaging of GnRH -R HEK WT 
Effects of GnRH (100nM) on [Ca2 +]i in HEK -293 cells expressing the WT GnRH -R. Data represents 
changes in [Ca2 +]i in a population of cells with time (s). Fluorescent images were obtained by 
exposing Fura -2 loaded cells (41.tM final concentration) to 320 nm and 380 nm light using dynamic 
video imaging. Each frame represents the ratio of 320:380 nm measurements, the frames were taken 
approximately 4s apart and GnRH added after frame 2 (left- right). 
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Northern Blot analysis was used to compare the expression of the GnRH mutant 
RNA with WT RNA. Figure 7.9 shows a Northern blot of total RNA extracted from 
HEK -293 cells stably expressing the HEK -WT GnRH -R (clones 1 and 2) and the 
mutants HEK- His305Arg (clones 1 and 2) and HEK- Asn314Asp (clones 1, 2, 3, 4 
and 5). RNA extracted from aT3 -1 cells was used as a positive control and RNA 
from untransfected HEK -293 and COS -1 cells were negative controls. The GnRH -R 
WT and mutants were cloned into the EcoRI site in the expression vector pcDNA 3. 
This site lies approximately 700 bp from the beginning of the CMV promoter - the 
transcription start site. Therefore as the size of the GnRH -R cDNA is 2.2 kb, an 
expected RNA transcript size would be - 2.9 kb. A 2.9 kb transcript was observed in 
the HEK -WT clone 1, HEK- His305Arg clones 1 and 2 and the HEK- Asn314Asp 
clones 1 and 5 (Figure 7.8a). The other clones, WT clone 2 and HEK- Asn314Asp 
clones 2, 3 and 4 displayed a larger transcript size of - 3.6 kb. A faint band 
corresponding to a 3.6 kb transcript size was observed in the total RNA extracted 
from aT3 -1 cells. No hybridisation occurred in total RNA derived from the 
untransfected HEK -293 or COS -1 cells (Figure 7.8a). 
Hybridisation of a radiolabelled 18S oligonucleotide probe with a 1.9 kb band 
corresponding to 18S RNA showed that equivalent amounts of RNA were loaded 
into each well (Figure 7.8b). 
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Figure 7.8 Northern Blot of GnRH -R WT and mutants stably expressed in HEK -293 cells 
(a) Northern Blot probed with an [a32P]dCTP labelled 2.2 kb rat GnRH -R cDNA probe showing 
RNA expression levels in total RNA (15µg) from GnRH -R HEK -WT and mutants HEK- His305Arg 
and HEK- Asn314Asp stably expressed in HEK -293 cells. The individual lanes represent HEK - 
His305Arg clone 5 (lane 1), clone 4 (lane 2), clone 3 (lane 3), clone 2 (lane 4) and clone 1 (lane 5), 
HEK- His305Arg clone 2 (lane 6 & 7) and clone 1 (lanes 8 & 9) and WT -HEK clone 2 (lanes 10 -13) 
and clone 1 (lanes 14 & 15). COS -1 cells and untransfected HEK -293 cells (lanes 16 & 17) and aT3- 
1 cells (lane 18) 
(b) Northern Blot probed with a [y32P]dATP labelled anti -18S oligonucleotide to check for the 
presence of even RNA loading in the corresponding wells. Experiments were carried out on at least 
n =3 independent occasions using different batches of RNA. 
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7.3 Discussion 
The Baldwin model is a tentative model of GPCR structure with the heptahelical 
arrangement of the TM domains based on the analysis of GPCRs sequence data, and 
superimposed onto the known three -dimensional arrangement of rhodopsin. Using 
this model as a template, a specific model of the GnRH -R was constructed and 
amino acids were targeted for study based on their location within the model. In 
total seven residues were highlighted and mutant GnRH -Rs subsequently generated 
(G1u90G1n, Lys 115Arg, Lys 121Arg, Gln 174G1u, Asn304Asp, His305Arg and 
Asn3l4Asp). All the modified amino acids were located in suitable positions to 
interact with the ligand, either in the middle of the TM domains or at the el/TM 
interface. In addition, the polar nature of these amino acids rendered them capable of 
forming either ionic interactions or H -bonds with the ligand. 
The properties of the WT and mutant GnRH -Rs Glu90G1n, Lys115Arg, Lysl2lArg, 
Gln174G1u, Asn304Asp, His305Arg and Asn314Asp were initially examined in a 
transiently expressing COS -1 cell system. Modifications of the GnRH -R structure at 
amino acid positions G1u90 (TM II), Lys 115 (el 1/TM III), Lys 121 (TM III) and 
Gln174 (TM IV) did not affect GnRH -R ligand binding or activation therefore 
implying that these sites are not involved in receptor binding processes. 
Alternatively, it is possible that any potential role of these residues in receptor 
function was maintained by the corresponding substitutions, particularly as the 
changes introduced at these sites were fairly conservative modifications. The 
rationale underlying the choice of substituting amino acids was based on the premise 
that residues of similar size /charge would prevent any gross changes in the tertiary 
folding of the receptor. Consequently, Lys residues were replaced by Arg, another 
highly basic-amino acid, and Asp and Asn or Glu and Gln were interchanged thereby 
altering the charge but not the size of the residue. Studies in other GPCRs have 
indicated that the choice of amino acid substitutions is a critical factor in determining 
the outcome of site -directed mutagenesis experiments (Caron and Lefkowitz, 1993). 
This aspect is further explored in section 10.2. 
The importance of Lys 121 in GnRH -R ligand binding mechanisms has also been 
highlighted by Zhou and co- workers (Zhou et al, 1995). This group constructed an 
identical substitution Lys121Arg in the human GnRH -R, and their site -directed 
mutagenesis results confirmed the findings reported in this study. In addition, Zhou 
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and colleagues generated three more drastic substitutions, Lys121G1n, Lys121Leu 
and Lys121Asp. Substitution with Gln, Leu or Asp rendered agonist binding below 
the detection limits of the binding assay. Lys121Leu and Lys121Asp showed no 
GnRH -stimulated second messenger production, whilst Lys121Gln showed 
functional 'activation although this was decreased by approximately three orders of 
magnitude compared to WT. Further studies on the second messenger properties of 
Lys121Gln revealed that the GnRH- induced rise in total IP production could be 
inhibited by the GnRH antagonist 27 [Ac- D- Na121, D- a- Me- 4- C1Phe2, D -Trp3, Ser4, 
Isopropy15, D -Trp 6, Leu7, Arg8 , Pro9, D- A1a10] -GnRH. The shift in the GnRH- 
stimulated IP dose -response curves in the presence of varying antagonist 
concentrations were comparable to those observed from the WT, despite the original 
decrease in the XGnRH ED50 values (nM range for WT versus µM range for 
Lys121G1n). From these results Zhou et al, concluded that the presence of a charged 
strength H -bond donor, either Lys or Arg, is required at position 121 for high affinity 
agonist but not antagonist binding. These conclusions, however, are entirely based 
on the ability of antagonist 27 (co- administered with GnRH) to further reduce second 
messenger production in a system already partially disabled due to the Lys121Gln 
mutation. Moreover, these experiments failed to detect any agonist or antagonist 
binding in mutant Lys121G1n, a factor related to the low expression levels displayed 
by the human GnRH -R cDNA clone. In the absence of any direct measurement of 
GnRH analogue binding, these conclusions must be viewed with a degree of 
scepticism. However, it is clear from both studies that the functional role served by 
Lys at position 121 is maintained by substitution to Arg. Analysis of the computer 
GnRH ligand receptor model (Figure 7.9) reveals that Lys 121 lies in close proximity 
to the peptide, between Arg8 and Leu7, and hence it is possible that a H -bond 
interaction might occur between the Lys ( -NH group) in the receptor and the peptide 
backbone of the ligand (-CO = group). 
Mutant Asn304Asp at the el 3/TM VII interface showed a normal WT receptor 
binding IC50 value but displayed a 10 fold decrease in GnRH- stimulated IP 
production. The presence of a negatively charged Asp residue at this site may result 
in changes to the three- dimensional extracellular receptor configuration and therefore 
a greater peptide concentration was required to fully stimulate the G- protein coupled 
effector system. 
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Asn 304 
Asn 314- 
Figure 7.9 Position of TM located polar amino acids in the computer- derived GnRH -R 
model 
Computer model of the TM domains of the GnRH -R with GnRH inserted into a putative binding 
location. The position of G1u90, Lys115, Lys121, Asn304, His305 and Asn314 are highlighted. The 
close proximity of the ligand to TM II, TM III and TM VII can be observed. 
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Substitution of His to Arg at position 305 (TM VIUel 3) and Asn to Asp at position 
314 (TM VII) prevented.ligand recognition and hence GnRH -A/GnRH -stimulated IP 
production. To further examine the affects of these mutations, stable cell lines of the 
WT and mutant receptors were generated in HEK -293 cells. 
The HEK -WT GnRH -R showed a slightly different receptor affinity when compared 
to the transiently expressed receptor. This observation probably reflects certain cell 
specific mechanisms. It is likely that processes mediating RNA transcription, 
receptor expression and membrane insertion will differ between individual cell types 
(i.e. HEK -293 cells versus COS -1 cells) and that phenotypic properties of the cells, 
such as the cómplement of G- proteins and cell surface ion channels, will 
differentially affect receptor binding and second messenger coupling. In addition, 
certain cell types -are intrinsically easier to transfect than others (Titus, 1991). 
Two indicators of second messenger function were examined in the HEK -WT 
GnRH -R. HEK -WT cells showed a dose -dependent rise in total IP when stimulated 
with different concentrations of ligand. In addition, GnRH- induced Cat+ responses 
were measured in single cells using dynamic Calf. imaging. Interestingly, HEK -WT 
cells produce monophasic Cat+ transients in response to a single pulse of GnRH. 
This contrasts with the biphasic responses observed in pituitary gonadotroph cells 
(Anderson et al, 1993) and most probably reflects cell specific mechanisms. 
GnRH -R binding and second messenger coupling were observed in the stably 
expressing GnRH -R mutant cell lines, HEK- His305Arg and HEK- Asn314Asp, but 
levels were markedly reduced compared to the HEK -WT. These results indicate that 
the mutations seriously affect ligand- receptor binding and second messenger 
activation mechanisms. However, the detection of small amounts of binding and 
functional activity implies that the mutant receptors are expressed at the cell surface. 
The position of His305 at the TM VII/el 3 interface suggests that it is unlikely to be 
directly involved in ligand- receptor activation mechanisms. However, a recent study 
in the GnRH -R has implicated an extracellularly positioned amino acid in ligand 
modulation. Davidson and co- workers (Davidson et al, 1994) have shown that the 
G1u301 residue in el 3, located approximately one turn of the helix above His305, 
interacts with Arg8 in GnRH. The Glu301 /Arg8 interaction has been postulated to 
conform and stabilise the ligand prior to its entry into the TM domain. It is therefore 
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possible that the modification of His305 to Arg may interfere with the ligand 
conforming role of G1u301 and hence alter the binding of GnRH to its receptor. 
Levels of cell surface protein expression in GnRH -R mutant His305Arg have not 
been determined and, therefore, alternative explanations for the decrease in receptor 
binding activity displayed by this mutant must also be considered. His305Arg may 
interfere with receptor expression or membrane protein trafficking but the detection 
of some receptor binding and second messenger activity indicates that functionally 
active receptors are present. However, it is impossible to determine whether receptor 
numbers have been reduced by the mutation or if the receptor levels are unchanged 
and the mutation2affects ligand binding function following cell membrane insertion. 
It is also possible that the mutation does not have a direct affect on ligand- receptor 
interactions but that the loss of binding is due to changes in the receptor tertiary 
structure. Furthermore, the substitution of a strongly basic Arg residue, in place of a 
weakly basic His residue, may repel the ligand and thus either preclude access of 
GnRH into the receptor pore or alter its correct course into the TM domains. 
In contrast, the position of Asn314 in the middle of TM VII, with its side chain 
orientated in towards the central receptor pore, positions it in a favourable location to 
directly interact with the ligand. From the computer GnRH ligand- receptor 
simulation studies, Asn314 lies in close spatial proximity to Arg8 in GnRH and also 
to Phe312 (Chapter 8) and Asp318 (Chapter 6) in the receptor structure. During the 
course of this study, Phe312 and Asp318 have been identified as amino acids 
important in receptor binding and activation respectively and therefore it is possible 
that these three amino acids (Phe312, Asn314 and Asp318) act together as a 
functional unit converting ligand- induced receptor conformational changes into the 
activation of the second messenger effector system. However, the effects of the 
Asn314Asp substitution on receptor expression levels or the folding of the 
membrane bound protein are at present unknown. It is also feasible that the 
introduction of a positively charged Asp residue close to the putative binding region, 
distorts the shape of the ligand binding pocket or creates an unsuitable electrostatic 
potential around it. 
In the course of this investigation two different transfection procedures were utilised. 
Initially, the mutant receptors were transiently expressed in monkey kidney 
fibroblast COS -1 cells. The mutants that failed to show ligand binding (His305Arg 
Chapter 7 Role of polar amino acids in the TM helices of the GnRH -R 147 
and Asn314Asp) were subsequently stably expressed in HEK -293 cells, a human 
embryonic epithelial kidney cell line. The primary advantage of using a stable 
expression system is the increase in receptor numbers, a factor which facilitates the 
detection of very low levels of receptor expression. In addition, the clonal expansion 
of single cell colonies provides a homogenous cell population. However, there are 
also certain disadvantages from using this approach. Foremost, it is impossible to 
control either the position of DNA integration or the receptor copy number into the 
host cell genome. Both these factors may have crucial affects on transfection 
efficiency. 
Northern Blot afíalysis was used to study the effects of levels of transcription of the 
mutant receptors;. A variation in transcript sizes was observed in the WT and mutant 
clones with two prominent bands occurring at 2.9 kb and 3.6 kb. RNA transcription 
initiation from the CMV promoter is likely to account for the 2.9 kb transcript, 
whereas the larger transcript size probably arises from either initiation of 
transcription upstream of this site or its continuation past the polyadenylation site 
into the host cell genome. It is possible that the mutant receptor has been 
incorporated into the host cell at a site close to another stronger promoter signal and, 
therefore, RNA transcription can occur from both the CMV promoter and also at a 
position 700 bp upstream of this site. Alternatively, transcription may not be 
terminated by the mutant DNA polyadenylation signal and could continue for an 
additional 700 bp downstream. The size of the a -T3 -1 mRNA, 3.6 kb, is in 
agreement with results obtained from other groups (Reinhart et al, 1992; Wu et al, 
1994). However, a number of different transcript sizes have been reported in a -T3 -1 
cells, suggesting that RNA transcription initiation is possible at several different sites 
(Reinhart et al, 1992; Tsutsumi et al, 1992). Post -transcriptional modifications may 
also account for the differences in transcript size. 
The composite Baldwin model of the GnRH -R provided the first three -dimensional 
image of the receptor structure. However, when this receptor model was generated, 
the spatial dimensions of the ligand and its possible docking site within the receptor 
were completely unknown. This factor made the targeting of amino acids potentially 
involved in receptor binding particularly difficult. Predictions were therefore based 
entirely on possible hypothetical bonding interactions between ligand and receptor 
residues, and were only limited by constraints on the location and orientation of the 
TM amino acids. Out of the seven amino acids targeted, five (G1u90, Lys 115, 
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Lys 121, Gln 174 and Asn304Asp) appeared to have no role in receptor binding. With 
the exception of Lys121, these amino acids are in positions (as viewed in the 
computer generated GnRH -R model, Figure 7.9) outside the putative binding site, 
and are therefore unlikely to participate in ligand- receptor interactions. Initial site - 
directed mutagenesis information implied that Lys 12l was also not involved in 
ligand- receptor binding processes. However, the position of this amino acid, with its 
side chain directly pointing inwards into the putative binding pocket, suggests that it 
may interact with the ligand. It is possible that substitution of another highly basic 
amino acid residue, Arg, at this site fulfils the role of the naturally positioned Lys 
residue. The other two GnRH -R mutants His305Arg and Asn314Asp prevented 
ligand- induced receptor binding and activation. The position of His305 at the TM 
VII/el 3 interface is likely to preclude a direct interaction with the ligand and thus the 
His305Arg mutation probably affects the tertiary structure of the TM /extracellular 
domain. In contrast, amino acid Asn314 is located in an ideal position to interact 
with the ligand (Figure 7.9) and the nature of the amino acid together with its 
location would favour a H -bond interaction with GnRH. 
This chapter has examined the role of TM- located polar residues in mediating 
aspects of GnRH ligand binding function. It is also possible that hydrophobic 
bonding between the ligand and receptor plays an important part in GnRH ligand- 
receptor interactions and this has been explored in the following chapter. 
8 Role of amino acids Phe312 and Leu83 in 
the GnRH -R 
8.1 Introduction 
In this chapter, computer- derived models of the GnRH ligand and receptor were used 
to predict possible hydrophobic interactions between GnRH and its receptor. Analysis 
of the GnRH -R model revealed a suitable site, between TM II, III and VII, capable of 
accommodating the biologically active GnRH hairpin structure. The position of 
GnRH, within the receptor model, was adjusted to orientate the ligand in a low energy 
conformational state. With the ligand positioned in a putative optimal binding site it 
was possible to simulate potential ligand- receptor interactions and identify amino acids 
in the receptor structure capable of interacting with the ligand. Inspection of the 
GnRH model shows that Trp3 and Leu7 are exposed on either side of the hairpin loop 
configuration, surrounded by the other eight amino acids. In the simulated ligand- 
receptor model, Trp3 and Leu7 of GnRH lie in close proximity to amino acid Phe312 
in TM VII and Leu83 in TM II of the GnRH -R respectively (Figure 8.1). In the 
Baldwin model of the GnRH -R these residues are also positioned within the putative 
binding pocket (see Figure 8.2). Leu, Phe and Trp are all hydrophobic amino acids 
and therefore it is possible that the docking of GnRH with its receptor involves 
hydrophobic interactions between these pairs of amino acids. To test this hypothesis, 
six mutant GnRH -Rs were generated by site -directed mutagenesis. To establish if 
these specific amino acids in the receptor formed hydrophobic interactions with the 
ligand, each residue was substituted for an alternative hydrophobic amino acid 
(Leu83Val and Phe312Tyr), or for a hydrophilic residue (Leu83Lys and Phe312Arg). 
In addition, modification of each site to Ala, Leu83Ala and Phe312Ala, was carried 
out to monitor any changes in receptor function resulting from the presence of a 
smaller amino acid. Receptor mutants generated are shown in Table 8.1. 
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Figure 8.1 Position of Phe312 and Leu83 in the computer -derived GnRH -R model 
Computer model of the TM domains of the GnRH -R with GnRH inserted into a putative binding 
location. The position of Phe312 in TM VII and Leu83 in TM II of the GnRH -R model are 
highlighted. The close proximity of Trp3 and Leu 7 in GnRH to Phe312 and Leu83 respectively can 
be observed. 
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Figure 8.2 : Position of Phe312 and Leu83 in the Baldwin model 
Structural model of the TM domains of the rat GnRH -R as predicted by the Baldwin model. The 
model is a view from the extracellular surface of the receptor, looking inwards down the central pore, 
towards the intracellular face. The TM domains are represented by cylinders and the individual tilts 
and relative positions of the helices can be observed. Mutated amino acids are highlighted. 
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F to Y 
F to A 
F to R 
L to V 
L to A 
L to K 
Table 8.1 GnRH -R Phe312 /Leu83 mutations 
Amino acids targeted for site -directed mutagenesis and their corresponding amino acid substitutions. 
8.2 Results 
The receptor affinity (Kd) and receptor number (B max) were calculated by Scatchard 
analysis of saturation binding data. COS -1 cells transiently transfected with GnRH -R 
mutant Phe312Tyr showed a significant increase (p <0.05) in receptor affinity [Kd 
values (± SEM) of 0.65 ± 0.38 nM] for the radiolabelled GnRH -A, compared to the 
WT [Kd values (± SEM) of 1.49 ± 0.38 nM] (Figure 8.3). The B max value of 
Phe3l2Tyr was - 50% of the WT (Table 8.2). The increase in GnRH -R affinity 
displayed by Phe312Tyr was also reflected in the activation of the second messenger 
coupling system. GnRH- stimulated total IP production of the Phe312Tyr mutant 
showed a significantly lower ED50 (± SEM) value of 0.25 ± 0.05 nM (p <0.05) 
compared to the GnRH -R WT value of 3.9 ± 0.9 nM (Figure 8.4a), with maximum 
level of IP production equivalent to that observed for the WT receptor (Table 8.3). In 
contrast, mutant Phe312A1a showed a comparable receptor affinity to WT with a Kd 
value of 1.7 ± 0.45 nM (Figure 8.3). However, the number of receptors was 
markedly reduced to - 33% relative to that observed for the WT receptor (Table 8.2). 
These findings are in agreement with GnRH- stimulated total IP production, as the 
ED50 value of 4.2 ± 0.5 nM was similar to WT (Table 8.3) but the maximum level of 
GnRH stimulated total IP production was reduced to - 28% of WT activity (see Figure 
8.4a). Receptor mutant Phe312Arg showed no GnRH -A binding nor a GnRH- 
stimulated IP response as shown in Figure 8.4a. 
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Figure 8.3 GnRH -R WT and Phe312 /Leu83 mutants agonist binding data 
Scatchard Plot of GnRH -A binding to GnRH -R WT and mutants Leu83 and Phe312. Saturation 
binding assays were performed using an iodinated GnRH -A [des Gly1 °, D -Trp6, Pro9 NEt] -GnRH on 
membrane preparations from COS -1 cells transiently expressing the GnRH -R WT or mutants. Data 
points are the mean of duplicate /triplicate samples and the graph is a representative example from n =4 
individual experiments. 
Figure 8.4 GnRH -R WT and Phe312 /Leu83 total inositol phosphate production 
(following page) 
Total IP production in COS -1 cells transiently expressing the GnRH -R WT and mutants following 
stimulation with GnRH (10 pM to 1 mM) (a) GnRH WT and mutants Phe312Tyr, Phe312Ala and 
Phe312Arg (b) GnRH WT and mutants Leu83Val, Leu83Ala and Leu83Lys. Untransfected COS -1 
cells were used as a negative control showed only basal stimulation at all GnRH concentrations. Data 
points represent the mean of duplicate /triplicate samples and these graphs are representative examples 
from n =3 individual experiments. 
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GnRH -R Construct Kd ± SEM (nM) B max (% WT) 
Wild -Type 1.49 ± 0.38 100% 
Phe312Tyr 0.65 ± 0.35 ( *) 52% 
Phe312Ala 1.70 ± 0.45 33% 
Phe312Arg no binding - 
Leu83Val 1.08 ± 0.54 40% 
Leu83Ala no binding - 
Leu83Lys 2.91 ± 0.81 ( *) 104% 
Table 8.2 Summary of GnRH -R WT and Phe312 /Leu83 mutant binding data 
Table summarising, receptor binding assay data. Receptor dissociation constant (Kd) and receptor 
numbers (B max) were calculated from Scatchard analysis of saturation receptor binding assays. Kd 
and B max values are the average (± SEM) of n =3 individual experiments. Statistical analysis was 
carried out using t -tests and ( *) represents a p value of p <0.05. 
GnRH -R construct ED 50 GnRH 
± SEM (nM) 
Maximum IP production 
(% WT) 
Wild -Type 3.6 ± 0.9 100% 
Phe312Tyr 0.25 ± 0.05 ( *) 89.3 ± 22.5 
Phe312Ala 4.2 ± 0.5 28.2 ± 8.4 
Phe312Arg no IP production - 
Leu83Val 6.1 ± 0.7 56.9 ± 16.3 
Leu83Ala no IP production - 
Leu83Lys 1398 ± 808 ( *) 21.3 ± 4.4 
Table 8.3 Summary of GnRH -R WT and Phe312 /Leu83 mutant total inositol 
phosphate data 
Table summarising total IP production. The ED50 values were calculated from GnRH (10 pM to 1 
mM) stimulated IP production dose response curves. ED50 values and maximum IP production are 
the average (± SEM) of n =3 individual experiments. Statistical analysis was carried out using t -tests 
and ( *) represents a p value of p <0.05. 
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COS -1 cells transiently expressing the GnRH -R mutant Leu83Val showed similar 
receptor binding to WT with a Kd (± SEM) value of 1.08 ± 0.54 (Figure 8.3). The B 
max values were - 40% of the WT receptor. GnRH -stimulated total IP production for 
this mutant also yielded a similar ED50 (± SEM) value of 6.1 ± 0.7 nM, relative to 
WT (Table 8.3). A reduction in the maximum level of IP production to 57% of the 
WT value was observed (see Figure 8.4b). In contrast, receptor mutant Leu83Ala did 
not bind GnRH -A nor couple to the second messenger IP pathway (Figure 8.4b). 
GnRH -R mutant Leu83Lys showed a significant decrease (p <0.05) in receptor 
binding affinity with a Kd (± SEM) value of 2.91 ± 0.81 nM (Figure 8.3). This 
mutant, however, had a similar receptor number compared to WT (Table 8.2). Mutant 
Leu83Lys displayed a marked reduction in second messenger coupling with GnRH- 
stimulated total IP production detectable only above 11.1,M GnRH concentrations. The 
maximum level of total IP production reached only 21% of the WT level when COS -1 
cells were stimulated with 1mM GnRH (Figure 8.4b). 
Northern Blot analysis was used to compare the expression of GnRH -R mutant RNA 
with WT RNA. Figure 8.5 shows a Northern Blot of total RNA extracted from COS - 
1 cells transiently expressing the WT and mutant GnRH -Rs, Phe312Tyr, Phe312Ala, 
Phe312Arg, Leu83Val, Leu83Ala and Leu83Lys. RNA extracted from aT3 -1 cells 
together with RNA from HEK -293 cells stably expressing the GnRH -R HEK -WT and 
mutants. HEK- His305Arg and HEK- Asn314Asp were used as positive controls. 
RNA from untransfected COS -1 cells and HEK -293 cells were negative controls. In 
the Phe312 and Leu83 mutants, a major transcript size of 2.9 kb was observed (Figure 
8.5a). This contrasts with the results from the WT and mutants stably expressed in 
HEK -293 cells (see Chapter 7, Figure 7.8). An aT3 -1 RNA transcript is not visible 
in Figure 8.5a but further exposure of the blot to autoradiographic film (24 hours) 
revealed a faint band corresponding to a transcript size of 3.6 kb (as previously 
described in Chapter 7). Hybridisation of a radiolabelled 18S oligonucleotide probe 
with a 1.9 kb band corresponding to 18S RNA was used to compare the relative RNA 
signal between each well (Figure 8.5b). 
Chapter 8 Role of amino acids Phe312 and Leu83 in the GnRH -R 157 






Figure 8.5 Northern Blot of GnRH -R WT and Phe312 /Leu83 mutants 
(a) Northern blot probed with a [32P]adCTP labelled 2.2 kb rat GnRH -R insert showing RNA 
expression levels in total RNA (151.1g) from COS -1 cells transiently expressing GnRH -R mutants 
Leu83Lys (lane 1), Leu83Ala (lane 2) and Leu83Val (lane 3), Phe312Arg (lane 4), Phe312Ala (lane 
5), Phe312Tyr (lane 6) and the GnRH -R WT (lane 7). Untransfected COS -1 cells (lane 8), and HEK - 
293 cells (lane 9) were negative controls. HEK -293 cells stably transfected with the rat GnRH -R 
mutants HEK- Asn314Asp clone 1 (lane 10), HEK -WT clone 2 (lanes 11 & 12) and HEK- His305Arg 
clone 3 (lane 13) together with aT3 -1 cells (lane 14) were positive controls. 
(b) Northern blot probed with [32P]ydATP labelled anti -18S oligonucleotide. 
Experiments were carried out on at least n =3 independent occasions using different batches of RNA. 
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8.3 Discussion 
Hydrophobic interactions are important in ligand- receptor binding in the ß- adrenergic 
receptor (Strader et al, 1989). To investigate the role of similar interactions in the 
GnRH =R two potentially important sites were targeted using computer simulation 
studies. The generation of computer- derived models of the GnRH ligand and receptor 
has allowed potential ligand- receptor interactions to be examined in a three - 
dimensional spatial orientation. With the aid of these models, possible hydrophobic 
interactions between Phe312 (TM VII) in the GnRH -R and Trp3 in the ligand together 
with Leu83 (TM II) in the GnRH -R and Leu7 in GnRH were hypothesised. To 
investigate the postulated interactions, Phe312 and Leu83 were targeted for site - 
directed mutagenesis study. Results from Chapter 7 indicated that the choice of 
substituting amino-acid was critical in the outcome of site -directed mutagenesis 
experiments. Therefore, three individual mutations were constructed at each site. To 
examine the role of putative hydrophobic interactions between Phe312/Leu83 and 
GnRH, these residues were mutated to amino acids of similar hydrophobicity 
(Phe312Tyr and Leu83Val), and residues of a hydrophilic nature (Phe312Arg and 
Leu83Lys). In addition, to investigate the effects of introducing a small amino acid, 
Phe312 and Leu83 were also replaced by Ala. 
Substitution of the hydrophobic Phe residue to Tyr at position 312 resulted in an 
increase in GnRH -R affinity together with an increase in coupling efficiency to the 
phospholipase C second messenger pathway. The number of mutant receptors was 
decreased to. 50% of WT, whilst the maximum GnRH- induced IP production was 
retained at WT levels. The presence of a highly hydrophilic Arg, however, completely 
abolished.receptor binding and activation, whilst the incorporation of Ala created a 
receptor displaying a WT -like receptor affinity. The second messenger coupling of the 
Ala substituted receptor also showed a similar profile to WT but maximum GnRH- 
induced IP production was decreased in accordance with the reduction in mutant 
receptor numbers. These results suggest that the hydropathicity of the amino acid 
present at position 312 plays a critical role in GnRH ligand- receptor interactions, and 
is involved in the functional coupling of the receptor to its appropriate G- protein. 
The original hypothesis postulated a putative hydrophobic interaction between Phe312 
in TM VII of the GnRH -R and Trp at position 3 in the GnRH ligand. Replacement of 
Phe with Tyr maintained the binding and functional activities of the receptor. In fact, 
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this mutant receptor showed higher receptor affinity and more efficient GnRH -induced 
total IP production, despite its apparent decrease in receptor numbers. Tyr, like Phe, 
contains an hydrophobic aromatic ring and this close structural relationship permits 
Tyr to function in a manner akin to the normally positioned Phe. Therefore, if Phe312 
is involved in a hydrophobic interaction with Trp3 of the ligand, substitution of Tyr at 
this position would be expected to maintain this putative bonding role. Tyr also 
contains an additional hydroxyl group, and it is feasible that the increase in receptor 
affinity and functional activity results from stabilisation of GnRH through the 
interaction of the Tyr hydroxyl group with carbonyl groups of the peptide backbone. 
The decrease it receptor number displayed by Phe312Tyr is a commonly observed 
fording in mutagenesis studies. Mutant receptors tend to express at only 40 -80% of 
WT levels (persónal observations). The reason for this phenomenon is unknown but 
possible alterations in receptor structure /function must occur post -transcriptionally as 
Northern Blot analysis revealed similar levels of RNA transcripts present in both WT 
and mutant GnRH -Rs. Mutagenesis may, however, have adverse effects on mRNA 
translation or interfere with post -translational processing, such as receptor packaging 
and/or the insertion of the receptor into the membrane. In addition, the mutation may 
also affect three -dimensional receptor folding. Site -directed mutagenesis- induced 
alterations in receptor structure, particularly around the ligand binding region, may 
reduce the accessibility of the ligand to its receptor resulting in an apparent decrease in 
receptor number. In this case, the receptor binding site is normal but the mutation 
alters the tertiary receptor structure thereby reducing ligand accessibility. 
The presence of a highly hydrophobic residue at position 312 completely abolished 
detectable levels of receptor binding and activation implying that a hydrophobic 
residue is necessary for ligand binding. The lack of binding observed for mutant 
Phe312Arg may be due to a loss of critical interactions between the ligand and 
receptor. This observation is in accord with the hypothesis that a hydrophobic 
interaction exists between Phe312 and Trp3. If this is the case, then the presence of a 
highly polar Arg residue would not be expected to support such a bonding pattern. 
However, this provides only one explanation for the loss of receptor function 
displayed by Phe312Arg and it is possible that the mutation alters cell surface receptor 
expression (for further discussion see Chapter 9). 
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The size of amino acid also appears important, as the incorporation of a smaller 
hydrophobic Ala residue resulted in a reduced receptor number (a higher receptor 
concentration was required to detect receptor binding) and a corresponding decrease in 
the maximal second messenger production. This substitution, however, retained a 
receptór with WT -like properties of receptor affinity and ED50 value of GnRH- 
stimulated total IP production. These results suggest that the presence of Ala at 
position 312 maintains a functional active receptor, displaying WT characteristics, but 
with a reduced receptor level. In addition, this mutation may alter the three - 
dimensional structure of the ligand binding domain, particularly as Ala is a much 
smaller and less hydrophobic amino acid compared to Phe. This difference in amino 
acid size together with the absence of an aromatic side chain may disrupt the three - 
dimensional conformation of the ligand binding pocket and/or decrease any putative 
hydrophobic interactions with the ligand. 
Together these results imply that a large hydrophobic residue is critical at position 312 
in the GnRH -R in order to maintain a fully functional receptor. It is possible, as 
indicated by the GnRH ligand- receptor computer modelling studies, that Phe312 might 
interact directly with the Trp3 of the ligand. Further analysis of the models reveals 
that Trp3 lies in a position sandwiched between two Phe residues, Phe312 and 
Phe308. This arrangement would create an extremely stable structure and facilitate 
aromatic ring stacking interactions between it electrons of all three aromatic rings 
(Figure 8.6). 
In addition to the importance of a hydrophobic amino acid at position 312 in the 
receptor, the presence of a hydrophobic residue at position 3 in the ligand is required 
for high affinity ligand binding. Structural modification of GnRH at position 3 reveals 
that the presence of a hydrophobic residue at this site is essential for the generation of 
active analogues. Most of the GnRH analogues constructed to date contain Trp 3 or a 
similar hydrophobic structure at this position, and include the agonists Tyr -OMe3, 
4C1Phe -3 and 1-Nal3 (3- (- 1- napthyl) alanine) (Haviv et al, 1992) and the antagonists 
structures D -Pa13 (D 3- pyridinyl alanine) and D -Trp3 (Janecka et al, 1993). 
Substitution of the indole ring by the polar photoreactive 2- nitro -4- 
azidophenylsulphenyl group leads to a complete loss in activity (Nikolics et al, 1988). 
The importance of a hydrophobic residue at position 3 in the ligand also supports the 
hypothesis that a hydrophobic interaction might occur between Trp 3 in the ligand and 
Phe312 in the GnRH -R. 
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Figure 8.6 Space -filling model highlighting GnRH ligand and receptor interactions 
Space -filling model of the GnRH -R showing a possible arrangement between the TM domains of the 
GnRH -R (blue) and GnRH (yellow). The position of Phe312 (left) and Phe308 (right) in the GnRH -R 
are marked by arrows and the position of Trp 3 in GnRH is represented by an *. 
Chapter 8 Role of amino acids Phe312 and Leu83 in the GnRH -R 162 
Substitution of the hydrophobic Leu83 to Val resulted in a mutant receptor displaying 
a similar receptor affinity and GnRH -stimulated total IP ED50 value to the WT 
receptor. The number of cell surface receptors and maximum GnRH- induced total IP 
production was decreased to 40% and 57% of the WT values respectively. The 
presenée of a smaller Ala amino acid at this site, however, completely abolished 
receptor binding and activation whilst the incorporation of a strongly polar Lys residue 
significantly decreased GnRH -R affinity and resulted in an impaired second 
messenger coupling system. These findings suggest that the presence of a Leu residue 
at position 83 maintains a high affinity receptor binding site and permits the coupling 
of the receptor to the membrane bound G- protein. However, these results indicate that 
the most important factor mediating receptor binding and functional activation at Leu83 
is the size of the -amino acid residue and not its hydrophobic nature. 
The original hypothesis predicted a putative interaction between Leu83 in the TM II 
domain of the GnRH -R and Leu 7 in the GnRH peptide. As expected, substitution of 
Leu83 to another hydrophobic residue Val resulted in a fully functional mutant 
receptor with receptor affinity and second messenger function comparable to the 
GnRH -R WT. The maximum level of the second messenger response decreased in 
accordance with the decrease in receptor number. Again, this finding was in accord 
with the predicted hydrophobic interaction between Leu83 in the GnRH -R and Leu? in 
GnRH.. 
Substitution by a strongly hydrophilic residue, however, did not completely abolish 
receptor binding but resulted in a significant reduction in receptor affinity. The effect 
of this receptor mutation was primarily on second messenger coupling with ligand- 
induced total IP production only elevated above basal levels when the system was 
stimulated with high concentrations of GnRH (above 1µM). These findings imply 
that the putative function of the hydrophobic residue at this site may be related to 
receptor activation. 
Modification of the receptor to incorporate Ala at position 83 gave the most surprising 
result. The presence of this small hydrophobic amino acid resulted in a complete loss 
of receptor binding and activation. It is possible that Ala alters the three -dimensional 
structure of the receptor binding domain to such an extent that it completely prevents 
ligand binding and receptor activation. Again, the possibility of a decrease in receptor 
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expression must be considered and without a suitable antibody it is impossible to rule 
out this factor (see Chapter 9). 
Analysis of GnRH analogue structures substituted at position 7 also provided 
information as -to the nature of the amino acid required at this site for high affinity 
binding. Substitutions yielding active analogues are also hydrophobic, with one 
exception, and include the substituents Phe7, cyclohexylalanine7 and cycloleucine7 
(Hazum et al, 1981). Only the mammalian, chicken I and catfish GnRH peptides 
contain Leu7 whilst the native salmon GnRH and chicken II GnRH peptide contain 
another hydrophobic residue Trp in position 7 (Folkers et al, 1984). The one 
exception to the position of a hydrophobic amino acid involves the interchange of 
Leu7 and Arg8 to yield a potent antagonist with low histamine releasing properties. 
This substitution, hówever, is only active if Leu is present in position 8 (Floret et al, 
1992). 
Collectively, these results indicate that whilst a putative hydrophobic interaction could 
exist between the Leu83 in the GnRH -R and the Leu7 in GnRH any such interactions 
mainly affect receptor activation. The size of amino acid appears more important and 
this suggests that the role of Leu83 may be structural. Substitution by a much smaller 
amino acid may alter the three -dimensional structure of the receptor at a critical point 
within TM II, thereby affecting ligand binding and receptor activation. As previously 
highlighted in Chapter 6 Asn87, located approximately one helix turn above the 
Leu83, appears important in receptor binding and thus it is feasible that alterations in 
the protein structure at this point may have a detrimental effect on receptor function. 
In conclusion, the hydropathicity of the amino acid at 312 in the GnRH -R appears 
important in receptor binding with high affinity binding requiring the presence of a 
hydrophobic amino acid at this position. In contrast, the size of the amino acid at 
position 83 appears to be the most critical factor for receptor binding but the presence 
of a large hydrophobic residue is important in G- protein activation. The three - 
dimensional computer- simulated models of the GnRH -R and GnRH ligand predicted a 
putative interaction between Phe312 and Trp3 and between Leu83 and Leu7, and from 
the site -directed mutagenesis data these interactions are still feasible. 
Inevitably measurements of receptor protein expression at the cell surface membrane 
will determine whether these assumptions are valid and the monitoring of cell surface 
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GnRH -Rs is described in the following chapter. However, ultimately only the three - 
dimensional structural determination of the GnRH ligand and receptor will establish 
the precise nature of the interactions between them. In the meantime it is important to 
utilise all thv tools available, including molecular modelling, to advance our 
undersfariding of the mechanisms underlying GnRH -R activation 
9 Monitoring levels of receptor expression 
9.1 Introduction 
Site -directed mutagenesis studies are one of the first approaches used by molecular 
biologists to examine protein structure -function relationships. However, a major 
problem associated with this method is the distinction between mutational effects on 
local structures and those which affect more global factors such as protein folding 
and stability. At present there are no algorithms to predict the possible perturbations 
in protein structure caused by amino acid substitutions and it is possible that single 
base changes, in appropriate locations, may drastically affect protein expression 
(Sambrook et al, 1989). However, such problems can be overcome if independent 
measurements of receptor function can be ascertained. Several methods were used 
to monitor mutant receptor expression and these include (i) the development of 
GnRH -R antibodies, (ii) measurements of differential receptor function and (iii) 
epitope tagging of the GnRH -R. The development of the GnRH -R epitope tagging 
system is the first system which has enabled the measurement of cell surface GnRH- 
R protein. 
9.2 Results 
9.2.1 Monoclonal and polyclonal antibody screening 
A polyclonal antibody, raised against a 15 amino acid sequence in the el 2 of the 
GnRH -R, and a monoclonal antibody raised against 1 -29 residues in the NH2 
terminus were tested using Western Blot analysis. However, neither antibody 
detected a specific GnRH -R protein band from solubilised HEK -WT GnRH -R 
membrane preparations. 
9.2.2 Functional Studies 
In the absence of any suitable antibodies, alternative measurements of receptor 
expression were sought. One possible method is to examine other functional 
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properties exhibited by the protein. However, in the case of the GnRH -R functional 
properties are intrinsically tied to its ligand- receptor binding capacity. Hence, if the 
mutant receptor fails to bind its ligand then receptor activation properties will 
automatically be affected. Nevertheless, it is possible to measure some functional 
activation in situations where receptor binding levels are below assay detection 
limits by stimulating receptor mutants with very high concentrations of native ligand 
(Perlman et al, 1994a, b; 1995). Using this approach partial receptor second 
messenger function has been demonstrated in the TRH -R Cys98Ser, Cys98Ala and 
Cys 179Ala (Chapter 5). These mutants showed no detectable levels of receptor 
binding activity and, therefore, total IP production at 1µM of stimulating ligand was 
also greatly reduced. The ability of these mutants to show a significant rise in total 
IP production, above basal levels, at higher peptide concentrations indicated that 
some functionally -active receptors were present at the cell surface. It is unclear, 
however, if these observations reflect an amplified response in a structurally normal 
receptor, with low expression levels, or the activation of a receptor with normal 
numbers but an abnormal tertiary protein structure. Whilst this approach cannot 
localise the precise site of the mutational effect, it does indicate that the substituting 
amino acid does not completely abolish receptor trafficking to the cell surface or 
receptor insertion into the membrane. 
Another approach testing for normal levels of receptor expression and protein 
folding is to examine the differential mutation effects on agonist verses antagonist 
binding. It has been postulated that the complement of receptor residues involved in 
agonist binding differs from those involved in antagonist binding and therefore 
whilst certain receptor amino acids may be critical for ligand- receptor activation by 
one analogue they may not be involved in the binding mechanisms of another 
(Janovick et al, 1993). Antagonist binding studies have only been carried out on the 
GnRH -R mutations Asn87Asp, Asp318Asn and the double mutation (Chapter 6). In 
this study, the agonist and antagonist binding data showed similar trends with the 
Asn87Asp and the double mutation unable to bind either analogue. However, only 
one radiolabelled antagonist was tested and to investigate this aspect more 
thoroughly it would be necessary to examine the binding of a large cohort of 
antagonist structures. Antagonist binding studies are not feasible with the TRH -R 
mutants as no highly specific antagonists are presently available. 
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9.2.3 Epitope Tagging 
The final approach undertaken was the epitope tagging of the GnRH -R. This system 
has been used in GPCRs site -directed mutagenesis studies to monitor levels of 
receptor expression in mutant constructs (Kim et al, 1995; Lee et al, 1994; Ng et al, 
1994; Qian et al, 1993). Two different tagging systems were tested, the Kodak Flag - 
tag and the human influenza hemagglutinin (HA) tag. The Kodak flag -tag was 
inserted into the GnRH -R sequence directly following the ATG start site, whereas 
both the single (HA- GnRH -R) and triple (3HA- GnRH -R) HA -tag sequences were 
incorporated 20 bp from the ATG start site. The positions of these epitope tags in 
the GnRH -R amino acid sequence are illustrated in Figure 9.1 and their protein 
epitope sequences shown in Table 9.1. The epitope tagging methods are described 
in detail in Appendix III (sections B and C). 
Flag -tag protein 
sequence 
NH2- Asp- Tyr- Lys- Asp- Asp- Asp- Asp- Lys -COOH 
HA- epitope tag 
protein sequence 
NH2- Tyr- Pro -Tyr- Asp -Val- Pro -Asp- Tyr -Ala -COOH 
Table 9.1 The Flag -tag and single HA tag amino acid epitope sequences 
The Flag -tag sequence consists of 8 amino acids and many of these residues are highly polar. The 
HA -tag contains a 9 amino acid epitope. 
The tagged receptors were tested for receptor binding function and second 
messenger activation. The Flag -tag showed no receptor binding and therefore no 
further studies were carried out. In contrast, the HA- GnRH -R showed receptor 
binding and functional properties similar to the WT receptor. Receptor binding was 
measured using Scatchard analysis of saturation receptor binding assay data. 
Figure 9.1 Position of epitope tag sequences in the rat pituitary GnRH -R (following page) 
Schematic representation of the GnRH -R highlighting the position of the (a) Kodak Flag-tag (yellow) 
and (b) HA -Tag (green) in the rat GnRH -R. The Flag -tag sequence was incorporated in the GnRH -R 
directly after the ATG start site whereas the HA -tag was positioned at the Esp31 restriction enzyme 
site (20 bps from the ATG start site). 
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The HA- GnRH -R displayed comparable receptor affinity and receptor numbers to 
the WT receptor (Figure 9.2). The second messenger function was assessed through 
GnRH stimulated [Ca2 +]i measurements by dynamic video imaging (Figure 9.3). 
Like the WT receptor, GnRH induced biphasic Ca2+ transients in COS -1 cells 
transiently expressing the HA- GnRH -R. These results indicate that the 
incorporation of a HA -tag sequence does not interfere with normal binding and 
functional properties of the receptor. Following characterisation of the ligand 
binding and activational properties of the tagged receptor, it was necessary to 
optimise the methods of detection. Three different methods were utilised, Western 
Blot analysis, indirect immunofluorescence FITC and an ELISA method (see 








HA- tagged Wild -Type 
0 2000 4000 6000 8000 10000 
Bound (cpm) 
Figure 9.2 HA- tagged WT GnRH -R agonist binding data 
Scatchard Plot of GnRH -A binding to GnRH -R WT and the HA- tagged GnRH -R WT. Saturation 
binding assays were performed using an iodinated GnRH -A [des Glyt °, D -Trp6, Pro9 NEt] -GnRH on 
membrane preparations from COS -1 cells transiently expressing the WT or HA- tagged GnRH -R WT. 
Data points are the mean of duplicate /triplicate samples and the graph is a representative example 
from at least n =2 individual experiments. 
Chapter 9 Monitoring levels of receptor expression 170 
0 200 400 600 800 1000 
Time (seconds) 
Figure 9.3 GnRH- induced calcium responses in HA- tagged GnRH -R WT 
Effects of GnRH (111M) on [Ca2 +]i in COS -1 cells transiently expressing the rat HA- tagged GnRH -R 
in a population of cells with time (seconds). Graph represents an average plot of [Ca2 +]i 
measurements versus time from 3 individual cells in a field of 18 cells. GnRH (11.1M) added at 60 
seconds produced a biphasic rise in [Ca2 +]i. 
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COS -1 cells transiently transfected with HA- GnRH -R and 3HA- GnRH -R were 
examined using Western Blot analysis (Figure 9.4). A HA- tagged Gq (HA -Gq) and 
a triple HA- tagged TRH -R (3HA- TRH -R) were used as positive controls (Figure 
9.4). No specific band was apparent (compared to the COS -1 negative control 
membranes) in the HA- GnRH -R but a faint band was seen at approximately 37 kDa 
in the 3HA -GnRH -R. The HA -Gq showed a prominent band at 42 kDa and the 3HA - 
TRH-R displayed a diffuse specific banding pattern . 
Detection of the HA- GnRH -R, 3HA -TRH -R and HA -Gq was also carried out using 
immunofluorescence (FITC). A strong fluorescent signal was seen in COS -1 cells 
transiently expressing the HA- GnRH -R, the 3HA -TRH -R and the HA -Gq. The 
untransfected COS -1 cells showed little background fluorescence (Figures 9.5 and 
9.6). 
Both the Western Blotting and FITC are non -quantitative analysis methods. 
Therefore in order to establish a quantitative detection system an ELISA method was 
set up. Figure 9.7 shows the ELISA results for COS -1 cells transiently transfected 
with the 3HA -GnRH -R, the 3HA -TRH -R and the HA -Gq. Significant differences 
(p<0.01) in the 492 nm absorbance readings, compared to the untransfected COS -1 
cells, were obtained for the 3HA -GnRH -R, 3HA -TRH -R and the HA -Gq protein. 
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Figure 9.4 Western Blot analysis of HA- tagged Gq, GnRH -R and TRH -R 
Detection of HA- tagged proteins by Western Blot analysis. Membranes were prepared from either 
cells expressing the Gq protein (lane 1), 3HA- tagged GnRH -R (lane 2), 3HA- tagged TRH -R (lane 3). 
Untransfected COS -1 cells were used as a negative control (lane 4). Arrows indicate the position of 
the specific 42 kDa band for Gq (lane 1) and 37 kDa band for the 3HA- tagged GnRH -R (lane 2). 
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Figure 9.5 Indirect immunofluorescence detection of HA- tagged GnRH -R and TRH -R 
Localisation of HA- tagged proteins in COS -1 cells transiently transfected with (a) GnRH -R and (b) 
3HA- tagged TRH -R using indirect immunofluorescence (FITC). Cells are viewed by fluorescent 
(upper) and light microscopy (lower) and are representative pictures from n =2 experiments. 
Untransfected COS -1 cells demonstrated low background FITC fluorescence. 
Figure 9.6 Indirect immunofluorescence detection of HA- tagged Gq and GnRH -R 
(following page) 
Localisation of HA- tagged proteins in COS -1 cells transiently expressing (a) HA- tagged Gq (b)HA- 
tagged GnRH -R, and (c) untransfected COS -1 cells using indirect immunofluorescence (FITC). Cells 
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Figure 9.7 ELISA detection of HA- tagged GnRH -R, TRH -R and Gq 
Detection of HA- tagged proteins using ELISA. Absorbance measurements were made at 492 nm 
using an anti -HA antibody dilution of 1:10 in untransfected COS -1 cells (negative control), COS -1 
cells transfected with either 3HA- tagged GnRH -R, 3HA- tagged TRH -R or the HA- tagged Gq 
(positive control). Each sample was carried out in triplicate and this experiment is a representative 
example from n =2 individual experiments. Statistical analysis was carried out using t -tests and ( * *) 
represents a p value of p <0.01. 
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9.3 Discussion 
To detect receptor expression in mutant receptors, three different experimental 
approaches were developed and tested. Initially, polyclonal antibodies raised against 
the GnRH -R were generated in rabbits. However, these antibodies were non -specific 
when tested by Western Blot analysis. This finding may be due to the complex 
three -dimensionalstructure of the receptor, so limiting the availability of antigenic 
epitopes or it may reflect the low antigenic properties of the synthetic peptides used 
for immunisation. A monoclonal receptor antibody was also tested but again this 
proved unsuccessful. Currently, a chicken host is being used for antibody 
production as the greater evolutionary differences between the avian and mammalian 
GnRH -R should increase antibody production. 
Secondly, attempts were made to measure receptor function in mutant receptors with 
decreased receptor activity by increasing the receptor concentration in the assay 
systems. The generation of clonally derived stable cell lines (HEK- His305Arg and 
HEK- Asn314Asp) increased the receptor number /mg of total protein, allowing for 
the detection of low levels of receptor binding. Alternatively, it is possible to 
measure second messenger total IP production, in COS -1 cells transiently expressing 
mutant receptors, by stimulating cells with very large concentrations of peptide. 
This approach has been extensively used in site -directed mutagenesis studies in the 
TRH -R where specific antibodies are also unavailable (Perlman et al, 1994a, b; 
1995). In addition, preliminary studies have been carried out to determine whether 
mutations affecting GnRH -R agonist binding also interfere with the binding of 
antagonist analogues. The demonstration of differential agonist and antagonist 
binding function would be particularly useful as it would show an intact receptor 
tertiary structure. 
Finally, two different epitope tags, the Kodak Flag -tag and the HA -tag have been 
incorporated into the GnRH -R sequence. The Kodak Flag- tagged GnRH -R 
prevented receptor binding and this may have resulted from a lack of receptor 
expression or receptor inactivation. The small size of the GnRH -R makes it difficult 
to incorporate a foreign epitope without affecting ligand binding. In particular, the 
highly charged nature of the Flag -Tag sequence together with its position close to 
the ATG start site in the NH2 terminus may have disrupted receptor expression, 
insertion into the membrane or protein folding. Following the failure of the Kodak 
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Flag -tag labelled receptors to bind radiolabelled GnRH no further studies were 
carried out. In contrast, the HA- GnRH -R displayed ligand binding and second 
messenger functions comparable to the WT GnRH -R, indicating that the HA -tag 
does not interfere with normal receptor binding and second messenger activation 
mechanisms. Western Blot analysis carried out with the single HA- GnRH -R showed 
a similar banding pattern to the COS -1 control cells. However, using cell 
membranes transfected with the 3HA- GnRH -R, a faint but specific band was 
detected of - 37 kDa in size. These results suggest that the presence of a triple HA- 
epitope sequence is necessary to amplify the antigenic signal to detectable levels. In 
contrast, the FITC HA -tag detection method showed a fluorescent signal with the 
single HA- GnRH -R tag, and presently other fluorescent linked fluorochromes such 
as Rhodamine are also under investigation. ELISA measurements of the HA- tagged 
receptors again revealed that detection methods improved with the triple HA -tag 
sequence. Using this method it will now be possible to quantify mutant receptor 
expression levels at the surface membrane of the cell. 
These results represent preliminary data and once the system has been optimised for 
the WT HAI3HA- GnRH -R, then the tag sequence will be incorporated into all the 
receptor mutants. In the absence of suitable receptor- specific antibodies, the 
development of the tagging system has provided an alternative measurement of cell 
surface GnRH -Rs. Whilst this approach tackles the problem of monitoring mutant 
receptor expression, the location of the tag in the NH2 terminus means that 
alterations in the three -dimensional structure of the TM domains, resulting from site - 
directed mutagenesis, may still go undetected. 
10 Summary of results and concluding discussion 
10.1 Introduction 
Over the last 25 years, the action of GnRH at its specific pituitary receptor has been 
exploited in clinical medicine to treat a wide range of reproductive conditions. 
However, the molecular mechanisms underlying the interaction of GnRH with the 
GnRH -R remain largely unknown. Therefore, knowledge relating to ligand- induced 
receptor activation will aid in the development of more efficacious and 
therapeutically safe GnRH analogues. The aims of this study were to delineate 
amino acid residues in the GnRH -R which are integral in (i) stabilisation of the 
receptor, (ii) formation of a ligand binding pocket and (iii) ligand- induced receptor 
activation. Moreover, the analysis of GnRH -R structure -function relationships is 
imperative to understanding the molecular processes at the centre of ligand- receptor 
binding. 
10.2 Targeting of potentially important amino acids 
Potentially important amino acids within the GnRH -R and TRH -R were initially 
targeted based on their structure -function roles in other GPCRs. This approach 
provided the basis for examining the role of extracellular Cys residues in these 
receptors. Sequence analysis also revealed the transposed positions (relative to other 
GPCRs) of GnRH -R amino acids Asn87 and Asp318. The advantage of sequence 
homology analysis is that a great deal of mutagenesis data is already available for 
many different GPCRs. As GPCRs share the same topographical conformation, 
structural information relating to one specific receptor can often be applicable to 
other members of this receptor superfamily. However, comparative sequence 
analysis is of limited use in identifying amino acids involved in ligand receptor 
specificity, as individual receptors will have a different complement of residues 
involved in this process. To identify amino acids that interact directly with the 
ligand, and hence form the ligand binding pocket, it was necessary to devise an 
alternative targeting approach. This second strategy involved the use of three 
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different molecular models: (i) the Baldwin model, (ii) a computer -generated model 
of the GnRH -R and (iii) a simulated model of the GnRH ligand and receptor. 
The Baldwin model (Baldwin, 1993) highlights the position of TM- located polar 
residues. By definition, the TM helices are primarily hydrophobic and so the 
presence of polar, hydrophilic amino acids is unusual and may have a specific 
functional significance. The side chains of these polar amino acids are orientated 
away from the hydrophobic membrane, towards the central pore of the receptor 
channel, and thus are positioned in an ideal location to interact with GnRH. In order 
to investigate the role of these residues in GnRH -R binding processes, seven amino 
acids located either within the TM domains or at the TM/extracellular interface were 
mutated. 
Whilst the Baldwin model provided the first three -dimensionalview of the GnRH -R, 
the possible position of the ligand within the receptor structure was still completely 
unknown. A computer- derived model of the GnRH -R and a model of the GnRH 
ligand (generated at the MRC, Reproductive Biology Unit, Edinburgh) were 
therefore integrated to simulate potential receptor -ligand interactions. From the 
dynamic modelling studies of the GnRH ligand and receptor, a hypothetical 
interaction between Phe312 and Leu83 in the GnRH -R and Trp3 and Leu7 in the 
ligand was proposed. 
The computer -simulated targeting approach provided greater scope (compared to the 
Baldwin model) for identifying amino acids crucial in receptor specificity, as it 
permitted the analysis of the receptor structure with direct relevance to the structure 
and possible positioning of the ligand. It has also allowed for a reciprocal exchange 
of information, whereby hypotheses based on the molecular modelling studies could 
be tested by site -directed mutagenesis, and the results of such studies then utilised to 
further redefine the model's structure. This strategy, whereby feedback information 
can be integrated back into the system has resulted in a dynamic model to study 
potential GnRH -R structure- function relationships. 
However, as purely hypothetical structures, the accuracy of these models should not 
be overemphasised. Consequently, predictions made from computer models have to 
be treated with caution and it is imperative that these models are used within a 
framework of clearly defined parameters. 
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10.3 Site -directed mutagenesis 
Once the amino acids had been targeted, oligonucleotides were constructed to 
incorporate the specific modifications required. Recent studies have demonstrated 
that the choice of substitute amino acids is a critical factor in determining the final 
outcome of site -directed mutagenesis experiments. In the ß- adrenergic receptor, 
Lefkowitz and co- workers demonstrated that the substitution of A1a293, in the it 3, 
resulted in variable levels of constitutive activation depending on the nature of the 
amino acid introduced (Kjelsberg et al, 1992). In this study, the Ala residue was 
individually modified to all other 19 possible amino acids, and constitutive 
activation levels ranged from 21% to 250% (above basal activity). Furthermore, in 
the TRH -R Cys amino acid study (Chapter 5), substitution of extracellular Cys 
residues to Ala, favoured an increase in receptor function compared to the 
corresponding Cys to Ser substitutions. 
In the Asn87 /Asp318 experiments, the single mutations Asn87Asp and Asp318Asn 
introduced an amino acid of similar size but carrying a different charge, whilst the 
function of the double reciprocal mutation (Asn87AspAsp318Asn) was to recreate 
the situation normally observed in other GPCRs. In Chapter 7, the amino acids 
highlighted by the Baldwin model were either replaced by residues of similar charge 
or size. In this experimental investigation, Lys residues were modified to another 
highly basic amino acid Arg, Asn residues substituted for a similarly sized Asp, and 
Glu residues interchanged with Gln or vice versa. The only radical change was the 
alteration of His305 to Arg. These conservative changes were incorporated to 
reduce the possibility of any gross changes occurring in the receptor tertiary 
structure. In the final series of experiments (Chapter 8), any possible hydrophobic 
interactions between GnRH -R residues Leu83 and Phe312 and the ligand were 
examined by modifying each amino acid to either another hydrophobic amino acid, a 
hydrophilic amino acid or a much smaller, slightly hydrophobic, Ala residue. 
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10.4 Receptor binding, activation and expression of mutant 
receptors 
Table 10.1 summarises all the effects of the mutant receptors on receptor binding 
and second messenger production. 
Table 10.1 Summary of GnRH -R and TRH -R mutational effects 
Summary of receptor binding and second messenger responses in COS -1 cells (transiently 
transfected) or HEK 293 cells (stably transfected) with mutant TRH -Rs and GnRH -Rs. The receptors 
constructed in the expression vector pcDNA 1 are indicated with the presence of a (1) after the 
mutation and those generated in expression vector pcDNA 3 by (3). 
+ ++ increased receptor binding/second messenger function compared to WT 
++ represents WT -like activity 
+ decreased receptor binding/second messenger function compared to WT 
-1+ Small amount of receptor binding /second messenger function detectable 
- No receptor binding /ligand induced IP production 
Note: Double mutant refers to GnRH -R mutant Asn87AspAsp318Asn 
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Receptor Mutant Ligand binding Second messenger 
properties 
Chapter 5 
GnRH -R Cysl4Ser (1) - - 
GnRH -R Cys 114Ser (1) - - 
GnRH -R Cys 195Ser (1) - - 
GnRH -R Cys 199Ser (1) - 
TRH -R Cys98Ser (1) - - 
TRH -R Cys 179Ser (1) - - 
TRH -R CyslOOSer (1) ++ ++ 
TRH -R Cys98Ala (1) - - 
TRH -R Cys 179Ala (1) - - 
TRH -R Cys 100Ala (1) ++ ++ 
Chapter 6 
GnRH -R Asn87Asp (1) - - 
GnRH -R Asp318Asn (1) ++ - 
GnRH -R double mutant (1) - - 
GnRH -R Asp318Asn (3) ++ - 
GnRH -R double mutant (3) -/+ - 
Chapter 7 
GnRH -R Glu90Gln (3) ++ ++ 
GnRH -R Lys 115Arg (3) ++ ++ 
GnRH -R Lys121Arg (3) ++ ++ 
GnRH -R Gin174Glu (3) ++ ++ 
GnRH -R Asn304Asp (3) ++ + 
GnRH -R His305Arg (3) - - 
GnRH-R Asn314Asp (3) - - 
GnRH -R HEK- His305Arg (3) -/+ + 
GnRH -R HEK- Asn314Asp (3) -/+ + 
Chapter 8 
GnRH -R Phe312Tyr (3) + ++ + ++ 
GnRH -R Phe312Ala (3) ++ ++ 
GnRH -R Phe312Arg (3) - - 
GnRH -R Leu83Val (3) ++ ++ 
GnRH -R Leu83Ala (3) - - 
GnRH-R Leu83Lys (3) + -/+ 
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10.4.1 Role of extracellular Cys residues as determinants of GPCR tertiary 
structure 
In both the GnRH -R and TRH -R, replacement of the extracellular Cys residues 
(GnRH -R, Cys 14Ser, Cys 114Ser, Cys 195Ser, Cys 199Ser and TRH -R Cys98Ser, 
Cys98Ala, Cys 179Ser and Cys 179A1a) by either Ser or Ala resulted in a loss of 
ligand binding and ligand- induced receptor activation (see Table 10.1). These 
results highlight the importance of a correct tertiary structure for the maintenance of 
receptor function. The majority of GPCRs contain at least one pair of conserved Cys 
residues, with the formation of disulphide bonds between extracellular Cys residues, 
integral in maintaining receptor stability. The disruption of these bonds radically 
alters the shape of the extracellular receptor domains and therefore prevents ligand- 
induced receptor activation. In the GnRH -R, the loss of receptor function displayed 
by all four mutant receptors suggests the presence of at least two disulphide bridges, 
involving both conserved and non -conserved extracellular Cys residues. In contrast, 
in the TRH -R, only one disulphide bond is present between conserved extracellular 
Cys residues, Cys98 and Cys 179. TRH -R residue Cys 100 does not appear to have a 
disulphide bonding role, as mutations generated at this site showed WT -like receptor 
binding and activational properties. Moreover, the retention of receptor function by 
mutants Cys 100Ser and Cys 100Ala, indicates that a normal three - 
dimensionalreceptor structure is maintained by these mutations, despite their close 
proximity to Cys98. Furthermore, this suggests that only very specific amino acids 
are involved in the maintenance of receptor tertiary structure. Chemical 
modification studies in the TRH -R have also confirmed the importance of disulphide 
bonding interactions. 
This experimental study highlighted the role of extracellular Cys residues in 
disulphide bonding interactions. However, the processes which underlie the 
formation of disulphide bonds and the factors which determine which specific 
extracellular Cys residues are involved in each disulphide bridge structure (i.e. 
conserved or non -conserved) are unknown. 
10.4.2 Role of Asn87 and Asp318 residues in GnRH -R function 
Results from Chapter 6 indicate that the GnRH -R residue Asn87 (TM II) is 
important in mediating receptor binding function, whilst the amino acid Asp318 (TM 
VII) is responsible for G- protein activation. The failure of the double reciprocal 
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mutant, Asn87AspAsp318Asn, to restore significant receptor binding function 
suggests that the functional roles of these two amino acids are not interchangeable. 
Moreover, this implies that their positional differences, relative to other GPCRs, are 
linked to evolutionary mutations. Furthermore, the computer -simulation studies 
position Asn87 and Asp318 in favourable locations to interact with GnRH. From 
these computer models, Asn87 is in close proximity to Arg8 at the COOH terminus 
of the ligand - the amino acid thought to be responsible for mediating ligand 
specificity in mammalian GnRH (Davidson et al, 1994). 
10.4.3 Role of TM polar amino acids in GnRH -R function 
Chapter 7 identified two amino acids important for ligand- receptor binding; His305 
positioned at the TM VII/extracellular interface and Asn314 in the middle of TM 
VII. Initial experimental work, using a transient transfection protocol, revealed that 
substitution of His305 to Arg and Asn314 to Asp prevented GnRH ligand binding 
and second messenger coupling. Further investigations, expressing these mutations 
in a stable cell line, showed that His305Arg and Asn3l4Asp had small, but 
detectable, levels of receptor function (binding and second messenger coupling) 
compared to the WT GnRH -R. 
The position of His 305 at the extracellular interface suggests that is unlikely to form 
part of the TM- located ligand binding pocket. However, it may indirectly affect 
ligand- receptor binding by channelling the ligand into the receptor pore, or by 
maintaining the tertiary structure of the extracellular domains. The role of 
extracellular residues in GnRH -R binding processes has not been extensively 
studied. However, one residue in the el 3, G1u301, has been implicated in 
conforming the ligand prior to binding (Davidson et al, 1994). In other GPCRs, for 
example the neurokinin (Fong et al, 1992) and glycoprotein hormone receptors 
(Byrant et al, 1995; Ji and Ji, 1995), amino acids in the extracellular domains are 
important in mediating receptor binding function. 
In contrast, GnRH -R residue Asn314 lies in the middle of TM VII and thus is in an 
ideal location to form part of the ligand binding pocket. Further analysis of the 
computer- derived GnRH/GnRH -R model reveals that Asn314 lies in close proximity 
to the amino acid side chain of Arg8 in GnRH. 
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10.4.4 Role of Phe312 and Leu83 in GnRH -R function 
Only one GnRH -R mutant constructed to date, Phe312Tyr, showed an increase in 
receptor affinity and a greater production of total IPs when stimulated with low 
concentrations of GnRH. This finding suggests that certain structural modifications 
to the GnRH -R can enhance ligand binding interactions and receptor activation 
mechanisms. Tyr contains a hydroxyl group, capable of forming H- bonds, and it is 
possible that further bonding interactions between Tyr312 and the ligand, function to 
stabilise the ligand- receptor complex or increase its resistance to protein degradation. 
Mutant Phe312Arg, failed to show any ligand binding or activational properties, 
indicating that the presence of a hydrophobic residue was necessary at this site for 
maximum receptor function. Moreover, the presence of a small slightly hydrophobic 
residue, Ala at position 312, retained partial receptor binding and second messenger 
coupling properties. The computer simulation studies position Trp3 of GnRH in 
close proximity to both Phe312 and Phe308 in the receptor, and these locations 
would allow for interactions between the aromatic rings of all three residues. 
GnRH -R mutant Leu83Val showed a similar receptor affinity to the WT. However, 
this mutation exhibited a decrease in receptor numbers and hence a decrease in the 
maximum level of second messenger production. During the course of this study, 
mutant receptors often displayed normal WT -like receptor binding (Kd) and 
activation (ED50) profiles but showed a decrease in receptor numbers. The reasons 
underlying this finding are unknown, but may be related to decreased receptor 
expression following transfection. Moreover, the position of the mutation appears 
critical, and changes in receptor residues at important loci within the receptor may 
have marked effects on receptor expression levels. Some mutations generated in the 
TM domains, however, had no effect on receptor function (TRH -R mutants 
CyslOOSer, Cys 100Ala and GnRH -R mutants Glu90Gln, Lys 115Arg, Lys 121 Arg, 
Gln174G1u), suggesting that only very specific sites within the TM domains are 
important for ligand- receptor binding. Furthermore, even at very critical sites for 
example Leu83, the radical alteration to Lys maintained some degree of receptor 
binding whereas the smaller change to Ala completely prevented ligand- receptor 
binding and activation. These factors therefore suggest that the effects of mutations 
are highly specific and dependent on both the nature and the position of the amino 
acid substitutions. 
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The incorporation of a smaller, less hydrophobic residue, Ala at position 83 resulted 
in a complete loss of ligand receptor binding and second messenger coupling. This 
finding may have resulted from one or more of the following factors; a decreased 
ability to form suitable hydrophobic interactions, a decrease in receptor expression, a 
partial loss of tertiary receptor structure, receptor destabilisation or increased 
receptor degradation. In contrast, GnRH -R mutant Leu83Lys showed a decrease in 
receptor affinity compared to WT but its most marked effect was on second 
messenger production. It is possible therefore that Leu83 forms an important link 
site, representing a lynchpin whereby ligand binding interactions are converted into 
the activation of the G- protein effector system. The position of Leu83, in the GnRH 
ligand receptor models, is in close proximity to Leu7 in GnRH and it is possible that 
hydrophobic interactions between this amino acid pair are important in ligand- 
receptor activation mechanisms. 
10.4.5 Receptor expression 
To pinpoint more accurately the site of the mutational effects, receptor mutants were 
examined for alterations in RNA transcription, processing and levels of cell surface 
receptor protein. Northern Blots were used to establish if the mutations affected 
RNA transcription. Results showed that the mutants had comparable levels of 
receptor RNA to the WT, indicating that RNA transcription was not affected 
following mutagenesis. Interestingly, the stably expressed GnRH -R WT and 
mutants showed different transcript sizes compared to the transiently expressed 
receptor constructs. These findings are probably reflective of the different 
mechanisms of DNA expression. In the transient transfection protocol, the DNA is 
expressed episomally whereas in the stable cell lines it becomes integrated into the 
host cell genome. 
The detection of cell surface receptors was assessed by either antagonist binding, 
agonist binding (in the presence of high concentrations of total protein), or second 
messenger function (in the presence of high concentrations of stimulating ligand). In 
addition, an epitope tag has also been incorporated into the WT and mutant TRH -Rs 
and GnRH -Rs, so that cell surface receptor proteins can be measured directly (see 
Appendix V). 
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10.5 Conclusions 
This study indicates that extracellular Cys residues are likely to be important in 
maintaining the three -dimensional structure of both the GnRH -R and TRH -R, 
through disulphide bonding interactions. Furthermore, the molecular modelling 
studies postulated that the ligand binding domain pocket of the GnRH -R was 
localised around the TM domains, TM II, TM III and TM VII. This hypothesis has 
been substantiated by results presented in Chapter 6, 7, and 8. Mutagenesis studies 
so far have highlighted Asn87 (TM II), Phe312 (TM VII) and Asn 314 (TM VII), as 
residues potentially important in ligand binding and amino acids Leu83 (TM II) and 
Asp318 (TM VII) as important in receptor activation. A pattern is already emerging 
whereby amino acids involved in receptor binding are positioned in the upper /middle 
part of the TM domains whereas those involved in receptor activation are located in 
the lower /middle part of the a- helices. The position of the TM domains is not 
absolutely defined and there may in fact be some flexibility in their positions. 
However, Asn87, Phe312 and Asn314 residues are all positioned approximately in 
the middle third of the TM domains whereas Leu83 and Asp318 are positioned much 
further down the receptor channel towards the intracellular side of the membrane. It 
is therefore possible that the GnRH ligand only penetrates half way down the 
receptor pore and hence amino acids critical for binding are found in this location. 
The observation that residues critical in activation are located further down the 
receptor channel is also in accord with the involvement of the it 3 in signal 
transduction mechanisms (Savarese and Fraser, 1992). 
The lack of receptor binding activity displayed by mutations at the GnRH -R sites, 
Asn87, Phe312 and Asn314 could also arise from the absence of functional cell 
surface receptors and the answer to this question resides in the pending receptor 
epitope tagging studies. 
10.6 Directions for future study 
The epitope tagging system described in Chapter 9 (section 9.2.3) has now been 
characterised in the WT GnRH -R and TRH -R, and the next step is to incorporate this 
epitope tag into the all the receptor mutants constructed to date. The development of 
specific GnRH -R antibodies would also greatly aid in the measurement of GnRH -R 
mutant expression levels, and research is currently ongoing in this area. The use of 
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specific GnRH -R antibodies has advantages over the tagging system, since it would 
eliminate the need to modify the structure of the receptor. 
Further comparative experimental studies are necessary to clarify the role of Cys 
residues in the GnRH -R, as has been carried out in the TRH -R. These studies could 
include the incorporation of the Cys /Ser mutants into a higher expression vector, the 
generation of corresponding Cys to Ala mutations, and chemical modification 
studies. Additional investigations are also necessary to identify the precise location 
of the disulphide bridges. 
The majority of work contained within this thesis relates to mutations of the GnRH- 
R. In future, it may also be possible to design complementary ligand and receptor 
mutagenesis experimental studies, whereby direct interactions between ligand and 
receptor can be examined by mutating the ligand structure to complement mutations 
generated in the receptor. This double mutagenesis approach would be useful in the 
Leu83/Phe312 work. 
To date, only preliminary investigations into the role of agonist verses antagonist 
binding sites have been carried out. Currently, there is a wide range of specific 
GnRH antagonists available and it would be interesting to examine variations in 
analogue binding between different receptor mutations. Janovick et al ( Janovick et 
al, 1993), postulated the existence of a differential agonist and antagonist binding 
site in the GnRH -R. However, the majority of studies to date have been limited 
mainly to the delineation of GnRH/GnRH agonist ligand binding site. 
The molecular modelling approach was vital to the evolution of this study and the 
possible use of supercomputers (for example the Cray parallel computer, Edinburgh 
University) would facilitate more complex molecular dynamic simulations. 
However, in the long term it is hoped that further developments in the 
overexpression and purification of the GnRH -R will enable the production of large 
quantities of peptide for x -ray crystallographic structural determination. 
Finally, this work must be considered in terms of its potential clinical applications. 
Detailed structural knowledge relating to the GnRH -R should lead to an improved 
understanding of GnRH -R binding and second messenger activation, which in turn 
could permit the design of more efficacious drugs, in particular orally- active non- 
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peptide analogues. Furthermore, the combination of these analogues with steroid 
replacement could provide new contraceptive agents and improve positive health 
care, for example in the treatment of breast and prostate cancer and osteoporosis. 
In the light of the extensive use of GnRH analogues in the regulation of human 
reproduction and in the treatment of a wide range of endocrine related disorders, this 
study provides important new insights into the mechanisms underlying GnRH -R 
function. 
Appendix I Buffers and Stock Solutions 
A Bacterial media 
1. LB (Luria -Bertani Media) broth 
12.5g Luria Broth Base in 500m1 of H2O (autoclaved). 
2. LB agar 
12.5g Luria Broth Base in 500m1 of H2O, 7.5g agarose (autoclaved). 
3. SOC medium 
2% Bactotryptone (w /v), 0.5% Bacto yeast extract (w /v), 10mM NaC1, 2.5mM KC1, 
10mM MgC12, 10mM MgSO4, 20mM glucose. Autoclave and then add glucose. 
4. 2xYT Medium 
1.6% Bacto tryptone (w /v), 1% Bacto yeast extract (w /v), 100mM NaC1 
(autoclaved). 
B Antibiotics 
1. Ampicillin: 50mg /m1 in H20, filter -sterilised, stock solutions stored at -20 °C. 
2. Chloramphenicol: 34mg /m1 in ethanol, stock solutions stored at -20 °C. 
3. Kanamycin: 10mg /m1 in H20, filter -sterilised, stock solutions stored at -20 °C. 
4. Tetracycline: 5mg /m1 in ethanol, stock solutions stored at -20 °C. 
C General reagents 
1. 10M Ammonium Acetate 
Dissolve 770g of ammonium acetate in 1000m1 of H20. 
2. Chloroform 
24:1 (v /v) mixture of chloroform and isoamyl alcohol. Stored at room temperature. 
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3. 50xDenhardt's 
2% (w /v) FicollTM, 2% (w /v) polyvinylpyrrolidone, 2% (w /v) bovine serum albumin 
(BSA), Pentax Fraction V. Stored at -20 °C. 
4. 0.5M EDTA 
Add 186.1g of disodium ethylenediaminetetraacetate .2H20 in 1000 ml H20. Adjust 
pH to 8.0 with 20g of NaOH pellets. 
5. 6xGel-Loading buffer (Agarose Gels) 
0.25% (w /v) bromophenol blue, 0.25% (w /v) xylene cyanol FF, 30% (v /v) glycerol 
in H2O, stored at 4 °C. 
6. Phenol (TE- saturated) 
Phenol is removed from -20 °C, warmed to room temperature and melted at 68 °C. 
Add hydroxyquinoline to final concentration of 0.1% (w /v). To melted phenol, add 
an equal volume of buffer (0.5M Tris /HC1, pH8.0) at room temperature, stir for 
15minutes and leave to separate. Remove upper layer and add an equal volume of 
0.1M Tris /HC1, pH8.0, repeat extractions until pH of the phenol is >7.8. After 
equilibration, add 0.1% (v /v) 0.1M Tris /HC1, pH8.0 containing 0.2% ß- 
mercaptoethanol. Store in dark at 4 °C for 1 month. 
7. Phenol/chloroform 
1:1 (v /v) phenol and chloroform equilibrated with TE buffer (pH8.0). Stored at 4 °C, 
protected from light. 
8. Phosphate buffer pH 7.2 
Add 400m1 of 1M Na2HPO4 solution to 150m1 1M NaH2PO4.2H20 while stirring 
and monitoring pH (autoclaved). 
9. Phosphate- buffered saline (PBS) 
Dissolve 8g NaC1, 0.2g KC1, 1.44g Na2HPO4 and 0.24g KH2PO4 in 1000 ml. Adjust 
to pH 7.4 with HC1. 
10. 3M Sodium acetate 
Dissolve 408.1g of sodium acetate.3H20 in 800m1 H20. Adjust pH to 5.2 with 
glacial acetic acid or pH to 7.0 with dilute acetic acid. Adjust volume to 1000m1. 
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11. 20% SDS (sodium dodecyl suphate/lauryl sulphate) 
20% SDS (w /v) in distilled of H2O (autoclaved). 
12. 20XSSC (sodium salt citrate) 
3M NaCI, 0.3M Na3 citrate.2H20, 0.02M EDTA, pH 7.0 (autoclaved). 
13. TE buffer 
10mM Tris/HC1, pH7.8, 0.1mM EDTA (autoclaved). 
14. 1M Tris 
Dissolve 121.1g of Tris base in 800m1 of H20. Adjust to desired pH with 
concentrated HC1 (pH7.4, 70m1 HCl/ pH7.6, 60m1 HC1 /pH8.0, 42ml HC1) 
15. 10XTBE Electrophoresis Buffer 
108g Tris base, 55g boric acid, 40m1 0.5M EDTA in 1000m1 of H2O (autoclaved). 
D Tissue culture solutions 
1. DMEM complete medium 
To a 500m1 bottle of Dulbecco's modified Eagle's medium (DMEM) add 10m1 stock 
L- glutamine (0.3mg /m1 final concentration), 5m1 stock penicillin /streptocmycin 
(P /S) solution (100IU penicillin final concentration, 10011g streptomycin final 
concentration) and 10% (v /v) heat -inactivated foetal calf serum ( HIFCS). 
2. Inositol -free DMEM media for IP assays 
To a 500m1 bottle of Special DMEM add 10m1 stock L- glutamine (0.3mg /ml final 
concentration), 5ml stock penicillin /streptocmycin (P /S) solution (100IU penicillin 
final concentration, 100µg streptomycin final concentration) and 1% (v /v) dialysed 
heat -inactivated foetal calf serum (HIFCS). 
3. Trypsin -EDTA solution 
Trypsin -EDTA is available as a X10 liquid solution (GIBCO -BRL) containing 5.0g 
trypsin (0.5% w /v) and 2g EDTA in 100m1 and is stored at -20 °C. The working 
concentration of trypsin is 0.1% w/v and the stock solution is diluted 1/5 with 
phosphate buffered saline (PBS). Aliquots are stored at -20 °C. 
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4. G418 Sulphate 
Stock solution of 100mg /m1 in H20, filter sterilised. 
E f3 Galactosidase detection assays 
1. Glutaraldehyde solution 
0.1M phosphate buffer, pH 7.0, 1mM MgC12 and 0.25% glutaraldehyde. 
2. X -gal solution 
0.2% X -gal, 1mM MgC12, 150mM NaC1, 3.3mM K4Fe(CN)63H20, 3.3mM 
K3Fe(CN)6, 60mM Na2HPO4 and 40mM NaH2PO4. 
F Buffers and solutions for IP assays and calcium imaging 
1. Buffer A 
lmg /ml Fatty acid -free BSA, 140mM NaCI, 20mM Hepes, 4mM KC1, 8mM D- 
Glucose, 1mM MgC12 and 1mM CaC12. Adjust to pH 7.2 with concentrated NaOH. 
2. 2%Perchoric acid (PCA)/ 0.5M EDTA Stopping solution 
Dissolve 1.86g of EDTA in 800m1 of H2O add 28.6m1 of PCA, adjust volume to 
1000m1. 
3. 0.5M KOH/60mM Hepes Neutralisation Buffer 
Dissolve 28.055g KOH and 14.3g Hepes in 1000m1 of H2O. 
4. 0.6M Ammonium formate /500mM sodium tetraborate 
Dissolve 37.83g of ammonium formate and 19.07g of sodium tetraborate in 1000m1 
of H2O. 
5. 1M Ammonium formate /0.1M formic acid 
Dissolve 31.53g ammonium formate in 500m1 of H2O. Add 2.56 ml of formic acid. 
6. Calcium imaging buffer 
NaC1 (127mM), KC1 (5mM), MgC12 (2mM), NaH2PO4 (0.5mM), NaHCO3 (5mM), 
CaC12 (1.8mM), HEPES (10mM), and BSA (0.1 %) pH 7.2. 
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G Buffers and solutions for receptor binding assays 
1. Membrane buffer 
20mM Tris -HC1 pH 7.2, 2mM MgC12. 
2. TRH -R binding assay buffer 
20mM Tris -HC1 pH 7.2, 2mM MgC12. 
3. GnRH -R binding assay buffer 
40mM Tris -HC1 pH 7.4, 2mM MgC12. 
4. 1M Dithiothreitol (DTT) 
Dissolve lg DTT in 6.49m1 of distilled H2O. 
5. 50mM p- chloromercuribenzoic acid (p -CMB) 
Dissolve 89.3mg of p -CMB in 1M NaOH. 
H Buffers and solutions for RNA extraction/Northern Blots 
1. DEPC (diethylpyrocarbonate) treated solutions 
Solutions were treated with 0.1% DEPC for at least 12 hours at 37 °C prior to 
autoclaving. 
2. Dye solution - RNA gel electrophoresis 
7.5% (w /v) Ficoll 400, 0.1% (v /v) bromophenol blue, 1 mg /ml ethidium bromide. 
3. 10xMOPS/EDTA running buffer - RNA gel electrophoresis 
8.36g MOPS (3 -[N- morpholino]propranesulfonic acid) (200mM), 0.744g EDTA 
(10mM), 0.82g sodium acetate (50mM), dissolved in 150m1 DEPC- treated H2O and 
adjusted to pH 7.0 with sterile 5M NaOH. 
4. Sample buffer - RNA gel electrophoresis 
200µ1 (10X) MOPS /EDTA running buffer, 1ml deionised formamide, 356111 
formaldehyde (37% v /v). 
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5. 50% Formamide hybridisation buffer (cDNA probes) 
50% (v /v) deionised formamide, 5XSSC, 1XDenhardt's, 20mM sodium dihydrogen 
orthophosphate (NaH2PO4) pH 6.8, 0.1% SDS, 10% dextran sulphate, 1014/ml 
polyadenylic acid, 1014/m1 polycytidylic acid. Add 100µg /m1 freshly boiled, 
sonicated salmon sperm DNA just before use. 
6. 15% Hybridisation buffer (oligonucleotide probes) 
15% (v /v) deionised formamide, 200mM phosphate buffer pH 7.2, 1mM EDTA, 7% 
(w /v) SDS, 1% (w /v) BSA. 
7. Washing buffer (oligonucleotide probes) 
40mM phosphate buffer pH 7.2, 1mM EDTA pH 8.0 and 1% SDS. 
Appendix II Chemical and Equipment Suppliers 
Advanced Protein Products Ltd., Premier partnership estate, Leys Road, 
Brockmoor, Brierly Hill, Westmidlands, DY5 3UP UK. 
American Type Culture Collection, Maryland USA. 
Amersham International plc, Amersham Place, Little Chalfont, Bucks. HP7 9NA, 
UK. 
Applied Biosystems, Kevin Close, Birchwood Science Park, Warrington, Cheshire, 
UK. 
BDH Ltd., Burnfield Avenue, Thornliebank Glasgow G46 7TP, UK. 
Bio -Rad Laboratories Ltd., Bio -Rad House, Maylands Ave. Hemel Hempstead, 
Herts. HP2 7TD, UK. 
Biosoft, Cambridge, Cambs, UK. 
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd., Bell Lane, 
Lewes, E.Sussex BN7 1LG, UK. 
Cambridge Research Biochemicals Ltd., Gadbrook Park, Northwich, Cheshire. 
Costar, 205 Broadway, Cambridge, MA 02139, USA. 
Dupont (UK) Ltd., Medical Products, NEN products, Wedgewood Way, Stevenage, 
Herts. UK. 
Falcon, Becton Dickinson UK Ltd., Between Towns Road, Cowley, Oxford, UK. 
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Flow Laboratories Ltd., PO Box 17, Second Avenue, Industrial Estate, Irvine, 
Ayrshire, Scotland. 
Flowgen, FMC Bioproducts, High Wycombe, Bucks, UK. 
GIBCO -BRL, Life Technologies Ltd., PO Box 35 Trident House, Renfrew Road, 
Paisley PA3 4EF, Scotland, UK. 
Invitrogen - British Bio -technology Products Ltd., 4 -10 The Quadrant, Barton 
Lane, Abingdon, Oxon OX14 3YS, UK. 
Joyce Loebl Ltd., Dukesway, Team Valley, Gateshead, Tyne and Weir, UK. 
Kodak - IBI Ltd., 36 Clifton Road, Cambridge CB 14ZR, UK. 
Kontron Instruments, 52 Telford Road, Lenziemill, Cumbernauld, UK. 
Northumbria Biologicals Ltd., Enzymes Division, South Nelson Industrial Estate, 
Cramlington, Northumberland NE23 9HL, UK. 
Nunc, NS Nunc, Kamstrupvej 90, Kamstrup, DK -4000 Roskilde, Denmark. 
Pharmacia Biotechnology Ltd., 23 Grosvenor Road, St Albans, Herts, AL1 3AW, 
UK. 
Peninsula, 611 Taylor Way, Belmont, CA 94002, USA. 
Promega Ltd., 2800 Woods Hollow Road, Madison, WI 53711 -5399, USA. 
Semat Technical (UK) Ltd., 1 Executive Park, Hatfield Road, St. Albans, Herts. 
AL 1 4TA, UK. 
Sigma Chemical Company Ltd., Fancy Road, Poole, Dorset BH17 7NH, UK. 
Stratagene Ltd., Cambridge Innovation Centre, Cambridge Science Park, Milton 
Road, Cambridge CB4 4GF, UK. 
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Vilber Lourmat, 77202 Marne la Vallee, Cédex 2, France. 
Whatman LabSales Ltd., Unit 1 Coldred Road, Parkwood, Maidstone, Kent UK. 
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A Fluorescent microscopy and dynamic calcium imaging 
Trypsin- treated cells were plated on sterilised glass coverslips and after 48 hours 
washed twice with buffer containing 127 mM NaC1, 5 mM KC1, 2 mM MgC12, 0.5 
mM NaHCO3, 1.8 mM CaC12, 10 mM Hepes and 0.1% (w /v) BSA, (pH 7.2). Cells 
were then loaded with Fura -2 pentaacetoxymethylester (Fura -2AM), to a final 
concentration of 4 ¡lmol/L, for 30 minutes at 37 °C in a 5% (v /v) CO2 humidified 
incubator and any unincorporated dye removed by washing three times with buffer. 
The coverslips were subsequently transferred to a heated stage (37 °C) of an inverted 
Nikon Diaphot epifluorescent microscope. Cells where incubated in a fixed volume of 
buffer (1m1). Drug solutions (5m1) could be added directly to the coverslip chamber 
and 1 ml volumes automatically obtained through suction. Dynamic video imaging of 
changes in [Ca2 +]i were carried out in single cells using MagiCal hardware and tardis 
software (Applied Imaging). The fluorescent images were obtained by exposing cells 
to filtered 340 nm and 380 nm light, alternating under computer control. Video 
images were captured and the changes in the [Ca2 +]i under the two different light 
wavelengths calculated. Fluorescent excitation shifts occur when Fura 2 binds Ca2+ 
i.e. the excitation increases at 340 nm and decreases at 380 nm and therefore 
alterations in these dual wavelength ratios represent changes in [Ca2 +]i levels. 
B Kodak -Flag tag method 
The Kodak -Flag tag sequence was inserted into the rat GnRH -R using a PCR based 
approach. A 5' oligonucleotide incorporating ATG and the Flag -tag DNA sequence 
(5' AGAAATATGGACTACAAGGACGACGATGACAAG 3' was designed 
together with a 3' oligonucleotide 5' GATTCTTATTCAGCAACA 3' matching 
nucleotides 1780 -1795 in the 3' untranslated region of the GnRH -R cDNA sequence). 
A PCR reaction was carried out, the PCR products run on a 1% agarose gel and the 
1.8 kb band excised for purification. The purified DNA was subsequently cloned into 
the TA cloning vector (Invitrogen) and then subcloned into the expression vector 
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pcDNA 3. The sequence of the Kodak Flag -tag was confirmed by automated DNA 
sequencing. 
C HA -tag method 
1 GnRH-R 
DNA oligonucleotides (5' TGAGTATCCATATGATGTTCCAGATTATGC 3' 
and 5' CTCAGCATAATCTGGAACATCATATGGATA 3') were annealed 
together by boiling 10 nmol of each oligonucleotide, in a total volume of 3O0111 for 2 
minutes, and then allowing the reaction mixture to cool slowly. The double- stranded 
oligonucleotide fragment was then ligated in frame into the rat GnRH -R cDNA, at the 
unique Esp31 restriction site in the NH2 terminus of the sequence. GnRH -R cDNA 
(3µg) was digested using 31,tl (4 units /µl) of Esp31 (Immunogen) in a total volume of 
3O111 for 16 hours at 37 °C. EGTA was then added to a final volume of 10mM, the 
digestion products treated with proteinase K (50µg /ml final concentration) for 10 
minutes at 37 °C and the DNA purified using phenol /chloroform extraction. The 
annealed double -stranded oligonucleotide (13.3 pmols) was then ligated into the 
purified Esp31 cut GnRH -R cDNA in a ratio of 24:1 (oligo to cDNA), using 1111 of 
ligase. The ligation mixture was subsequently transformed into Top 10 F' EColi cells 
by electroporation. The colonies were grown in LB broth and the DNA was extracted 
using the Promega miniprep DNA isolation system. The sequence of the HA- tagged 
GnRH -R was confirmed by automated DNA sequencing. 
2 TRH -R 
The TRH -R cDNA was modified by addition of a Sal l linker to the 5' end (5' ACG 
CGT CGA CGA GAA TGA AAC CGT CAG TGA AC 3') and a Xba 1 linker to the 
3' end (5' GCT CTA GAG CTC ATA TTT TCT CCT GTT TGG CAG 3'). PCR 
was performed, using 200ng of TRH -R cDNA as a template, with pfu polymerase 
(Stratagene) (95 °C 42 seconds, 58 °C lminute, 72 °C 3 minutes for 30 cycles followed 
by 95 °C 42 seconds, 58 °C 1 minute and 72 °C 5 minutes for 1 cycle). This PCR 
product was then subcloned between the Xho 1 and Xba 1 sites in the pcDNA 3 
expression vector, previously modified to encode the triple HA tag sequence 
immediately after the ATG codon (YPYDVPDYAGYPYDVPDYAYPYDVPDYA). 
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This construct was then transformed into DH5a cells and the presence of the construct 
confirmed by restriction enzyme digests and automated DNA sequencing. 
D Western Blotting 
Cell membranes (3x60mm plates for COS -1 cells transiently expressing the HA- 
tagged GnRH -R and the 3HA -TRH -R and lx60mm plate for the COS -1 cells 
transiently expressing the HA- tagged Gq) were resuspended with 2O0111 of loading 
buffer containing 0.5% Triton-X114 (Sigma) and boiled for 3 minutes prior to loading 
(20µ1 per sample) onto a 10% SDS polyacrylamide gel. The gel was run in 5x 
running buffer overnight at 60V and the protein transferred onto a Hybond C 
nitrocellulose xiembrane (Amersham). Non -specific binding sites on the membrane 
were blocked by immersing the membrane in non -fat milk diluted in TTBS (20mM 
Tris -HC1, 500mM NaC1, pH 7.5 and 0.005% Tween -20 ) for 1 hour at room 
temperature with shaking and the excess blocking solution removed by washing in 
TTBS. A primary mouse monoclonal anti -HA antibody 12CA5 (Boehringer 
Manniheim) was preabsorbed against a membrane blotted with COS -1 cells to remove 
any non -specific binding and then added in a 1:80 dilution (in TTBS) for 1 hour at 
room temperature or overnight at 4 °C. The membrane was rinsed in TTBS, washed 
xl for 15 minutes and then x2 for 5 minutes in TTBS. The sheep antimouse 
horseradish peroxidase secondary antibody (Amersham) was diluted 1:6000 in TTBS, 
added to the membrane for 1 hour at room temperature and immunodetection carried 
out using an ECL detection method ( Amersham). 
E Fluorescein isothiocyanate conjugate (FITC) immunoassay 
Twenty -four hours post -transfection cells were transferred into 4 well chamber slides 
(Nunc) incubated for a further 48 hours, then fixed with 4% formaldehyde, washed 
with PBS and the non -specific binding sites blocked with DMEM/HIFCS. The 
primary mouse monoclonal anti -HA antibody 12CA5 was added in a 1:10 dilution in 
DMEM overnight at 4 °C and subsequently removed by washing with (x2) PBS. The 
second antibody, a FITC conjugated goat anti -mouse IgG, was then added at a 1:50 
dilution in DMEM for 2 hours. This antibody is light -sensitive so the chamber slides 
were kept in the dark. Citifluor was added to the cells to prevent quenching of the 
fluorescent signal. This reaction was observed under a fluorescence microscope at a 
wavelength 495nm. 
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F Enzyme Linked Immunosorbent Assay (ELISA) 
COS -1 cells in 60mm plates were transfected with either 3µg of Control WT, HA- 
tagged receptor DNA or sham untransfected plates. Twenty -four hours later, cells 
were trypsinised, then transferred into 96 well plates (50, 000 cells /well) and after a 
further 48 hours fixed using 4% formaldehyde in PBS (30 minutes at room 
temperature). Following fixation the cells were washed (x3) with PBS, the non- 
specific binding sites blocked with DMEM containing 10% HIFCS and a primary 
mouse monoclonal anti -HA antibody 12CA5 added in 1:10 or 1:250 dilutions in 
DMEM. This anti -HA antibody recognises the HA peptide sequence (YPYDVPDYA) 
derived from the human influenza hemagglutinin protein. Cells were incubated with 
anti -HA overnight at 4 °C, subsequently washed with PBS (x3) and then further 
incubated with a 1:1000 dilution of a peroxidase conjugated goat/sheep anti -mouse 
IgG (Sigma) in DMEM for 1 hour at 37 °C. The final substrate (2O011.1), 5mM o- 
phenylenediamine /0.03% H2O2 in O.1M citrate /phosphate buffer (pH 5.0), was added 
in a light- sensitive environment for 30 minutes at room temperature and the enzymatic 
reaction stopped with 50111 of 2N H2SO4 solution. An orange colour reaction was 
produced when the substrate reacted with the peroxidase enzyme conjugated on the 
second antibody and the colour density of each well measured using a Labsystems 
Multiscan MCC /340 reader at 492 and 639 nm wavelengths. 
Appendix IV Publications and Presentations 
Publications: 
JV Cook, E Faccenda, L Anderson, KA Eidne and PL Taylor: Effects of Asn87 
and Asp318 mutations on ligand binding and signal transduction in the rat 
GnRH receptor. J. Endocrinol. (1993) 139, R1-R4 
JV Cook and KA Eidne: A disulfide bonding role for extracellular cysteine 
residues cysteine 98 and cysteine 179 in the rat thyrotropin -releasing 
hormone receptor. Endocrinology (accepted subject to review) * 
Presentations to Scientific meetings: 
JV Cook, PL Taylor and KA Eidne: Effects of GnRH receptor transmembrane 
region mutations on GnRH recognition and signal transduction. American 
Endocrine Society 77th Annual Meeting, June 1995, Washington, DC, 
USA. 
L Anderson, JV Cook, K Chatzati and KA Eidne: Studies on the intracellular 
responses of pituitary and extrapituitary GnRH receptors. American 
Endocrine Society 77th Annual Meeting, June 1995, Washington, DC, 
USA. 
JV Cook, E Faccenda, L Anderson, PL Taylor and KA Eidne: The GnRH 
receptor ligand binding domain: Molecular modelling and site -directed 
mutagenesis studies. American Endocrine Society 76th Annual Meeting, 
June 1994, Anaheim, California, USA. 
JV Cook, L Anderson, PL Taylor , G Couper and KA Eidne: Site Directed 
Mutagenesis of the Extracellular Domains of the Rat Thyrotropin Releasing 
Hormone Receptor (TRH -R). International Congress of Physiological 
Sciences, August 1993, Glasgow, UK. 
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L Anderson, GC Couper, G Milligan, JV Cook, PL Taylor and KA Eidne: 
Characterisation of the G- protein coupled events of the rat Thyrotropin 
Releasing Hormone receptor (TRH -R). The Endocrine Society, June 1993, 
Las Vegas, USA. 
L Anderson, GC Couper, G Milligan, JV Cook, PL Taylor and KA Eidne: 
Putative intracellular phosphorylation sites within the rat Thyrotropin 
Releasing Hormone Receptor (TRH -R) which are potentially involved in 
receptor desensitisation. The 3rd International Pituitary Congress, June 
1993, Los Angeles, USA. 
KA Eidne, R Sellars, PL Taylor, JV Cook and L Anderson: Cloning, expression 
and site -directed mutagenesis of the rat GnRH receptor. The 3rd 
International Pituitary Congress, June 1993, Los Angeles, USA. 
* In the interim the results of this study have been confirmed by Gershengorn and co- 
workers in a manuscript entitled 
'A disulphide bond between conserved extracellular cysteines in the thyrotropin- 
releasing hormone receptor is critical for receptor binding'. 
published in The Journal of Biological Chemistry, Volume 270, No.42, Issue of 
October 20th, pp. 24682 -24685, 1995. 
Appendix V Measurements of expression in 
TRH -R mutants (Chapter 5) 
The measurement of protein receptor expression levels has since been achieved in the 
extracellular TRH -R Cys mutation study (Chapter 5). Western Blot analysis of 
membranes prepared from COS -1 cells expressing the 3HA- tagged TRH -R WT and 
mutants is illustrated in Figure Al. Receptor expression levels similar to WT are 
maintained in the TRH -R mutants Cys98Ser, Cys98Ala, Cys 179Ala, Cys 100Ser 
(Note mutant Cys 100Ala has not been included, but this mutation showed normal WT 
receptor binding levels). In contrast, the Cys 179Ser mutant shows no TRH -R 
expression. This data confirms the results obtained from the ligand- induced total IP 
measurements, whereby Cys 179Ser showed no increase in second messenger 
production when stimulated with concentrations of TRH above 111M (Figure 5.7). 
These results indicate that mutating Cys 179 to Ser interferes with the normal 
expression of the receptor at the membrane. In conclusion, the loss of receptor 
binding displayed by mutants Cys98Ser, Cys98Ala and Cys179Ala does not result 
from á decrease in receptor expression and must therefore be attributable to a loss of 
disulphide bridge formation. 
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